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Abstract 
 
The subjects of the present thesis are the formulation and evaluation of 
poly(lactide-co-glycolide) (PLGA) based nanoparticles addressing the biological 
barriers intestine and skin. Fluorescence labelled PLGA nanoparticles were developed 
and characterized to visualize and study interactions with such anatomical sites. Stable 
fluorescence labelling was accomplished by a covalent polymer modification with 
fluoresceinamine and the potential of these nanoparticles to investigate penetration and 
storage in hair follicles was examined in vitro and in vivo. Additionally, fundamental 
research has been carried out that proves that they represent powerful tools to study 
accumulation and retention in inflamed intestinal mucosa in inflammatory bowel 
diseases in future clinical studies. Subsequently, the fluorescence labelled 
nanoparticles were advanced to dually fluorescence labelled nanoparticles by 
incorporation of a fluorescence dye as model drug. Those nanoparticles were applied 
to demonstrate the impact of multiphoton microscopy to simultaneously study 
penetration and drug release on excised human skin. Employing flufenamic acid as 
hydrophilic model drug, the influence of nanoencapsulation on drug penetration into the 
skin was studied using PLGA nanoparticles as drug carriers. Finally, a technique to 
surface functionalize preformed PLGA nanoparticles was developed. This approach 
may allow subsequent versatile binding of proteins (targeting moieties, drugs) and dyes 
for various applications of interest like targeting the intestinal mucosa. 
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Kurzzusammenfassung 
 
Das Thema der vorliegenden Dissertation ist die Formulierung und Evaluierung 
von Nanopartikeln aus Polymilchsäure-co-glykolsäure (PLGA), die an der 
Darmschleimhaut und auf der Haut zum Einsatz kommen sollen. Zunächst wurden 
fluoreszenz-markierte PLGA Nanopartikel hergestellt und charakterisiert, um damit 
Wechselwirkungen mit diesen biologischen Barrieren zu visualisieren und zu 
erforschen. Zur stabilen Fluoreszenzmarkierung wurde PLGA kovalent mit 
Fluoreszeinamin modifiziert. Im Rahmen dieser Arbeit wurden diese Nanopartikel 
verwendet, um Transport und Deposition in Haarfollikeln in vitro und in vivo zu 
untersuchen. Des Weiteren erwiesen sie sich als viel versprechend, um künftig eine 
Anreicherung und Retention in entzündeter Darmschleimhaut bei Patienten mit 
chronisch entzündlichen Darmerkrankungen im Rahmen einer klinischen Studie zu 
überprüfen. 
Die beschriebene Nanopartikel-Formulierung wurde weiter entwickelt, indem zusätzlich 
ein Fluoreszenzfarbstoff inkorporiert wurde, um als Modellarzneistoff zu dienen. An 
derartig modifizierten Nanopartikeln konnte gezeigt werden, dass es Multiphotonen-
Mikroskopie ermöglicht, simultan Penetration und Arzneistofffreisetzung aus 
Nanopartikeln auf exzidierter Humanhaut zu visualisieren. Des Weiteren wurden PLGA 
Nanopartikel eingesetzt, um den Einfluss einer Verkapselung des lipophilen 
Modellarzneistoffs Flufenaminsäure auf den Transport in die Haut zu untersuchen. 
Abschließend wurde eine Technik entwickelt, mit Hilfe derer die Oberfläche von PLGA 
Nanopartikeln nach ihrer Formierung modifiziert werden kann. Dadurch können 
vielseitig Proteine wie „Targeting“-Komponenten oder Proteinarzneistoffe und 
Fluoreszenzfarbstoffe an Nanopartikel gebunden werden. 
Table of contents 
 5 
Table of contents 
 
 
Abstract / Kurzzusammenfassung ……………………………………………..…....... 3 
 
Table of contents………………………………………………………………………... 5 
 
1 General introduction …………………………………………………………….. 7 
 
2 Objectives………………………………………………………………………... 15 
 
3 Essential experimental aspects of the present study………………………… 17 
3.1 Poly(lactic acid-co-glycolic acid) as polymer for pharmaceutical applications…….. 17 
3.2 Preparation techniques of poly(lactic acid-co-glycolic acid) nanoparticles………… 18 
3.2.1 Solvent evaporation and solvent extraction process…………………………………. 19 
3.2.2 Salting-out……………………………………………………………………………….. 21 
3.2.3 Nanoprecipitation……………………………………………………………………….. 21 
3.3 Loading of active compounds in poly(lactic acid-co-glycolic acid) nanoparticles 
and their release………………………………………………………………………… 22 
3.4 Characterization techniques for nanoparticles………………………………………... 23 
3.4.1 Photon correlation spectroscopy………………………………………………………. 24 
3.4.2 Laser doppler electrophoresis…………………………………………………………. 25 
3.4.3 Scanning probe microscopy…………………………………………………………… 26 
3.4.4 Nuclear magnetic resonance spectroscopy…………………………………………... 27 
3.4.5 Differential scanning calorimetry……………………………………………………….. 27 
 
4 Results and discussion…………………………………………………………. 29 
4.1 Preparation, characterization, and evaluation of fluoresceinamine labelled PLGA 
nanoparticles…………………………………………………………………………….. 29 
4.2 Application of fluorescent and drug containing nanoparticles to investigate skin 
permeation and penetration……………………………………………………………. 33 
4.2.1 Nanoparticles – an efficient carrier for drug delivery into the hair follicles…….……. 33 
4.2.2 Multiphoton microscopy for the investigation of dermal penetration of nano- 
particle-borne drugs…………………………………………………………………….. 36 
4.2.3 Influence of nanoencapsulation on human skin transport of flufenamic acid………. 39 
4.3 Surface biotinylated nanoparticles for coupling of versatile ligands ………………… 41 
 
5 References……………………………………………………………………….. 45 
 
 
Table of contents 
 6 
6 Forthcoming publications………………………………………………………. 57 
6.1 Nanoparticles made of fluorescence-labelled poly(L-lactide-co-glycolide):  
preparation, stability, and biocompatibility…..……….……………………………….. 59 
6.2 Nanoparticles – an efficient carrier for drug delivery into hair follicles………………. 79 
6.3 Multiphoton microscopy for the investigation of dermal penetration of nano- 
particle-borne drugs…………………………………………………………………….. 103 
6.4 Influence of nanoencapsulation on human skin transport of flufenamic acid………. 113 
6.5 Coupling of biotin-(polyethyleneglycol)amine to poly(D,L-lactide-co-glycolide) 
nanoparticles for versatile surface modification………………………………………. 121 
 
7 Summary / Zusammenfassung……………………………………………….... 163 
 
Publication list…………………………………………………………………………… 175 
 
Curriculum vitae…………………………………………………………………………. 177 
 
General introduction 
 7 
1 General introduction 
 
In the past 30 years, the explosive growth of nanotechnology has burst into 
challenging innovations in pharmacology with tremendous impact on both therapeutics 
and diagnostics.1-13 In this context, colloidal systems are in the current limelight of 
interest due to their outstanding potential to target physiological sites, organs, tissues, 
or cells where the pharmacological activity of a drug is required or where physiological 
conditions have to be examined. 
The concept of targeted drug delivery was already proposed by the immunologist 
Nobel laureate Paul Ehrlich in the beginning of the 20th century as so called “magic 
bullet”.14 However, today´s demands on colloidal targeted drug delivery devices have 
even become more complex: in addition, new systems should be non-toxic, 
biocompatible and biodegradable, the carrier core itself should be shielded by a 
protective layer against harmful environmental effects and/or charged for adsorption of 
active compounds or to facilitate tissue approach; frequently, they should also exhibit 
attributes like antigen detection, fluorescence labelling and shape/surface recognition. 
Thereby, the active compound is, preferentially, either entrapped in the core or 
specifically bound to linker groups on the particle surface (Figure 1).2 
Nowadays, delivery technologies are still far away from the realization of such perfect 
systems, however, research is in continuous progress.15-21 
 
 
Figure 1: Approaches to the construction of an ideal colloidal drug delivery system2 
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Colloidal systems are generally defined to be in a size below 1 μm. Consequently, in 
literature, one can find an ocean of materials and formulations in this size range for 
potential applications in diagnostics and therapy: colloidal gold,22 iron oxide crystals,23 
and quantum dot semiconductor nanocrystals24 as examples of promising diagnosis 
tools in medicine, and nanosuspensions,25, 26 nanoparticles,3, 4 nanoemulsions,27 
liposomes,28 and micelles29 as examples of approaches for drug delivery. 
Solid nanoparticles (NP) are of special impact for targeted drug delivery since exhibiting 
significant interactions with various tissues of interest e.g. accumulation in tumors,6, 7 
penetration into skin,8, 30 overcoming membrane barriers, particularly in the nose31, 32 and 
in the gastrointestinal tract,10, 33, 34 and improvement of drug transport over the blood 
brain barrier.9, 31 
 
Major subjects of this thesis are the formulation of NP with specific properties and 
investigations of interactions with the biological barriers skin and intestine. Hence, the 
subsequent part of this chapter aims current advances of research in these fields and 
represents a placement of present work. 
 
Interactions of nanoparticles with the skin 
Structure and composition of the skin provide an excellent barrier which confines 
percutaneous drug delivery.35, 36 Many approaches have been introduced in order to 
enhance transdermal delivery such as increasing the drug concentration in the vehicle, 
improving the partitioning between the vehicle and the skin, chemical penetration 
enhancers, and physical enhancement methods like iontophoresis and 
electroporation.37-41 In the recent years, NP have attracted considerable interest as 
penetration enhancers not only for topical administration but also as an alternative route 
for the systemic drug administration.  
Different penetration pathways into and through the stratum corneum, the main barrier 
of the skin, are known: the transepidermal pathway which means mainly intercellular 
penetration (the transcorneocyte is only of minor relevance) and the transappendageal 
routes i.e. via sweat glands and hair follicles. Different approaches have been 
undertaken in order to distinguish between follicular and intercellular penetration. E.g. 
Alvarez-Román et al.42 used confocal laser scanning microscopy for more 
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semiquantitative studies of the distribution of topically applied substances in different 
skin layers and appendages, Toll et al.43 performed histological investigations, and 
Teichmann et al.44 closed hair follicles artificially to investigate their influence on the 
penetration process of hydrophilic compounds. 
Although comprising only 0.1% of the total skin surface, hair follicles45 in particular have 
recently moved into the centre of interest for the topical application of free and NP 
associated drugs.3, 30, 45, 46 Different research groups showed that hair follicles provide a 
pathway for the penetration of NP,8, 46 thereby also acting as long-term reservoir.30 In 
contrast, in the stratum corneum NP are stored mainly in the upper cell layers of 
corneocytes being quickly depleted by normal desquamation, textile contact, and 
washing.30 
However, as with most other biological barriers, the use of NP as drug carriers is 
strongly size-dependent. Here, NP were shown to penetrate better, the smaller the 
particle size.8, 46 Interestingly, large particles (> 5 μm) acted as highly efficient follicle 
blockers.45 
Besides nanoparticular microfine metallic oxides used as powerful agents in 
sunscreens, NP described in literature for topical administration of cosmetics and drugs 
can be assigned to polymeric NP and solid lipid nanoparticles (SLN). A limited number 
of polymeric NP have been investigated with respect to their potential for transdermal 
drug administration. Hereby, biodegradable polymeric NP have clearly shown to 
significantly enhance the penetration of highly lipophilic compounds, when compared 
to non-particulate formulations.3, 46 Moreover, bioadhesive polymer NP have been 
studied as a sustained drug delivery system offering the possibility of improving the 
therapeutic index and the frequency of treatment.47 
During the past twenty years, SLN have been introduced as an alternative topical carrier 
system to traditional carriers, such as emulsions and liposomes. They have been 
studied to exhibit numerous advantages like protection of labile compounds from 
chemical degradation,48 occlusion effects which can increase the water content in the 
skin, thus favouring drug penetration, 49, 50 sustained release,51, 52 reduced systemic 
absorption,53 and reduction of skin irritations.49 Moreover, SLN are frequently described 
to act as UV sunscreen systems in cosmetics.54, 55 Especially in the last decade, intense 
research was focused on the use of SLN for the delivery of pharmaceutical compounds, 
General introduction 
 10 
either topical (e.g. podophyllotoxin,56 triptolide57) or transdermal (e.g. insulin58 and 
flurbiprofen52). 
However, facing problems like polymorphic transformations of the lipid matrix, low drug 
pay-load and drug expulsion during storage, nanostructured lipid carriers (NLC) have 
been recently introduced as new generation of SLN.59, 60 The concept is based on a 
blending of solid with liquid lipids, thus giving the lipid matrix a certain nanostructure 
and excluding the obstacles as with SLN.61 
Transcutaneous vaccination represents a rather new concept of NP application to the 
skin; it has been evaluated as an attractive alternative to subcutaneous injection due to 
a high population of dendritic cells in the skin.62-64 However, this field appears to be 
rather unexplored so far, and mainly NP-based DNA vaccine systems facilitating DNA 
penetration into the skin have been studied.63, 64 Recently, Lademann´s group found a 
size effect with 40 nm particles showing best properties for transcutaneous vaccine 
delivery.62 
 
Interactions of nanoparticles with the intestine 
NP uptake from the gut is important as an additional route of entry to the systemic 
circulation65 with high potential as a means of drug and vaccine delivery. Several 
studies have been done at cellular and tissue level in order to illuminate the way of 
particle uptake.66-68 Particles are described to be taken up either at the level of Peyer´s 
patches (i.e. follicle-associated epithelium and M cells) or through the enterocytes 
(persorption).68 In literature, it is clearly stated that neither of the possible ways of 
particle uptake is exclusive,69, 70 and conditions favouring one or the other are still 
subject to present investigations. Particle uptake is supposed to be greatly influenced 
by physicochemical properties such as size, zeta potential and hydrophobicity. In 
general, the absorption of particles is promoted by a smaller size.71, 72 Desai et al.68 
studied poly(lactic acid-co-glycolic acid) (PLGA) NP in the size range from 100 nm to 
10 μm in a rat intestinal model and found a significantly increased uptake in case of the 
100 nm particles. Furthermore, they found that particle uptake of all sizes was to a 
higher extent mediated by Peyer´s patch tissue than by nonpatch tissue, whereas both 
tissues had comparatively higher uptake when collected from the ileum than from the 
duodenum. Shakweh et al.70 investigated influences of particle size and zeta potential 
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on the uptake of fluorescent PLGA NP by means of histological localization in intestinal 
tissue in mice. They saw that particles (300 nm; 1 μm and 3 μm) were taken up by 
Peyer´s patches as well as bound to nonpatch tissue. They showed that smaller 
particles are taken up into the deep region of Peyer´s patches and at greater rate than 
microparticles, which were found to remain localized in the dome region. In addition to 
particle size effects, they also found an influence of surface charge on the uptake via 
Peyer´s patches: particles of negative or neutral zeta potential exhibited higher affinity 
than positively charged particles. The authors hypothesized that this finding is an effect 
of electrostatic interactions between the positively charged particles and the negative 
charged mucus gel layer slowing down the penetration of those particles and thus 
reducing the uptake. In contrast, other authors stated a preferred uptake of positively 
charged NP as consequence of NP interactions with negatively charged intestinal 
epithelial cells and mucus.73, 74 
Absorption of NP made of diverse materials has been enhanced by coupling the 
particles to molecules like lectins75-77 or invasin.78, 79 As consequence, the site of particle 
uptake shifts from the Peyer´s patches to the nonpatch tissue, greatly augmenting the 
effective surface area, and thus increasing absorption.69 Mucoadhesion represents 
another approach to improve drug absorption from orally administered NP; NP of 
different materials80, 81 and with diverse surface modifications33, 82 have been studied to 
exhibit mucoadhesive properties. Sandri et al.83 investigated strong mucoadhesion with 
NP made of a chitosan modification. They also found that mucoadhesion delayed the 
absorption of NP, though, they produced an increase in contact time with the intestinal 
epithelia, hence offering a better chance for internalization. 
Research on the use of NP for the oral route of administering active compounds, the 
most convenient way of delivering drugs, has shown that nanoencapsulation can 
protect active compounds from harmful attacks in the gastrointestinal milieu84 and, 
conversely, also improve gastric tolerance of agents irritant to the stomach.85 Moreover, 
nanoencapsulation can enhance drug absorption and bioavailability of entrapped or 
adsorbed molecules.33, 34 This is especially valuable with respect to the delivery of 
peptide and protein drugs with particular instability in the gastrointestinal tract and low 
permeability through the intestinal mucosa.86 Intense research has been done on the 
oral delivery of nanoencapsulated insulin; in comparison to non-encapsulated orally 
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administered insulin, several authors showed an improvement in oral absorption and 
prolongation of the hypoglycaemic effect.87-89 Luo et al.90 studied an increased 
absorption and a significant (4.17-fold) improve in the oral bioavailability of vinpocetine 
when entrapped into SLN in comparison to a solution of the free drug. Hariharan et al.73 
encapsulated the well absorbable but poorly bioavailable drug estradiol into NP from 
PLGA demonstrating sustained release from those formulations up to 7 days; in 
comparison, a steep fall in blood levels was observed in oral and i.v. administration of 
pure drug within a period of 2 h. 
The feature of being adsorbed via Peyer´s patches is the rationale of using NP for the 
development of formulations for mucosal immunization. Thereby, major interest of 
mucosal vaccination is that the resulting immunity will be expressed at the level of all 
mucosae, independently of where it has been induced.91 However, as with 
transcutaneous vaccination, the application of NP does not appear as well-investigated 
in this field up to now; only few studies can be found describing the development and 
evaluation of NP-based antigen (e.g. deriving from Bordetella pertussis92 or Toxoplasma 
gondii93) and DNA vaccines94 for oral administration. 
Of special interest for an oral delivery of NP is the effect of gastrointestinal disease on 
important features of the intestinal barrier like mucus layer, epithelial permeability and 
capillary innervations; they can be changed, thus altering NP uptake pathways and 
processes.95 Recently, new experimental therapeutic strategies have been described 
using particles as targeted drug carrier in inflammatory bowel disease (IBD). This 
approach is mainly based on two pathophysiological changes in inflamed tissue as 
under the conditions of IBD: first, a highly increased number of immune-related cells, 
and second, elevated mucus production allowing a higher adhesion of particulate 
carriers in the inflamed regions and enhanced permeability of the tissue leading to 
intense particle uptake.96, 97 This accumulation phenomenon was observed to be 
particle size dependent with an increasing effect for smaller particle diameters and 
highest efficiency in case of NP of around 100 nm.10, 98 Based on these results, several 
studies have been performed in rodent models with experimentally induced colitis 
comparing the effects of orally administered drugs in NP formulations with those of free 
drug solutions. Lamprecht et al.96 showed the same efficiency in mitigating the 
inflammation, a sustained effect and a significant reduction of adverse effects after 
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administration of the anti-inflammatory drug rolipram encapsulated into NP. Meissner et 
al.99 confirmed these results showing reduced nephrotoxicity when applying the 
immunosuppressive drug tacrolimus in nano-encapsulated formulation; in their case 
the drug effect was even increased in comparison to the free drug solution. Moreover, 
with the same drug tacrolimus, Lamprecht et al.98 studied an about 3-fold higher 
penetration into the inflamed tissue compared to healthy tissue when using NP as drug 
carriers. 
  14 
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2 Objectives 
 
The present work was focused on the formulation, characterization, and 
evaluation of PLGA based NP systems addressing the biological barriers intestine and 
skin. As first step, fluorescence labelled PLGA NP were developed to study and to 
visualise interactions with such anatomical sites. Within the scope of this work, the 
potential of those NP to investigate penetration and storage in hair follicles was 
examined in vitro and in vivo. Moreover, they may represent valuable tools in future 
clinical studies in inflammatory bowel diseases (IBD). Additionally incorporating a 
model drug compound, fluorescence labelled NP were advanced to dually 
fluorescence labelled NP; they were applied to demonstrate the impact of multiphoton 
microscopy to investigate dermal penetration and drug release. Using PLGA NP as 
drug carriers, their influence on drug penetration into the skin was studied employing 
flufenamic acid as hydrophobic model. Finally, the development of a technique to 
surface functionalize PLGA NP may allow subsequent versatile binding of proteins 
(targeting moieties, drugs) and dyes for various applications of interest e.g. targeting 
the intestinal mucosa. 
The specific aims of each study were (the corresponding chapter is indicated within 
parenthesis): 
 
- to develop and to characterize a formulation of stable fluorescence labelled non-
toxic NP in order to investigate the potential of NP to target inflamed intestinal 
mucosa in IBD in a future clinical study. (4.1) 
- to investigate the penetration and storage behaviour of fluorescence labelled NP 
in hair follicles in comparison to a free fluorescence dye. (4.2.1) 
- to simultaneously study and visualize NP penetration and drug release in dermal 
administration employing a dually fluorescence labelled model system. (4.2.2) 
- to investigate the effect of nanoencapsulation on the permeation and penetration 
of the lipophilic model drug flufenamic acid into excised human skin. (4.2.3) 
- to develop a procedure to surface functionalize preformed polymeric NP for 
subsequent versatile conjugation of targeting ligands and fluorescence dyes 
under mild conditions. (4.3)
  16 
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3 Essential experimental aspects of the present study 
 
The following chapter briefly presents and discusses the principles of essential 
materials and methods applied in this thesis. The techniques described are focussed 
on the formulation and physicochemical characterization of polymeric NP. 
 
3.1 Poly(lactic acid-co-glycolic acid) as polymer for pharmaceutical applications 
Since the last three decades, synthetic biodegradable polymers have been 
increasingly used to deliver drugs. Amongst them the aliphatic poly(esters) poly(lactic 
acid) (PLA), poly(glycolic acid) (PGA), and their copolymers poly(lactic acid-co-glycolic 
acid) (PLGA) (Figure 2) have generated special interest due to their excellent 
biocompatibility and biodegradability.100 
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Figure 2: Chemical structures of poly(lactic acid) (A), poly(glycolic acid) (B), and poly(lactic acid-co-
glycolic acid) (C) 
 
During the late 1960s and early 1970s, pioneering work on the utility of lactide/glycolide 
polymers to make bioresorbable sutures/fibres was published first.11 Since then, 
especially PGA was and still is used as biodegradable suture material. The wide 
acceptance of the lactide/glycolide polymers made them further attractive to various 
biomedical applications like tracheal replacement, vascular grafts, or dental and 
fracture repair.100 Nowadays, because they are part of FDA approved drug products for 
parenteral administration, those polymers are most common for the fabrication of 
modern controlled release devices like microparticles, NP, films, and implants.100 
PLGA can be directly synthesized from monomers. However, it is also commercially 
available in different molar ratios of glycolic and lactic acid and in different molecular 
weights of the polymer chains. Thereby, the physicochemical properties of PLGA are 
strongly dependent on the nature of the monomers. L-PLA was generally found to be 
semi-crystalline in nature whereas D,L-PLA is amorphous due to irregularities in the 
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chain structure; PGA was reported to be highly crystalline. Lactic acid is more 
hydrophobic than glycolic acid, hence, by variation of the glycolic acid/lactic acid ratio 
important polymer features like mechanical strength, crystallinity, swelling, polymer 
degradation rate and hydrolysis can be controlled.11, 100 
Both in vitro and in vivo PLGA undergoes degradation in aqueous environment through 
scission of its backbone ester linkages.101 In general, degradation time will be shorter 
for low molecular weight, hydrophilic, amorphous polymers, and for copolymers with 
higher content of glycolide.102 E.g. the most widely used PLGA copolymer composition 
of 50:50 has the fastest degradation rate of the D,L-lactic acid/glycolic acid materials. 
This polymer degrades in about 50-60 days.11 It is well known that bulk erosion is the 
main degradation mechanism with PLGA devices.18, 103 Polymer chains are cleaved 
randomly throughout the polymer matrix leading to a subsequent decrease of 
molecular weight without any appreciable weight loss. For PLGA biodegradation a 
three-phase mechanism has been proposed where first, a random chain scission 
results in a decrease in molecular weight of the polymer without any significant weight 
loss. Second, the decrease in molecular weight is accompanied by rapid loss of mass 
due to the formation of soluble degradation products. Third, soluble monomer products 
are formed from soluble oligomeric fragments leading to a complete polymer 
solubilization.100 Finally, the degradation products are easily metabolized in the body via 
the Krebs cycle and subsequently eliminated.104  
In conclusion, from the toxicological point of view, PLGA represents a well 
characterized, biocompatible and biodegradable polymer. Its tissue response is 
characterized by minimal localized inflammation and a foreign body reaction that 
decreases with time. The monomers D,L-lactide and glycolide posses a low acute 
toxicity, probably as a consequence of rapid metabolism, and no apparent long-term 
effects.11 
 
3.2 Preparation techniques of poly(lactic acid-co-glycolic acid) nanoparticles 
The choice of the process employed for NP preparation governs the formation of 
either nanocapsules or nanospheres. Nanocapsules are defined as hollow NP where a 
polymer membrane encloses a drug reservoir; nanospheres consist of a solid polymer 
matrix in which the active compound is embedded. 
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Several methods have been developed to obtain polymeric particles in the nanosize 
range. Roughly, they can be categorized into two main strategies: formation of NP by 
emulsion polymerization of monomers and preparation of NP from preformed 
polymers.11 Nowadays, the use of preformed polymers is first choice for the preparation 
of PLGA NP due to a good commercial availability of diverse PLGA polymers with 
standardized physicochemical characteristics. The following overview of the basic 
methods of NP preparation from preformed polymers provides some background 
information about the applicability and the mechanism from a physicochemical point of 
view.  
Generally, NP preparation methods have to meet the following requirements: 
 
- No adverse effect on stability and biological activity of the encapsulated active 
compound 
- Reproducible quality and drug release profile of the NP within specified limits 
- High encapsulation efficiency 
- High yield of NP in the desired size range; narrow size distribution 
- Stability of the NP in aqueous medium or as lyophilized product 
 
3.2.1 Solvent evaporation and solvent extraction process 
Single emulsion process 
The preformed polymer is dissolved in an organic volatile solvent (e.g. 
dichloromethane105, ethyl acetate106); the drug is added to the polymer solution to 
further produce a solution or dispersion of the drug. The organic phase is emulsified in 
a larger volume of aqueous solution (with appropriate stirring and temperature 
conditions) in presence of a stabilizer (e.g. poly(vinyl alcohol)106, didodecyl dimethyl 
ammonium bromide),11 to yield an oil-in-water (o/w) emulsion. The emulsion is then 
subjected to a solvent displacement and a subsequent hardening of the oil droplets 
(Figure 3). 
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Figure 3: General procedure of a solvent displacement process used for NP preparation 
 
In case of a water-immiscible organic solvent, the emulsion is maintained at reduced 
pressure107 or at atmospheric pressure and the stir rate is reduced to enable the organic 
solvent to evaporate (solvent evaporation). In case of a partially water-miscible organic 
solvent, the emulsion is transferred into a large quantity of aqueous medium into which 
the solvent associated with the oil droplets can diffuse (solvent extraction).11, 108 The 
single emulsion process is ideal for the encapsulation of water insoluble drugs such as 
steroids.12, 100 
 
Double (multiple) emulsion process 
The single emulsion method is confined to the entrapment of lipophilic compounds; 
hydrophilic compounds tend to show diffusion and partitioning from the dispersed oil 
phase into the continuous aqueous phase. Therefore, for an encapsulation of 
hydrophilic agents, the single emulsion method has to be upgraded to a double 
emulsion process. A buffered or plain aqueous solution of the compound, additionally 
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containing a viscosity building and/or stabilizing agent if necessary, is added to the 
organic polymer solution under vigorous stirring to form the first microfine water-in-oil 
(w/o) solution. This emulsion is added gently with stirring into a second aqueous phase 
containing stabilizers to form a water-in-oil-in-water (w/o/w) emulsion. As described 
above, the organic solvent is removed by evaporation or extraction.  
This double emulsion process is best suited to encapsulate hydrophilic drugs like 
peptides and proteins, also in terms of protein stability.19, 105, 109 
 
3.2.2 Salting-out 
This technique can be considered as a special version of the emulsion method: 
the polymer and the active compound dissolved in a water-miscible organic solvent 
(e.g. acetone) are added to an aqueous solution of a stabilizer and the salting-out 
agent (e.g. MgCl2) in saturation under vigorous mechanical stirring. Thereby, diffusion 
of the water-miscible organic solvent in the outer aqueous phase is inhibited by the 
presence of the saturated salt solution (salting-out effect) until the volume of the 
aqueous phase is increased leading to subsequent formation of NP.13, 20, 110 
 
3.2.3 Nanoprecipitation 
The nanoprecipitation method was first developed and patented by Fessi and 
co-workers.111 It gives the advantage of a rapid, easy, and reproducible performance 
and it is best valuable for the entrapment of lipophilic compounds. In contrast to the 
emulsion processes, two miscible solvents are employed, only one of them being also 
a solvent for the polymer (e.g. water containing stabilizers and acetone). Briefly, both 
the polymer and the active compound are dissolved; nanoprecipitation occurs by a 
rapid desolvation of the polymer when the polymer solution is added to the non-solvent, 
thereby encapsulating the drug. The rapid NP formation is governed by the Marangoni 
effect, which describes turbulences at the interface of the solvent and the non-
solvent.111, 112 As for the emulsion process, first steps have already been made to adapt 
this technique for the entrapment of hydrophilic drugs. This is especially relevant for the 
encapsulation of hydrophilic proteins which might suffer from solvent interfaces, high 
shear rates, and hydrolytic degradation when employing the double emulsion 
process.113 
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All methods described above require purification of the NP to remove residual organic 
solvent, stabilizer, or non-encapsulated free drug. The purification method has to be 
selected carefully to avoid NP aggregation or drug loss; commonly applied techniques 
are ultracentrifugation, ultrafiltration, dialysis or cross-flow filtration.  
Due to the immense surface area and the resulting energetic and thermodynamic 
instability, NP tend to agglomerate during storage especially in liquid formulations; to 
overcome this problem lyophlization is best established.11, 114, 115  
 
3.3 Loading of active compounds in poly(lactic acid-co-glycolic acid) nanoparticles 
and their release 
The encapsulation capacity of NP and the release kinetics of active compounds 
are major criteria in the development of NP formulations.  
A successful NP system is considered to be the one, which has a high loading capacity 
to reduce the quantity of the carrier required for application. Thereby, the encapsulation 
efficiency depends on the preparation method, NP size and the nature of the polymer 
and drug. Generally, loading of active compounds into NP is achieved by two methods. 
First, agents can be incorporated at the time of NP preparation, i.e. during 
polymerization process or when the preformed polymer is dissolved (as described in 
chapter 3.2). Second, drugs can be physically adsorbed after formulation of the NP. 
Adsorption isotherms for the respective system give vital information on the best 
possible formulation; normally, adsorption of active compounds onto NP follows the 
Langmuir mechanism.116 Consequently, it is evident that a large amount of drug can be 
entrapped by the incorporation method when compared to the adsorption.117 In addition 
to the common methods adsorption and incorporation of drugs, new techniques of 
drug loading have been developed. Yoo et al.118 proposed a technique where the drug 
was chemically conjugated to the polymer PLGA prior to NP formation. However, this 
method is only applicable for compounds with active sites for chemical modifications. 
In order to enable a more versatile binding of substances to the surface of NP, various 
techniques have been developed recently where for instance polymers have been 
chemically linked with biotin. After NP preparations, those systems exhibit biotin surface 
groups for the binding of avidin (or homologues) which can be further conjugated to 
other compounds.15, 16, 21 
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Release profiles of active substances from NP are again dependent on both the kind of 
NP and the preparation method applied. Generally, the smaller the NP and the larger 
the surface, the faster the release can be expected. In case of a NP device where the 
drug is uniformly distributed or dissolved in the matrix, the release occurs either by 
diffusion or by erosion of the matrix, or both. In case of surface bound or surface 
adsorbed compounds, the release is governed by drug detachment and by partitioning 
processes. In order to study the in vitro release rates of NP the technical difficulty of NP 
separation from the release media has to be overcome. Most common methods for that 
approach are: side-by-side diffusion cells with artificial membranes, dialysis bag 
diffusion techniques, (ultra-) centrifugation, (ultra-) filtration and centrifugal ultrafiltration 
techniques110, 117, 119, 120 combined with HPLC analysis or spectroscopic measurements 
of the release media. 
 
3.4 Characterization techniques for nanoparticles 
The characterization of nanoparticulate systems for pharmaceutical applications 
can be categorized into physicochemical and biopharmaceutical aspects. The 
physicochemical characterization involves the determination of parameters like particle 
size, size distribution, morphology, and surface properties; the biopharmaceutical 
characterization covers determination of drug encapsulation and release, biodistribution 
and bioavailability. 
For the physicochemical analysis and characterization of polymeric NP the following 
methods are generally considered as state-of-the-art.11, 121 
 
- Photon correlation spectroscopy for the determination of particle size and size 
distribution 
- Laser Doppler electrophoresis for the measurement of zeta potential (surface 
charge density) 
- Scanning probe microscopy for the investigation of morphology, surface and 
mechanical properties 
- Scanning electron microscopy and transmission electron microscopy for 
imaging of the particle morphology 
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- X-ray photoelectron spectroscopy, Fourier transform infrared spectroscopy, and 
nuclear magnetic resonance spectroscopy for the investigation of polymer and 
surface chemistry 
- Differential scanning calorimetry for the determination of thermal properties of 
polymers and particles 
 
Subsequently, this chapter focuses on the characterization techniques for NP applied in 
the course of this thesis. 
 
3.4.1 Photon correlation spectroscopy 
It is well known that NP size is a crucial factor to the release of active 
compounds,122, 123 degradation,103, 123, 124 deposition,10 tissue penetration125 and even 
cellular uptake.11, 126 Furthermore, particle size is an important parameter in in-process 
control and quality assurance because the physical stability of particle dispersions 
depends on size and size distribution.127  
Photon correlation spectroscopy (PCS) represents a routine method to determine the 
NP mean hydrodynamic diameter and the particle size distribution (polydispersity). It is 
based on the scattering of a laser light employed onto a dispersion of spherical NP in 
Brownian motion; the light fluctuations increase as particle size decreases and 
Brownian motion increases. The scattered light is detected by a photomultiplier which is 
usually located in a 90° angle position transforming the variation of light intensity into a 
variation of voltage (Figure 4). Finally, PCS results derive from a correlation between the 
different intensities within short time intervals; generally, they determine the particle size 
distribution and the z-average which corresponds to the hydrodynamic diameter of the 
particles.127 The hydrodynamic diameter is strongly influenced by adhesion of water 
molecules on the particle surface and can differ significantly from the true physical 
diameter. For that reason, in all cases, an additional method like scanning probe or 
electron microscopy should be applied. 
The polydispersity index (PI) is a dimensionless measure for the broadness of a particle 
size distribution and can be used for the evaluation of NP preparation. In practice, NP 
dispersions with a PI between 0.03 and 0.06 can be denoted as mono-disperse, 
between 0.1 and 0.2 as narrowly distributed, and between 0.25 and 0.5 as broadly 
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distributed. Values above 0.5 indicate an extremely broad size distribution that can not 
be described by means of PI.128 
 
 
Figure 4: Schematic setup of a PCS apparatus 
 
3.4.2 Laser doppler electrophoresis 
Each non-neutral particle dispersed in a polar solution is surrounded by 
oppositely charged ions forming a fixed layer. Outside the fixed layer, there are ions of 
opposite polarities, forming cloud-like areas.129 When the particles move relative to the 
suspension medium, a part of this so called diffuse double layer will attach to the 
particles resulting in a potential at the shear zone; this potential is called zeta potential 
and can be measured by laser doppler electrophoresis (LDE). The magnitude of the 
zeta potential is an indication of the repulsive force between NP;129 high zeta potentials, 
either positive or negative, allow NP stability and avoid particle aggregation. Besides 
stability, the zeta potential can strongly influence parameters like mucoadhesion and 
intracellular trafficking of NP.11  
LDE applies an electrical field of known strength across the NP sample. The 
electrophoretic mobility of the colloid will determine the velocity of particle movement 
which can be measured by the frequency shift of an incident laser beam passing the 
sample. Using Henry´s equation, the dielectric constant of the sample, the solvent 
viscosity, and the measured electrophoretic mobility the zeta potential of the particles 
scan be calculated. 
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3.4.3 Scanning probe microscopy 
Scanning probe microscopy (SPM) is a valuable tool for non-destructive three-
dimensional visualization of NP. Moreover, it provides qualitative and quantitative 
information on various physical properties. Hence, it can be used for NP 
characterization and monitoring of changes in NP features e.g. due to drug loading, 
variation of the NP preparation method, or NP degradation. 
A SPM is scanning the surface using a micro-scale cantilever with a sharp, nanoscale 
tip at its end. When the tip is approached to the sample surface it is subjected to 
attractive or repulsive forces leading to a deflection of the cantilever. The extent of 
deflection is determined by the reflection of a laser beam from the top of the cantilever 
onto an array of 4 photodiodes. In order to move the tip over the sample surface, the 
cantilever is mounted on a piezoelectric tube, or vice versa the sample. For scanning in 
xy direction and to adjust the tip-to-sample distance during scanning the cantilever 
position is controlled by a feedback mechanism (Figure 5). 
 
 
Figure 5: Schematic depiction of a basic AFM setup 
 
In this work, Tapping ModeTM was employed to image samples. At this imaging mode, 
the cantilever oscillates at or close to its resonance frequency. A Tapping Mode 
measurement usually results in three signals: height, amplitude and phase signal. The 
height signal displays the topography of a sample, the amplitude signal highlights rapid 
changes in sample topography, and the phase signal qualitatively shows changes in 
the sample elasticity. 
Essential experimental aspects 
 27 
3.4.4 Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a non-destructive 
spectroscopic method based upon the physical property of atoms (generally atoms 
with odd numbers of nuclei) to exhibit magnetic moments; the most often used nuclei 
are 1H, 2H, and 13C. NMR spectroscopy studies the magnetic nucleus by alignment with 
a strong external magnetic field, which is perturbed by means of an electromagnetic 
field. The resulting change in the magnetisation of the atomic nuclei is detected to 
obtain detailed information about the molecular structure. In the field of NP technology, 
NMR spectroscopy is commonly used to characterize molecular structures of 
polymers,130 to evidence their assembly in NP,131, 132 and to analyse their degradation 
products.133 Moreover, NMR is a valuable tool to verify chemical integrity of drugs after 
nanoencapsulation.134 
 
3.4.5 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) represents a thermoanalytical method 
that measures the difference in the thermal energy required to increase the temperature 
of a sample and a reference with well-defined heat capacity as a function of the 
temperature. Ideally, both the sample and the reference are kept at identical 
temperature, while the temperature increases linearly as a function of time. As soon as 
the sample undergoes a physical transformation; either exothermic or endothermic, the 
heat flow to the sample will be decreased or increased relative to the reference, thus, 
resulting in a DSC signal. 
In NP technology, DSC is widely used to study e.g. polymer characteristics (glass 
transition, melting point)135, 136 and ageing phenomena,137 or to evaluate lyophilization 
procedures of NP.138, 139
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4 Results and discussion 
 
4.1 Preparation, characterization, and evaluation of fluoresceinamine labelled PLGA 
nanoparticles 
NP have recently been demonstrated in a rat model to be a promising tool for 
targeting inflamed areas of the intestinal mucosa in IBD whilst concentrating anti-
inflammatory drugs at their site of action.4, 10, 140 Considering these promising results in 
animals, a proof of concept for this novel targeting approach in IBD must be provided in 
humans. For such purpose, drug-free but fluorescence labelled non-toxic NP are 
needed to show their accumulation in inflamed areas of the colonic mucosa by means 
of fluorescence microscopy. 
As a first step, biodegradable and biocompatible fluorescent NP were prepared and 
characterized; fluorescein (FC) was chosen as a fluorescence marker since it is also 
applied even in high doses for diagnostic purposes. To achieve stable fluorescence 
labelling, the FC derivative 5-fluoresceinamine (FA) was covalently bound to the free 
carboxyl functions of the PLGA chains by a simple one-step reaction as described by 
Horisawa et al.141 1H NMR revealed a 65% modification rate of carboxyl-end groups of 
PLGA chains. The glass transition temperature of FA-PLGA was determined by DSC to 
roughly Tg = 29°C. 
From this modified polymer (FA-PLGA), NP (FA-PLGA NP) with a mean diameter of 
270 nm were prepared via nanoprecipitation. In regard to an in vivo application of the 
NP in IBD, this size order is expected to be adequate to act as a potential drug carrier 
whilst still likely to display an enhanced accumulation and retention in inflamed mucosal 
areas. The density of FA-PLGA NP was determined to 1.46 g/ml; it did not differ 
significantly from the density of pure PLGA. 
For the intended studies, it is crucial that the fluorescence label remains firmly 
associated with the NP over an appreciable period of time. In case of FA-PLGA NP, the 
leakage of fluorescence marker occurred in a strongly delayed manner as depicted in 
Figure 6. The initial burst effect led to 11.7% loss of fluorescence marker within 2 h 
which is most likely due to starting polymer degradation after re-hydration of the freeze 
dried NP. After 8 days, 60.8% of fluorescence marker was still bound to the NP. As 
generally known from PLGA devices, polymer swelling occurs under aqueous 
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conditions leading to subsequent polymer chain cleavage. By means of thin layer 
chromatography, it was found that polymer degradation led to different fluorescent 
products which were expected to be FA-linked PLGA fragments.  
 
 
Figure 6: Relative residual content of fluorescence marker in FA-PLGA NP as a function of time 
(mean ± SD).142 
 
Alternatively to a polymer modification, FC was entrapped into PLGA NP using the 
w/o/w emulsification method for the purpose of comparison with FA-PLGA NP. In 
contrast to FA-PLGA NP, it was shown that the release of encapsulated fluorescence 
marker from those particles (FC-PLGA NP) was very fast: 82.6% were already released 
after 30 min This result is in accordance with literature, where hydrophilic drugs are 
described to be released rapidly when encapsulated into PLGA NP using the w/o/w 
method.143-145 By SPM it was studied that the FC release was not associated with any 
surface phenomena. Shape and surface appearance of FC-PLGA NP did not differ from 
those of FA-PLGA NP. Possible explanations for the fast FC release are that either the 
hydrophilic compound diffuses out of the core very fast or that the w/o/w emulsification 
method led to an imperfect encapsulation due to the instable nature of the emulsion 
droplets during the preparation process. In conclusion, FC-PLGA NP, in contrast to FA-
PLGA NP, do not appear to be suitable for particle visualization studies over a longer 
period of time due to a rapid loss and a rather low and insufficient residual amount of 
encapsulated compound. 
The zeta potential of FA-PLGA NP was -1.4 mV. Generally, highly negative zeta potential 
values are expected for pure polyester NP from non-end capped PLGA due to the 
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presence of carboxyl groups on the polymeric chain extremities. 110 However, in this 
study, PLGA with around 65% of chain end groups being covalently bound to FA was 
used. This has possibly led to the less negative surface charge. Another factor may be 
residual PVA from the preparation process. It is reported that this polymer can create a 
shield between the NP surface and the surrounding medium, thus masking possible 
charged groups on the particle surface 110 whilst protecting the NP from aggregation. 
Using SPM, changes in morphology and in elastic and/or adhesive properties of the 
FA-PLGA NP were studied within long-term degradation (Figure 7).  
 
 
Figure 7: SPM topography and phase images of degrading FA-PLGA NP after week 0, week 1, and 
week 7. The size of all images is equal (bar = 500 nm).142 
 
NP made of PLGA have been shown to predominantly erode in bulk103 which is 
characterized by the formation of pores enabling water to penetrate into the particles 
followed by a random cleavage of the ester bonds. During that process, the particle 
core and size generally remain constant. This complies with the findings in size 
measurements: the mean particle size did not change notably during the experiment. At 
the beginning of the experiment, the NP were spherical and exhibited a smooth surface. 
After 1 week, pore development became apparent which continuously proceeded until 
week 7 followed by a surface smoothening after 15 weeks. In association with pore 
formation and degradation, a change in the elastic and/or adhesive properties was 
found which can be explained by a swelling process. This might also be a possible 
explanation for the particle surface smoothening found after 15 weeks of degradation. 
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Lyophilisation is one of the most suitable methods in order to stabilize and to facilitate 
the handling of nanoparticulate systems which would suffer alteration in a brief period of 
time if stored as suspension.138 With regard to application in a clinical study, it is highly 
important that lyophilised NP can be easily re-constituted before application to patients. 
Several authors have claimed that an addition of cryoprotectants is necessary in order 
to prevent PLGA NP from aggregation during lyophilisation and to maintain the integrity 
after re-hydration of the lyophilised samples.115, 138, 144, 146 However, in the present study it 
was found that NP from FA-PLGA maintained their size and still showed narrow size 
distribution when lyophilised without any additives. In literature, this behaviour was 
described as an effect of the stabilizer PVA used for the preparation of NP139, 147, 148 
forming a stable thick layer on the particle surface.147 Similar to other cryoprotectants, 
PVA is described to form a glassy state at low temperature due to hydrogen bonding 
between the polymer and the water molecules, thus stabilizing NP during lyophilisation 
and preventing particle aggregation.139 
Finally, FA-PLGA NP were applied on an in vitro model of the intestinal mucosa (Caco-
2 cell culture) in order to evaluate the interaction with intestinal epithelial cells, 
addressing absorption and potential cytotoxicity. A transport of FA-PLGA NP across 
Caco-2 monolayers was not observed. The transport of their fluorescent degradation 
products (~ 0.02% after 6 h) was even approximately 500 times smaller than that of the 
low permeability marker FC. This result was attributed to a high molecular weight when 
FA is additionally bound to short lactide-glycolide chains. No additional transport 
mechanism except diffusion seemed to be activated. 
For an in vivo application in a clinical study in humans, FA-PLGA NP were assayed for 
their cytotoxic effects on Caco-2 cells. The IC50 value was shown to be 10 mg/ml. It was 
of the same order as found with NP from pure PLGA which is well-known for its 
excellent biocompatibility.149 Apparently, covalent labelling of PLGA with FA did not 
affect the cytotoxic potential of the NP. With respect to a potential absorption of FA-
PLGA NP from the lumen of the intestine, the results from the Caco-2 transport 
experiments indicate that only the degradation products are transported across the 
intestinal epithelial barrier. Even if absorption due to a compromised barrier function of 
the intestinal mucosa under conditions of IBD might occur to some extent, a 
progressive shortening of the polymer chains would facilitate their elimination. 
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Excised intestine from pig served as a model for a first evaluation of particle 
visualization and quantification in intestinal tissue. Using confocal laser scanning 
microscopy (CLSM), FA-PLGA NP could be well visualized in different depths of the 
tissue. The detection limit of such NP in the presence of tissue samples is 3 μg/ml 
suggesting that extraction of biopsies taken from IBD patients may represent an 
additional way to quantify particle accumulation in inflamed intestinal tissue. 
 
4.2 Application of fluorescent and drug containing nanoparticles to investigate skin 
permeation and penetration 
 
4.2.1 Nanoparticles – an efficient carrier for drug delivery into the hair follicles 
Follicular penetration represents an important and encouraging pathway into the 
skin with potential use in selective dermatotherapy and cosmetics. Several studies have 
shown that not only single drug molecules but also NP can use this route of penetration 
into the skin.8, 43 However, penetration and storage features of topically applied NP 
formulations still need to be explored in detail. The aim of the present investigations 
was to compare the efficacy of penetration and storage in hair follicles of compounds in 
free and nanoencapsulated form. 
For that purpose, fluorescence labelled NP (referred to as `dye-in-particle-form´; 
formulation described in chapter 4.1) and a particle-free FC formulation of the same 
dye concentration (referred to as `dye-in-non-particle-form´) were employed. 
The penetration of the dye into the hair follicles was investigated in vitro using porcine 
ear skin, which is an appropriate model for human tissue.150 The penetration depths of 
the fluorescence dye deriving from both formulations were determined by analyzing 
biopsies by means of laser scanning microscopy. It was shown that the dye-in-particle-
form penetrated significantly deeper into the hair follicles than the dye-in-non-particle-
form, if a massage had been applied. Without massage, similar results were obtained 
for both formulations. Thereby, the penetration depth was significantly decreased in 
comparison to the penetration depth after a massage. 
Figure 8 exhibits superpositions of transmission and a fluorescence microscopy 
images. They demonstrate the penetration of dye-in-particle-form (A) and dye-in-non-
particle-form (B) into hair follicles of porcine skin after application of a massage. 
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Figure 8: Superposition of a transmission and a fluorescence microscopy image showing the penetration 
of dye-in-particle-form (A) and dye-in-non-particle-form (B) in vitro into the hair follicles of porcine skin 
after application of a massage. The dye derived from both formulations is displayed in red.151 
 
From structure analysis of hair surface and hair follicles, it is well known that the cuticle 
produced by keratinocyte desquamation forms a structured surface, which can be 
approximated by a zigzag relief.152 This relief is determined to a range of 500 to 800 nm 
by the thickness of the keratin cells. When the hairs are moved by a massage, the 
cuticle may act as a geared pump pushing particles in the size order of the surface 
structure of the hairs and hair follicles into the follicles. These results are in agreement 
with those obtained by Toll et al.43 They found that particles of 750 nm penetrated better 
into hair follicles of excised human skin than larger particles and that the penetration 
could even be enhanced by a mechanical massage. Under in vivo conditions, the 
assumed pump mechanism may occur without a massage on account of the 
continuous movement of the body stimulating the terminal and vellus hairs. 
The storage behavior of both formulations in hair follicles was analyzed in vivo on 
human skin by means of differential stripping after penetration times up to 10 days.44 
Thereby, the upper part of the stratum corneum, which serves as a reservoir for 
topically applied substances, was removed by tape stripping as described by 
Weigmann et al.,153 and the fluorescence dye (particle-form and non-particle-form) in 
the hair follicle infundibula was determined semi-quantitatively by extraction of 
cyanoacrylate biopsies at different time points after application. As depicted in Figure 9, 
the concentration of the fluorescence dye in the hair follicles decreased with time. If the 
skin had been treated with the dye in the non-particle-form, the dye was detected only 
up to 4 days. However, in case of the dye-in-particle-form, fluorescence was still found 
10 days after application. 
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Figure 9: Semi-quantitative determination of the fluorescence dye (particle-form and non-particle-form) in 
the hair follicle infundibula at different time points after application (mean ± SD).151 
 
The in vivo storage experiments demonstrated that penetration of the fluorescence dye 
out of the hair follicles is a relatively slow process for both formulations, when 
compared to the penetration into the hair follicles. The obtained results can be 
explained as follows: as soon as the reservoir of the skin surface and the stratum 
corneum, as source of the dye penetrating into the hair follicles, is depleted by textile 
contact and desquamation, the sebum production seemed to be mainly responsible for 
the removal of the formulations out of the hair follicles. Thereby, it is assumed that the 
dye in non-particle form was quickly removed joining the sebum excretion, whereas the 
release of particles from the hair follicles was retarded by the surface structure. 
Considering studies on follicle penetration of TiO2 microparticles,
154 it can be 
hypothesized that all particles larger than 100 nm, which penetrated into the hair 
follicles, will be removed after some time on account of the sebum production without 
having reached living cells.  
In conclusion, by means of fluorescence labelled NP it was possible to demonstrate the 
superiority of a particle versus a non-particle formulation concerning penetration and 
storage of the delivered dye as a model for any other compound in hair follicles. It is 
hypothesized that these results are effects of the surface structure of the skin, in 
particular of the cuticle, which may act as a geared pump pushing particles deeper into 
hair follicles than smaller sized compounds, at the same time decelerating their removal 
by sebum excretion. 
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4.2.2 Multiphoton microscopy for the investigation of dermal penetration of nano-
particle-borne drugs 
The study `Multiphoton microscopy for the investigation of dermal penetration of 
nanoparticle-borne drugs´ describes the application of multiphoton microscopy (MPM) 
to a non-invasive, high-resolution three-dimensional (3D) visualization of fluorescence 
labelled NP on excised human skin. It allowed to simultaneously localize the NP and to 
study the release, accumulation, and penetration of a model drug which was 
incorporated into the NP, thereby even discriminating between particle-bound and 
released compound.  
Major challenge of those investigations was the development of an appropriate NP 
model consisting of a carrier labelled by means of a fluorescence dye and a drug to be 
released. Since most pharmaceutical substances are basically non-fluorescent it was 
reasonable to use a second fluorescence dye as fluorescent drug model. The 
fluorescence label had to meet the demands (i) stable labelling in case of the dye for 
the NP cores, (ii) release from the NP in case of the model drug, (iii) different excitation 
and emission wavelengths, and (iv) preferably small cross-talk. In order to meet these 
criteria, the fluorescent PLGA NP formulation described in chapter 4.1 was advanced. 
FA-PLGA was used as a polymer for NP preparation employing a single emulsion 
method. Thereby, the second fluorescence dye Texas Red®, chosen as a model drug, 
was physically dissolved in the polymer matrix. The fluorescence dyes exhibited 
excitation and emission maxima at 485 and 510 nm in case of the green polymer bound 
dye FA, and at 596 and 615 nm in case of the red dye Texas Red. 
The mean size of two-colour labelled NP was 290 ± 5 nm (Figure 10A). Via SPM 
homogeneity, spherical shape and a smooth surface of the particles was verified 
(Figure 10B). 
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    A B       
Figure 10: Histogram of the particle diameter d obtained by PCS (the line is a Gaussian fit to the data) (A) 
and a 2 x 2 μm SPM topography image of two-colour fluorescence labelled NP (B) (bar = 200 nm).155 
 
In preliminary experiments, successful nanoencapsulation and different release 
characteristics of both fluorescence dyes were confirmed: simultaneous fluorescence 
imaging after excitation at 488 and 568 nm using CLSM revealed the same pattern of 
red and green fluorescent NP; it further indicated a release of the red label Texas Red, 
whereas the green label FA appeared to remain NP-bound. 
Multiphoton fluorescence imaging enabled 3D tracing of individual NP, embedded in a 
1.5% Natrosol® hydrogel, with diffraction-limited resolution and allowed detailed studies 
on the migration in the skin. Due to the significant endogenous fluorescence of keratin 
under two-photon excitation at a wavelength of 800 nm the outermost layer of the 
stratum corneum could be imaged and hence, the dermal topography. Obviously, the 
fluorescence labelled NP were not able to penetrate the stratum corneum and stayed in 
the gel-filled dermatoglyphs over 5 h. This corresponds with findings described in 
chapter 4.2.3 where penetration of flufenamic acid loaded PLGA NP into human skin 
was not found. Via this imaging mode, changes in the background fluorescence 
intensity of the ointment matrix and the stratum corneum were not observed as a 
consequence of the release and accumulation of Texas Red. The reason for this result 
is the comparable low two-photon absorption cross-section of Texas Red at 800 nm 
while FA and keratin are efficiently excited. 
To investigate the distribution of the model drug Texas Red as a function of time, two-
photon spectral imaging was performed. Whereas the Texas Red content in the NP 
showed up to be low and basically constant, the concentration of Texas Red in the gel 
matrix dropped significantly with time starting already from the earliest measurement 
after 30 min. This result indicated that the vast fraction of Texas Red was taken up from 
Results and discussion 
 38 
the gel to the stratum corneum surface almost immediately after application. 
Furthermore, the release of Texas Red from the NP to the matrix had obviously started 
well before application to the skin. An increase of Texas Red concentration in the 
deeper stratum corneum and stratum granulosum showed a slow penetration of the 
dye. 
Finally, a multitracking experiment was performed in order to co-localize the distribution 
of Texas Red, FA and keratin fluorescence roughly 5 h after the application of 
fluorescence labelled NP. By this technique optical sections were recorded up to a 
depth of -32 μm. Figure 11 shows an optical section in -20 μm depth. 
 
 
Figure 11: 325 x 325 μm2 optical sections in -20 μm depth obtained in multitracking experiments. Figure A 
represents a multiphoton excited image (predominantly keratin autofluorescence and FA), Figure B a 
488 nm excited image (FA), and Figure C a 543 nm excited image (Texas Red). Figure D was obtained by 
an overlay of the images A, B, and C (bar = 100 μm).155 
 
The 488 nm excited image proves, that FA was strictly bound to the NP and not 
released during the time of observation. In chapter 4.1 a leaking of fluorescent 
degradation products from particles of the same polymer FA-PLGA was shown. 
However, in this study, no such phenomenon was found. In the 543 nm excited images 
the distribution of Texas Red, which penetrated the skin and accumulated in the stratum 
corneum, is visible. The predominant fraction of the dye was found within the skin, but 
the particles were also slightly observable. Obviously, there was still a certain amount of 
the dye stored in the NP, though the release process had proceeded far. 
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In conclusion, MPM combined with spectral imaging was found to allow non invasive 
long term studies of the penetration of a particle-borne drug-model into skin with sub 
cellular resolution. Due to virtually no out-of-focus effects of the scanning laser beam,156 
this technique is considered as gentle for in vitro and in vivo studies. By dual colour 
labelling a clear discrimination between particle-bound and released drug-model was 
possible. Due to the excitation of endogenous fluorophores of the skin by multiphoton 
excitation and the correlation of the resulting autofluorescence image to the drug 
fluorescence pattern the identification of accumulative spots and penetration pathways 
was possible with sub-cellular resolution. 157, 158 
 
4.2.3 Influence of nanoencapsulation on human skin transport of flufenamic acid 
In the subsequent studies, the influence of nanoencapsulation on the permeation 
and penetration of the lipophilic model drug flufenamic acid (FFA) into excised human 
skin was investigated. Therefore, PLGA NP were chosen as a valuable carrier system 
and the NP mediated transport of FFA was compared with the transport of the free 
drug. 
For the preparation of flufenamic acid nanoparticles (FFA NP), a single emulsion 
method was studied to be most appropriate resulting in a drug entrapment of 64% 
(w/w). FFA NP were in the size order of 330 nm and narrowly distributed (PI = 0.16). By 
means of SPM imaging spherical particle shape and smooth surface were confirmed 
(Figure 12A). In order to increase the viscosity of the preparations applied on the skin, 
FFA NP were incorporated in a 1.5% Natrosol® hydrogel. SPM imaging evidenced 
homogeneous distribution and conserved integrity of FFA NP in the hydrogel 
(Figure 12B). 
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Figure 12: 3D SPM topography images of FFA NP in aqueous solution (A) and incorporated into a 
Natrosol hydrogel (B). 
 
Comparing the transport of FFA derived from a NP hydrogel with that from a hydrogel 
containing the same concentration of free drug, two different in vitro test systems were 
employed. Thereby, excised human skin from abdominal plastic surgery was used for 
all penetration and permeation experiments: For monitoring drug penetration, the 
Saarbruecken model159 was used where the skin itself acts as a receptor compartment. 
A tape stripping technique followed by cryosectioning of the deeper skin layers allowed 
quantification of the penetrated drug amount. Drug release from the formulation and 
drug permeation through the epidermis were studied using a static Franz diffusion cell 
technique. No difference in drug transport into the stratum corneum was found between 
nanoencapsulated and free drug. The drug accumulation in the deeper skin layers and 
the drug transport across human epidermis was slightly delayed for the 
nanoencapsulated drug compared to the free drug after shorter incubation times 
(< 12 h). In contrast, after longer incubation times (> 12 h) the nanoencapsulated drug 
showed a statistically significantly enhanced transport and accumulation (P < 0.05).  
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The mechanisms by which NP increased the amount of FFA in deeper skin layers at 
longer incubation times remained unclear. However, it may be speculated that the 
degradation of NP leads to some release of acidic compounds (lactic and glycolic 
acid). The acidification of particles and their surroundings might favour the non-ionised 
form of FFA, thus exhibiting improved penetration in the stratum corneum. PH changes 
of PLGA particles as consequence of degradation have also been reported by Fu et al. 
160 earlier. Another explanation might be that NP were able to cross the stratum 
corneum as described by Kohli et al.161 after a certain incubation time, subsequently, 
leading to an increase in the drug amount taken up. 
To verify the presence and to visualize the distribution of the applied NP on the skin, 
MPM was used after an incubation time of 30 min. As expected, structure and 
autofluorescence of the skin corresponded to published data.156 FFA NP were found 
homogeneously distributed on the skin surface and within the dermatoglyphs, but no 
NP were detected within or between the corneocytes. No hair follicles or sweat glands 
were observed. Consequently, possible transport of nanoparticles by transappendageal 
routes such as previously reported by several authors8, 43, 162 could not be confirmed in 
this study. However, visualization of drug transport processes of NP especially using 
longer incubation times (>12 h) is still ongoing and subject of further investigations. 
 
4.3 Surface biotinylated nanoparticles for coupling of versatile ligands 
Generally, nanoparticulate drug targeting systems may bear different 
functionalities. The inner functionality is reflected by the NP core which encapsulates 
the active moiety, thus acting as a stabilizer and controlling drug release. 
Complementarily, the outer functionality of a NP is represented by the NP surface which 
may establish specific and non-specific interactions with the target. However, in most 
cases, common preparation techniques of polymeric NP need to be specifically 
arranged for each compound to be entrapped or attached. The aim of the study 
`Coupling of biotin-(polyethyleneglycol)amine to poly(D,L-lactide-co-glycolide) 
nanoparticles for versatile surface modification´ was to develop a procedure for surface 
functionalization of preformed NP, which may eventually already contain active 
pharmacological ingredients, for subsequent versatile conjugation of targeting ligands 
and fluorescence dyes under mild conditions. For such purpose, the avidin-biotin 
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system was chosen as avidin (Av) and its homologues streptavidin (SAv) and 
NeutrAvidinTM (NAv) exhibit very high affinities (Kd = 10
 -13 – 10 -16 M) and a rapid and 
stable binding to biotin. 163, 164 Taking into consideration the presence of free carboxylic 
acid groups on the surface of NP made of poly(esters), it was opted for an approach 
where biotin-(polyethyleneglycol)amine (BPEG) functionalized NP (BPEG PLGA NP) 
bind to conjugates of Av (or homologues). Consequently, both targeting moieties as 
well as fluorescence labels can be easily linked to the surface of thus functionalized NP 
as long as they are available as conjugates of Av (or homologues) (Figure 13A). 
 
 
Figure 13: Schematic illustration of a surface modified PLGA NP by means of BPEG. Figure 13A gives an 
overview of the aims of the study. Versatile binding of targeting moieties is realized employing avidin (and 
homologues) conjugates. Binding of fluorescence dye conjugated avidin opens the possibility of an 
additional fluorescence labelling of the NP. Figure 13B represents a virtual zoom into the NP surface. 
Assuming homogenous distribution of the BPEG molecules on the NP surface, the mean distance is 
calculated to 69 Å. The length of the BPEG molecule is determined to roughly 46 Å. The size of avidin is 
reported to 50 Å × 50 Å × 40 Å with the biotin binding sites in a distance of 29.5 and 20 Å.165 
 
PLGA NP in the size of 210 nm were prepared by the classic oil-in-water method. 
Subsequently, BPEG PLGA NP were generated via a triazine-promoted amidation of the 
carboxylic acid groups present on the PLGA NP surface. The technique has been 
frequently described in the literature; 166-168 here it was adapted to surface modification 
of PLGA NP. Such functionalization did not involve an increase in size, i.e. any change 
in the hydrodynamic diameter was beneath the detection limit. The zeta potential 
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changed from -32 mV to -23 mV after surface functionalization. The negative surface 
charge of both particle species is attributed to the presence of carboxyl end groups 
deriving from PLGA chain ends. However, in case of the BPEG PLGA NP, the particle 
surface was partially shielded owing to covalent modification of the carboxyl groups by 
means of BPEG molecules. The amount of surface associated biotin was determined to 
850 pmol per mg polymer corresponding to roughly 2,650 biotin molecules on the 
surface of one single average-sized (210 nm) BPEG PLGA NP. Assuming that BPEG 
chains are evenly distributed on the NP surface, the mean distance of two chains would 
be 69 Å. The length of the BPEG chains was calculated to maximally 46 Å. In solution, 
one would expect the BPEG molecule to adopt a more or less coiled conformation, 
here however, to roughly estimate surface conditions it was deliberately assumed that 
the molecule exists in a stretched conformation. The size of Av is reported to 
50 Å × 50 Å × 40 Å with the biotin binding sites being in a distance of 29.5 and 20 Å to 
each other.169 The dimensions of such a BPEG functionalized NP surface is drawn to 
scale in Figure 13B indicating that each single BPEG graft on the NP surface should be 
well accessible to Av. 
SPM studies showed that surface modification of PLGA NP and binding of Av to BPEG 
PLGA NP did not lead to changes in particle shape and surface structure. Obviously, 
those modifications resulted in changes of elasticity or adhesion of the cantilever tip. By 
resonant mirror measurements the binding of BPEG PLGA NP with a NAv functionalized 
surface was studied (total binding) (Figure 14). A clear response was obtained, 
however the binding curve did not reach equilibrium during the measurement, possibly 
due to particle rearrangement on the NAv coated surface. Non-specific binding was 
studied by blocking the biotin binding sites of the same cuvette by free BPEG; it 
resulted only in a small response. The extent of specific binding of BPEG PLGA NP to 
the NAv surface is described by a calculated curve, which was obtained by subtracting 
the curve representing the non-specific binding from the curve representing the total 
binding. 
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Figure 14: Results of resonant mirror adhesion studies: interactions of BPEG PLGA NP with a NAv surface 
and a NAv surface with BPEG blocked biotin binding sites. An additional curve calculated as the 
difference of both binding curves represents the extent of specific binding.165 
 
Aiming for a quantification of protein binding to BPEG PLGA NP and PLGA NP, an 
inverse setup was applied in order to determine the non-particle associated amounts of 
FITC-NAv and horse radish peroxidase-streptavidin after incubation with BPEG PLGA 
NP and PLGA NP. In the course of this work, it was found that this method is not suited 
for such purposes as BPEG grafts may be sheared off the NP cores when separating 
the particles. Further complicating, the fluorescence intensity of FITC-NAv was studied 
to be dependent on the concentration of biotin and BPEG in the assay. Hence, applying 
a gentle NP separation method combined with a direct determination of particle bound 
proteins may represent a possibly successful alternative. 
For the first evaluation in a biological system, fluorescence labelled BPEG PLGA NP 
were used to demonstrate differences in binding and uptake behaviour between flat 
squameous epithelial cells from the alveolar epithelium (A549) in comparison to the 
relatively thick columnar epithelial cells from the intestinal mucosa (Caco-2). Dependent 
on the staining of the cell membranes NP decorated with different fluorescent NAv 
conjugates were applied, thus demonstrating the ease of versatile fluorescence 
labelling of BPEG PLGA NP.
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Nanoparticles have recently been demonstrated in a rat model to be a promising tool for targeting
inﬂamed areas of the intestinal mucosa in inﬂammatory bowel diseases whilst concentrating anti-
inﬂammatory drugs at their site of action. Still, however, this novel concept has to be proven in vivo
in humans. As a ﬁrst step biodegradable and biocompatible ﬂuorescent nanoparticles were pre-
pared and characterized to serve as markers for successful inﬂammation targeting in future clinical
trials. To achieve stable ﬂuorescence labelling, ﬂuoresceinamine was covalently bound to poly(L-
lactide-co-glycolide) (PLGA) as described by Horisawa et al. The modiﬁcation rate of carboxyl-end
groups of the PLGA chains determined by 1H NMR was 65%. From this modiﬁed polymer, nanopar-
ticles (FA-PLGA nanoparticles) of approximately 270 nm size were prepared via nanoprecipitation.
Apart from an initial burst effect, most of the label (>88%) appeared to be strongly bound and was
leaked only slowly from the particles. In contrast, we found an immediate leakage of encapsulated
sodium ﬂuorescein with nanoparticles prepared by a double emulsion method. In degradation exper-
iments we studied and visualized the changes in morphology and elastic properties of the FA-PLGA
nanoparticles within 15 weeks using atomic force microscopy. When FA-PLGA nanoparticles were
applied on an in vitro model of the intestinal mucosa (Caco-2 cell culture), only minor amounts of
their ﬂuorescent degradation products (∼0.02% after 6 h) were transported. In a cytotoxicity study
with Caco-2 cells, FA-PLGA nanoparticles yielded an IC50 value as for plain PLGA nanoparticles. In
conclusion, the polymer modiﬁcation method allows to prepare ﬂuorescently labelled nanoparticles
from a well-known biodegradable pharmaceutical polymer with sufﬁcient stability to be monitored
over a period of several days. Some initial leakage of ﬂuorescence label appears to be unavoidable
but negligible with respect to potential absorption and cytotoxicity when applied in vivo.
Keywords: Fluoresceinamine, PLGA Modiﬁcation, Atomic Force Microscopy, Caco-2 Cells,
Cytotoxicity, NMR.
1. INTRODUCTION
In the recent years, polymeric nanoparticles have turned
out to be a promising tool for the targeted delivery of drugs
to speciﬁc anatomical sites. Nanoparticles may exhibit sig-
niﬁcant interactions with the intestine,1 the skin,23 the
blood brain barrier,4 and various other tissues of interest.
In general, drug targeting at the cellular or tissue level
appears to be size-dependent.5 Smaller particles seem to be
taken up to a higher degree than larger ones, representing
a crucial advantage of nanoparticles over microparticles.
Concerning the intestine, polymeric particulate carrier
systems have potential for targeting of inﬂamed areas of
the gut mucosa in inﬂammatory bowel diseases (IBD).
∗Author to whom correspondence should be addressed.
Previously, some size dependent accumulation and pro-
longed retention of orally administered micro- and nano-
particles in the affected regions of the large intestine have
been studied in rats, suggesting that the smaller the parti-
cle size the better the binding to the inﬂamed tissue.1 The
standard treatment of IBD involves the frequent intake of
anti-inﬂammatory drugs at high doses. In general, these
drugs are administered orally and become systemically
bioavailable, often leading to strong adverse effects. Thus,
targeting the inﬂamed areas of the intestine and, hence,
concentrating the drug at its site of action can reduce pos-
sible systemic adverse effects. This has previously been
demonstrated in a rat colitis model by our group6 using
rolipram as an anti-inﬂammatory model drug. Further-
more, as generally known, polymeric nanoparticles can be
J. Nanosci. Nanotechnol. 2006, Vol. 6, No. 8 1533-4880/2006/6/001/009 doi:10.1166/jnn.2006.424 1
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designed to control drug release. Therefore, the use of
nanoparticles also implicates the possibility to reduce the
dosage frequency.
Considering these promising results in animals, a proof
of concept for this novel targeting approach in IBD must
be provided in humans. For such purpose, drug-free but
ﬂuorescence-labelled nanoparticles are needed to show
their accumulation in inﬂamed areas of the colonic mucosa
in IBD patients by ﬂuorescence microscopy. At the same
time non-toxicity and biocompatibility of the nanoparti-
cles are essential requirements, and as a consequence the
choice of their components is rather restricted. Among the
pharmaceutical polymers, poly(D,L-lactide-co-glycolide)
(PLGA) appears as most suitable because this material is
biocompatible, biodegradable, and part of several regis-
tered and marketed drug and medicinal products even for
parenteral applications.7–10 As a ﬂuorescence marker, ﬂuo-
rescein is well common, being also applied in high doses
for diagnostic purposes, e.g., the usual dose for retinal
angiography in adults is the equivalent of 500 mg given
by rapid intravenous injection.11
However, it is still crucial for intended studies that
the ﬂuorescence label remains ﬁrmly associated with the
nanoparticles over an appreciable period of time i.e., a
burst effect and a subsequent leakage of the ﬂuorescent
label must be minimized as far as possible. Though, this
is not trivial when dealing with nanoparticles made of a
biodegradable polymer.
In the present study, ﬂuorescent biodegradable and bio-
compatible nanoparticles for the purpose of future in vivo
endoscopic investigations of IBD in humans were pre-
pared. The ﬂuorescein derivative 5-ﬂuoresceinamine (FA)
was chemically bound to PLGA by a simple one-step
reaction.12 Nanoparticles made from this modiﬁed poly-
mer (FA-PLGA nanoparticles) were characterized for their
in vitro leakage of ﬂuorescence marker, size, charge,
and morphology. For comparison, ﬂuorescently labelled
nanoparticles were also prepared by nano-encapsulation
of sodium ﬂuorescein with non-modiﬁed PLGA using a
double emulsion method (FC-PLGA nanoparticles). The
morphology of nanoparticles was imaged within long-term
particle degradation using atomic force microscopy and the
development of the surface structure as well as the changes
of the physical parameter elasticity during degradation
were monitored. Furthermore, nanoparticles were applied
to Caco-2 cell monolayers in order to evaluate the interac-
tion with intestinal epithelial cells, addressing absorption
of degradation products and potential cytotoxicity.
2. METHODS AND MATERIALS
2.1. Materials
Poly(L-lactide-co-glycolide) (PLGA) (Resomer RG 50:50
H; inherent viscosity 0.31 dl/g) was kindly provided
by Boehringer Ingelheim (Boehringer Ingelheim GmbH
& Co., KG, Ingelheim, GE). 5-Fluoresceinamine (FA),
sodium ﬂuorescein (FC), and 1-ethyl-3-(3-Dimethyl-
aminopropyl)-carbodiimide hydrochloride (DMAP) were
obtained from Sigma (Sigma Chemical Co., St. Louis,
MO, USA). Polyvinylalcohol (PVA) (Mowiol 4-88) was
purchased from Kuraray (Kuraray Specialities GmbH,
Frankfurt am Main, GE). Dulbecco’s modiﬁed Eagle’s
medium (DMEM), non-essential aminoacids (NeAA), and
fetal bovine serum (FBS) were provided by GIBCO (Invit-
rogen Corp., Carlsbad, CA, USA). All other chemicals
were of analytical grade. Hank’s balanced salt solution
(HBSS) was composed of: NaCl 8.000 g/L, KCl 0.400 g/L,
NaHCO3 0.358 g/L, Na2HPO4 0.048 g/L, KH2PO4
0.06g/L, glucose 1.000 g/L, HEPES (C8H18N2O4S)
2.388 g/L, CaCl2 0.140 g/L, MgCl2 0.047 g/L, MgSO4×7
H2O 0.100 g/L. Phosphate buffered solution pH 7.4
(PBS) was composed of KCl 0.20 g/L, NaCl 8.00 g/L,
KH2PO4 0.20 g/L, Na2HPO4 × 2H2O 1.44 g/L. Graphs
were ﬁtted using SigmaPlot 8.0 (SPSS Inc., Chicago, IL,
USA) and results are expressed as mean±SD or as range.
2.2. Preparation of Nanoparticles
2.2.1. Polymer Labeling and Preparation of
FA-PLGA Nanoparticles
FA bound PLGA (FA-PLGA) was prepared based upon
the method described by Horisawa et al.12 Brieﬂy, PLGA
(3.07 g) and FA (0.0583 g) were dissolved entirely in
30 ml of acetonitrile with 0.0408 g of DMAP and incu-
bated at room temperature for 24 h under light pro-
tection and gentle stirring. The resulting FA-PLGA was
precipitated by the addition of puriﬁed water and sep-
arated by centrifugation. The polymer was rinsed from
excessive reagents (repeated dissolvation in acetone and
precipitation with ethanol) and then lyophilized (Alpha 2-
4 LSC, Martin Christ Gefriertrocknungsanlagen GmbH,
Osterode, GE).
FA-PLGA nanoparticles were prepared by interfacial
polymer deposition (nanoprecipitation) as described by
Fessi et al.13 100 mg of FA-PLGA were dissolved in
16 ml of acetone at room temperature. After addition of
3 ml of ethanol, the polymer solution (ﬁnal concentration
5.3 mg/ml) was pumped into 25 ml of a 0.5% PVA solu-
tion in puriﬁed water in order to induce polymer precipita-
tion and thus particle formation. Thereby, the system was
gently stirred with a magnetic stirrer. Finally, the resid-
ual organic solvent was removed using a rotary evaporator
and the nanoparticles were lyophilized. Nanoparticles were
prepared with a total of n= 4.
2.2.2. Preparation of FC-PLGA Nanoparticles
FC-PLGA nanoparticles were prepared employing a dou-
ble emulsion (W1/O/W2) method.
1415 The ﬁrst emulsion
(W1/O) was formed between an organic polymer solution
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(100 mg PLGA in 5 ml ethyl acetate) and an aqueous
solution, which was 100 l HBSS containing 0.5 mg/ml
of FC, under stirring on a magnetic stirrer for one hour.
Then, the W1/O emulsion was emulsiﬁed into 5 ml of 1%
PVA solution. Stirring was continued for two more hours
resulting in a W1/O/W2 double emulsion which was then
homogenized using an Ultra-Turrax T 25 Mixer (Janke
und Kunkel GmbH & Co., Staufen, GE) at 13,500 rpm.
Organic solvent was again removed by a rotary evaporator.
Nanoparticles were dialyzed using a standard dialysis tube
(cellulose ester, cut-off 14,000 Da) against 2 l of deminer-
alized water for 24 h and immediately lyophilized.
The FC content of FC-PLGA nanoparticles was deter-
mined after dissolvation in 0.1 N NaOH. Samples were
diluted in PBS, the ﬂuorescence was quantiﬁed using
a Cytoﬂuor II ﬂuorescence reader (PerSeptive Biosys-
tems, Wiesbaden-Norderstedt, GE) and the mean FC con-
tent per mg of nanoparticles was calculated. FC-PLGA
nanoparticles were prepared and analyzed with a total of
n= 3–5.
2.2.3. Preparation of PLGA Nanoparticles
PLGA nanoparticles were prepared from non-labelled
polymer according to the procedure described in 2.2.1
using a 5.3 mg/ml PLGA and a 0.5% PVA solution.
2.3. FA-PLGA Labelling Efﬁciency
The polymer labelling efﬁciency, i.e., the average per-
centage of modiﬁed PLGA chains by a covalent coupling
of FA, was determined via 1H NMR. About 30 mg of
a FA-PLGA sample were dissolved in 0.6 ml DMSO-
d6 (99.9% D) and a
1H NMR spectrum (500 MHz) was
measured using the standard pulse program for protons.
256 scans were used to get an adequate signal-to-noise
ratio especially for the protons of the FA moiety. The
relaxation delay was set to 10 s to allow the magnetization
to achieve equilibrium. To calculate the PLGA-FA ratio
the integrals of the six xanthene protons (6.4 to 6.8 ppm)
of FA and those of the three H atoms of the methine
and methylene groups of the lactide-glycolide dimer of
PLGA were deﬁned. The polymer labelling efﬁciency
was determined with n = 5 different polymer batches.
All measurements were performed at 298 K using a
Bruker Avance 500 spectrometer (Bruker BioSpin GmbH,
Rheinstetten, GE). Chemical shifts are given in parts per
million (ppm) on the  scale referenced to the DMSO-d6
solvent peak at 2.50 ppm.
2.4. Physicochemical Characterization of
the Nanoparticles
2.4.1. Particle Size and Surface Charge (Zeta Potential)
For determination of particle size and zeta potential,
the nanoparticle dispersions were 100 fold diluted in
demineralized water and analyzed using a Zetasizer 3000
(Malvern Instruments, Malvern, U.K.). The measurement
of the nanoparticle size was based upon photon correla-
tion spectroscopy (PCS). This technique yields the particle
mean diameter and the polydispersity index (PI) which is
a dimensionless measure for the broadness of the parti-
cle size distribution. The zeta potential was analyzed by
laser doppler electrophoresis (LDE) within a range from
pH 2 to pH 10 using the automatic titration device MPT-1
(Malvern Instruments, Malvern, U.K.).
2.4.2. Morphology Studies of FA-PLGA Nanoparticles
Nanoparticle surface and shape were imaged by atomic
force microscopy (AFM). For sample preparation, a drop
of a freshly prepared nanoparticle suspension was mounted
on a silicon wafer and air-dried. Imaging was performed
by a BioscopeTM AFM and a Nanoscope IVTM con-
troller (Veeco Instruments, Santa Barbara, CA, USA) in a
vibration-free environment. For all measurements, Tapping
modeTM was employed using a commercially available
pyramidal tip (silicon, Ultrasharp, MikroMasch, Tallinn,
EST) on a cantilever with a length of 230 m. The reso-
nance frequency was approximately 170 kHz, the nominal
force constant 40 N/m, and the scan frequency between
0.1 and 1 Hz.
2.4.3. In Vitro Leakage of Fluorescence Markers
Lyophilized nanoparticles (10–25 mg) were suspended in
a ﬂask containing 100 ml of PBS and incubated in a
horizontal oscillating water bath at 120 rpm and 37 C.
1.0 ml samples were withdrawn at appropriate time inter-
vals and centrifuged for 10 min at 23147± 66 g. The
supernatant was removed and assayed for the leakage
of ﬂuorescence markers from FA-PLGA and FC-PLGA
nanoparticles, respectively. In pre-experiments, a sepa-
ration of nanoparticles in the size order of 270 nm
under these centrifugation conditions has been conﬁrmed
(no nanoparticles in the supernatant detectable by PCS).
Nanoparticle suspensions were ﬁlled up to 100 ml again
with fresh PBS at each sample point. The amount of
leaked ﬂuorescence marker was evaluated by ﬂuorescence
spectroscopy using excitation and emission wavelengths of
485 nm and 510 nm, respectively. The loss of nanoparticles
and ﬂuorescence marker due to sampling was calculated
and accounted for the results. References were lyophilized
nanoparticles which were dissolved in 0.1 N NaOH and
then diluted in PBS in case of FA-PLGA nanoparticles,
and a FC solution in PBS in case of FC-PLGA nanopar-
ticles. Linearity was given from 0.5 to 26.5 g/ml of
FA-PLGA nanoparticles R2 > 0995	 and from 3.13 to
50.0 ng/ml of FC R2 > 0999	. The whole experiment
was performed under protection from light and with a total
of n= 6.
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2.4.4. Thin Layer Chromatography (TLC)
Approximately 2 l of each test substance and ref-
erence was spotted on a silica gel 60 TLC plate
(Merck, Darmstadt, GE). Plates were developed in a cham-
ber by the ascending technique and solvent ascend was
ﬁxed at the height of 9 cm. After development, the plates
were withdrawn from the chambers and dried at room tem-
perature. The developed plates were analyzed via ﬂuores-
cence detection at 366 nm. Test substance was a 1 mg/ml
particle suspension. Thereby, 0.1 N NaOH was used as a
solvent in order to accelerate particle degradation. After
incubation at room temperature for 12 h, the test substance
was centrifuged for 10 min at 23147±66 g and the super-
natant was used for TLC. Reference was a 2 mg/ml FA
solution in ethanol. The mobile phase consisted of a mix-
ture of isopropanol-acetic acid (15:2, v/v).
2.4.5. FA-PLGA Nanoparticle Degradation
The physical stability of aqueous FA-PLGA nanoparticle
formulations was assessed over 15 weeks. The nanopar-
ticle suspension was dialyzed against PBS at room tem-
perature and under gentle agitation. A dialysis membrane
with a cut-off of 100,000 Da (Spectra Por CE, Carl
Roth GmbH, Karlsruhe, GE) was used and the buffer was
renewed every week. Samples were withdrawn from the
dialysis tube at appropriate time intervals and the effect
of dialysis time on nanoparticle size and morphology was
assessed using PCS and AFM, respectively.
2.5. Caco-2 Cell Culture
Caco-2 cells, clone C2BBe1, were purchased at passage 60
from American Tissue Culture Collection (ATCC; Manas-
sas, VA, USA) and used at passages 70 to 91. Cells were
grown to a conﬂuency of approximately 90% in 75 cm2
T-ﬂasks with DMEM supplemented with 10% FBS and 1%
NeAA. Thereby, the culture medium was changed every
second day and the temperature was 37 C in an atmo-
sphere of around 85% relative humidity and 5% CO2.
2.5.1. Cytotoxicity
After trypsinization, Caco-2 cells were seeded on 96-
well tissue culture plates with ﬂat bottom (Greiner
Bio-One GmbH; Frickenhausen, GE) at a density of
roughly 60,000 cells/cm2 and grown for 7 days. Cyto-
toxicity was evaluated after 8 h incubation with a test
substance by the quantiﬁcation of plasma membrane dam-
age leading to a release of the cytosolic enzyme LDH.
It was then determined using the cytotoxicity LDH kit
as described by Roche Diagnostics (Roche Diagnostics
GmbH, Mannheim, GE). Experiments were performed
with n = 6 replications for each concentration using FA-
PLGA nanoparticles, PLGA nanoparticles and FC as test
substances.
2.5.2. Transport Assay
Cells were trypsinized and seeded on top of Transwell
permeable ﬁlter inserts (pore size 0.4 m, 4.67 cm2,
Corning Incorp., Life Sciences, Acton, MA, USA) at a
density of roughly 60,000 cells/cm2. 21 to 25 days after
seeding, Caco-2 monolayers with a transepithelial elec-
trical resistance (TEER) > 350 
 · cm2 (background sub-
tracted) were used for transport studies. The transport was
assessed in absorptive (apical to basolateral) direction.
Prior to the transport experiments, the monolayers were
incubated (30 min) with freshly prepared HBSS (pH 7.4,
37 C) on both sides. Subsequently, starting at t = 0 min,
a solution or suspension of the test substance was added
to the donor compartment and blank HBSS to the receiver
compartment.
Throughout the experiments, monolayers were agitated
using an orbital shaker (IKA-Werke GmbH & CO., KG;
Staufen, GE) at 100 rpm. Samples were taken after 30,
60, 120, 180, 240, and 360 min from the receiver com-
partment and the ﬂuorescence was determined using the
Cytoﬂuor II ﬂuorescence reader. After each sampling, an
equal volume of fresh transport buffer was added to the
receiver compartment. To ensure integrity of the monolay-
ers, TEER values were measured before the experiment,
after the 30 minutes of pre-incubation, and at the end of the
experiment. Maximum ﬂux was determined from a min-
imum of 4 data points using the steady-state part of the
permeated mass per cm2 versus time curve.
Test substances for the transport studies were (A)
lyophilized FA-PLGA nanoparticles freshly suspended in
HBSS at a concentration of 2 mg/ml, (B) lyophilized FA-
PLGA nanoparticles suspended in HBSS at a concentration
of 2 mg/ml and incubated at room temperature for 24 h
(partially degraded FA-PLGA nanoparticles), and (C) the
degradation products of FA-PLGA nanoparticles under the
conditions of (B) (supernatant of the partially degraded
FA-PLGA nanoparticles after centrifugation for 10 min at
23147± 66 g). Furthermore, a (D) 12 g/ml FC solution
in HBSS and a (E) 12 g/ml solution of FC in HBSS
containing additionally 2 mg/ml of PLGA nanoparticles
were used. All experiments were performed at 37 C with
n= 8–10 replications.
3. RESULTS
3.1. FA-PLGA Labelling Efﬁciency
As described by Horisawa et al.,12 FA was bound cova-
lently to the terminal carboxyl groups of the PLGA chains
by amide formation. By integration of well deﬁned pro-
tons of the PLGA polymer and those of the FA compo-
nent (see Section 2.3) the PLGA-FA ratio was found to be
1:220±13. Considering the mean molecular weight of the
polymer, which was 34,000 Da (according to the informa-
tions of the manufacturer) a modiﬁcation rate of approx-
imately 65% carboxyl-end groups could be estimated.
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1 µm
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Fig. 1. 1×1 m AFM topography images of FA-PLGA nanoparticles
in the size order of 270 nm (A) and FC-PLGA nanoparticles in the size
order of 250 nm (B) in 3D view.
This corresponds to a mean FA content of roughly
6000 ppm (w/w).
3.2. Physicochemical Properties
3.2.1. FA-PLGA Nanoparticles
PCS measurements showed that the mean particle size was
269.5± 21.1 nm with a PI of 0.13 to 0.21. FA-PLGA
nanoparticle shape and surface properties were visualized
by AFM. Figure 1A exhibits an AFM topography image
of the nanoparticles in the size order of 270 nm in 3D
view. The nanoparticle sample is prepared as a dense layer
on the silicon wafer. It is clearly visible that nanoparti-
cles are of spherical shape and feature a smooth surface
without any visible pores. The zeta potential of FA-PLGA
nanoparticles remained constant at −1.4± 0.5 mV in the
pH range from 2 to 9 (data not shown).
3.2.2. FC-PLGA Nanoparticles
In case of FC-PLGA nanoparticles, we determined a parti-
cle size of 249.3±8.5 nm (PI 0.01–0.16). As shown in the
AFM topography image (Fig. 1B) the shape and surface
properties of FC-PLGA nanoparticles do not differ from
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Fig. 2. Residual content of ﬂuorescence marker () in FA-PLGA
nanoparticles over 192 h (A) and 25 h (B). The experiment was per-
formed in PBS at 37 C. Data are shown as mean±SD n= 6	.
those of FA-PLGA nanoparticles. The mean FC content
was found to be 180±30 ppm (w/w).
3.2.3. PLGA Nanoparticles
PLGA nanoparticles exhibited a size of 187.6± 14.3 nm
(PI 0.06–0.10). Also, PLGA nanoparticles were spherical
and had a smooth surface (data not shown).
3.3. Leakage of Fluorescence Marker
3.3.1. FA-PLGA Nanoparticles
Decomposition of the FA-PLGA nanoparticles led to dif-
ferent ﬂuorescent degradation products and was assessed
via TLC where various ﬂuorescent bands besides the FA
band could be detected (data not shown).
Figure 2 shows the in vitro leakage proﬁle of FA-
PLGA nanoparticles in PBS, expressed as the percentage
of ﬂuorescence marker which is still nanoparticle bound
with respect to the amount of FA initially associated with
the nanoparticles 	. Obviously, an initial burst effect
occurred within the ﬁrst 2 h (Fig. 2B) resulting in a loss of
ﬂuorescence marker of 11.7%, followed by a simple expo-
nential decay of the form t	= 0+A · e−t with a time
constant of  = 001 s−1. This function was ﬁtted to the
data shown in Figure 2A. After 8 days (192 h) of incuba-
tion, still 60.8% of ﬂuorescence marker was nanoparticle
bound (Fig. 2A).
3.3.2. FC-PLGA Nanoparticles
In contrast to FA-PLGA nanoparticles where the ﬂuo-
rescence label is covalently bound to the polymer, FC-
PLGA nanoparticles obtained by nano-encapsulation of the
low molecular weight label sodium ﬂuorescein exhibited a
fast leakage which was 82.6± 15.7% of FC after 30 min
(Fig. 3).
J. Nanosci. Nanotechnol. 6, 1–9, 2006 5
6.1 Nanoparticles made of fluorescence-labelled poly(L-lactide-co-glycolide): preparation, stability, and
      biocompatibility
63
R
E
S
E
A
R
C
H
A
R
T
IC
L
E
Nanoparticles Made of Fluorescence-Labelled PLGA: Preparation, Stability, and Biocompatibility Weiss et al.
Time [hours]
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
R
es
id
ua
l F
C 
co
nt
en
t κ
 
[%
]
0
20
40
60
80
100
Fig. 3. Residual content of FC () in FC-PLGA nanoparticles over 4 h.
The experiment was performed in PBS at 37 C. Data are shown as
mean±SD (n= 6).
3.4. FA-PLGA Nanoparticle Degradation
Figure 4 presents the FA-PLGA nanoparticle morphology
over 15 weeks of incubation in PBS at room tempera-
ture. The AFM topography images show the changes of
the surface structure during the degradation process of the
sample. The changes of the elastic properties become vis-
ible in the phase contrast images. At the beginning of the
experiment, nanoparticles were spherical and exhibited a
Week 15
Week 7
Week 3
Topography Phase contrast 3D zoom
Week 1
Week 0
0.5 µm 0.5 µm
Fig. 4. AFM topography and phase contrast images of FA-PLGA
nanoparticles and a 3 D zoom of a random nanoparticle in the size order
of 280 nm. Nanoparticles were imaged after 0 weeks, 1 week, 3 weeks,
7 weeks, and 15 weeks of incubation in PBS at room temperature.
smooth surface. After one week of incubation, ﬁrst pit-
ting of the nanoparticle surface could be visualized. This
effect progressively continued until week 3 when the par-
ticles were observed to develop a porous outer appear-
ance. Until week 7 the number of indentations did not
rise signiﬁcantly whereas the depth of the indentations
increased. This could also be detected by measuring the
surface height properties in the AFM topography plot. In
week 15, the outer appearance of the nanoparticles did
not appear as porous any more. As indicated in the phase
contrast images, general changes in the surface seemed to
have occurred resulting in a smoothening of the surface.
PCS analysis of the nanoparticles revealed that the mean
particle size did not change notably. It was found to be in
the range of 282±8 nm in course of the incubation time
(data not shown).
3.5. Cytotoxicity
For experiments in biological systems, either in vitro or in
vivo, it is pivotal to obtain sufﬁcient ﬂuorescence signals at
particle concentrations well below the level that causes any
cytotoxic effects. Therefore, the cytotoxicity (tox) of FA-
PLGA nanoparticles, PLGA nanoparticles, and FC solu-
tion was studied, as diagrammed in Figure 5. In these
experiments, PLGA nanoparticles and FC were applied in
concentration ranges referred to their calculated content
within 0.02 to 64.00 mg/ml of FA-PLGA nanoparticles
(see Section 3.1).
It is obvious that the plots for either FA-PLGA or PLGA
nanoparticles are equally shaped and of the same scale,
in contrast to the FC solution curve which is signiﬁcantly
shifted to lower values. A sigmoidal function of the form
tox c	 = tox0+ acb/ICb50+ cb) was ﬁtted to each of the
curves in Figure 5. The IC50 values were 10.4±1.0 mg/ml
in case of the FA-PLGA nanoparticles (toxmax = 990%),
Concentration [mg/ml]
10–5 10–4 10–3 10–2 10–1 100 101 102 103
Cy
to
to
xic
ity
 (to
x) 
[%
]
0
20
40
60
80
100
FA-PLGA nanoparticles
PLGA nanoparticles
FC solution
Fig. 5. Cytotoxicity (tox) of FA-PLGA nanoparticles •	, PLGA
nanoparticles (), and sodium ﬂuorescein (FC) solution 	 on Caco-2
cells plotted against their concentrations. Data are shown as mean±SD
n= 6	.
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Table I. Flux and permeated amount of ﬂuorescence marker after 6 h in transport experiments across
Caco-2 monolayers n= 8–10	.
Permeated amount of
ﬂuorescence marker
Flux [g/cm2/min] after 6 h [%]
(A) FA-PLGA nanoparticles 1.58±0.59 ·10−6 0.016±0.006
(B) Partially degraded FA-PLGA nanoparticles 1.24±0.41 ·10−6 0.012±0.004
(C) Degradation products of FA-PLGA nanoparticles 0.97±0.26 ·10−6 0.010±0.002
(D) FC solution 6.24±0.36 ·10−4 4.767±0.448
(E) FC solution containing PLGA nanoparticles 4.75±0.96 ·10−4 3.117±0.780
205±35 mg/ml with the PLGA nanoparticles (toxmax =
765%	, and 268 ± 23 g/ml with the FC solution
(toxmax = 656%	.
A concentration of 2 mg/ml of FA-PLGA nanoparticles
corresponding to 2 mg/ml of PLGA nanoparticles and to
12 g/ml of FC (see Section 3.1) was chosen for transport
studies.
3.6. Transport Studies
Comparing the transport of the test substances across
Caco-2 monolayers, (A) FA-PLGA nanoparticles, (B) par-
tially degraded FA-PLGA nanoparticles, and (C) degrada-
tion products exhibited a maximum ﬂux between 0.97±
0.26 ·10−6 and 1.58±0.59 ·10−6 g/cm2/min and the per-
meated amount of the ﬂuorescence marker FA after 6 h
was in the range of 0.010± 0.002 to 0.016± 0.006%
(Table I). Both values were found to be roughly 500 fold
lower than with the (C) FC solution and the (D) FC solu-
tion containing PLGA nanoparticles, respectively. These
test substances exhibited a maximum ﬂux of 4.75±0.96 ·
10−4 to 6.24± 0.36 · 10−4 g/cm2/min. 3.117± 0.780 to
4.767± 0.448% of the ﬂuorescence marker FC were per-
meated after 6 h (Table I). All permeated mass per cm2
versus time curves run linear over 8 h (data not shown).
A centrifugation of the solutions in the acceptor
compartment in case of the test substances (A) FA-
PLGA nanoparticles and (B) partially degraded FA-PLGA
nanoparticles did not lead to any lowering of ﬂuorescence.
4. DISCUSSION
PLGA nanoparticles are well appreciated because of
their biocompatibility and biodegradability offering a wide
range of useful applications in the ﬁeld of advanced drug
delivery. However, drug encapsulation especially in case of
hydrophilic compounds still encounters difﬁculties namely
rapid diffusion out of the polymer. Several approaches
can be found in the literature in order to overcome this
problem.
Recently, it has been demonstrated that a wide range
of organic solvents with different polarities can be used
when employing the nanoprecipitation method and thus
enabling also the entrapment of hydrophilic drugs.16 Fur-
thermore, PLGA is not only available in an end-capped
form but also with free carboxy end groups which opens
the possibility of a covalent coupling of hydrophilic com-
pounds prior to nanoparticle formation. Fluorescein-linked
PLGA nanoparticles are used for various studies, amongst
others in biological systems.1718 For that purpose differ-
ent coupling methods have been described in the literature.
Recently, Tosi et al. reported a polymer preparation tech-
nique based on a covalent coupling of carboxy-ﬂuorescein
to PLGA after activation with dicyclohexylcarbodiimide
and N -hydroxysuccinimide for the preparation of in vivo
detectable nanoparticles in a rat model.17 Moreover, ﬂu-
orescein derivatives have been used for PLGA coupling
such as ﬂuorescein cadaverine18 and ﬂuoresceinamine.12
The method described by Horisawa et al.12 has been
applied in the present study because of its simplicity and
reproducibility, i.e., an amino derivative of sodium ﬂuo-
rescein was bound to the carboxy function of PLGA via
a one-step reaction. From this modiﬁed polymer, particles
with a mean diameter of 269.5 nm were prepared. In
regard to an in vivo application of the nanoparticles in
IBD, this size order is expected to be adequate for the
detection of even single particles in biological tissue whilst
still likely to display an enhanced accumulation and reten-
tion in inﬂamed mucosal areas. The leakage of ﬂuores-
cence marker occurred in a strongly delayed manner.
The initial burst effect led to a 11.7% loss of ﬂuores-
cence marker within 2 h (Fig. 2B) which is most likely
due to starting polymer degradation after re-hydration of
the freeze dried nanoparticles. As generally known from
PLGA devices, polymer swelling occurs under aqueous
conditions leading to a subsequent polymer chain cleavage.
After 8 days 60.8% of ﬂuorescence marker was still nano-
particle bound (Fig. 2A). We found by means of TLC anal-
ysis that polymer degradation led to different ﬂuorescent
products which we expected to be ﬂuoresceinamine-linked
PLGA fragments. The FA-PLGA degradation products,
however, were not identiﬁed in this study.
Alternatively to a covalent coupling to the polymer, the
standard method for the entrapment of hydrophilic drugs
is a W/O/W emulsiﬁcation process, encapsulating the
drugs within little aqueous droplets inside the polymeric
nanoparticles. In the present study this method has been
employed for the purpose of comparison with FA-PLGA
nanoparticles, using FC which is strongly hydrophilic.
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In contrast to FA-PLGA nanoparticles, it could be shown
that the release of encapsulated ﬂuorescence marker from
those particles was very fast: 82.6% were released immedi-
ately after 30 min as outlined in Figure 3. Via AFM it was
studied that this effect was not associated with any sur-
face phenomena i.e., shape and surface appearance of FC-
PLGA nanoparticles did not differ from those of FA-PLGA
nanoparticles (Fig. 1). Possible explanations for the fast FC
release are that either the hydrophilic compound diffuses
out of the nanoparticle core very fast or that the W/O/W
emulsiﬁcation method led to an imperfect encapsulation
due to the instable nature of the emulsion droplets dur-
ing the preparation process. Sampath et al. described this
burst release as an immediate dissolution of the adsorbed
drug onto the nanoparticle surface and as a consequence
of a big and more variable surface of smaller particles.19
Also, our results are in accordance with the literature
where hydrophilic drugs are described to be released more
or less rapidly when encapsulated into PLGA nanoparti-
cles using the W/O/W method. In case of the hydrophilic
low molecular weight model drug propranolol-HCl, Ubrich
et al.5 reported a release up to 45% from their propranolol-
HCl nanoparticles over 8 hours. Ahlin et al.20 detected
a release of 60 to 70% of enalaprilat encapsulated into
nanoparticles in different physiological release media even
at room temperature after 1 min. Saxena et al. encapsulated
indocyanine green, a tricarbocyanine dye. In their release
experiments, they found a liberation of 78% over the ﬁrst
8 h.21 In conclusion, FC-PLGA nanoparticles, in contrast
to FA-PLGA nanoparticles, do not appear to be suitable for
particle visualization studies over a larger period of time
due to a rapid loss and a rather low and probably insuf-
ﬁcient residual amount of encapsulated compound. How-
ever, in future studies the W/O/W emulsion technology
might also be further improved in order to achieve a more
stable FC entrapment.
Generally, highly negative zeta potential values are
expected for pure polyester nanoparticles from non-end
capped PLGA due to the presence of carboxyl groups on
the polymeric chain extremities.22 However, in this study
we used PLGA with around 65% of chain end groups
being modiﬁed by a covalent bonding of FA. This modiﬁ-
cation led to the less negative surface charge of −1.4 mV.
Another factor can be residual PVA from the prepara-
tion process. It is reported that this polymer may create
a shield between the nanoparticle surface and the sur-
rounding medium and thus is masking possible charged
groups existing on the particle surface22 whilst protecting
the nanoparticles from aggregation.
Degradation of insoluble, biodegradable polymers in
aqueous medium follows two main mechanisms, either
surface erosion, bulk erosion or both. Poly(-hydroxy
esters) like PLGA have been shown to predominantly
erode in bulk up to a relatively large size including nano-
and microparticulate drug carriers.23 Moreover, the PLGA
degradation rate is inﬂuenced by several parameters like
the polymer molecular weight, polydispersity index, crys-
tallinity, and glass transition temperature.24 Furthermore, it
is described in the literature that larger polymeric devices
show a greater degradation rate than smaller ones. This
is due to an accumulation of acidic degradation products
in the inner regions of a polymeric device which fur-
ther accelerates polymer decomposition (autocatalysis).25
Therefore, the degradation process described for micropar-
ticles e.g., by Dunne et al.24 and Fu et al.26 can not be
transferred without limitations to the size of nanoparticles.
Bulk erosion is characterized by the formation of pores
enabling water to penetrate into the particles followed by
a random cleavage of the ester bonds. During that process,
the particle core and size generally remain constant.
This also complies with our size measurements in the
nanoparticle degradation experiment. We visualized the
progression of pore formation via AFM (Fig. 4). In our
case, pore development was already apparent after week 1
proceeding until week 7. In association with pore forma-
tion and degradation, we found a change in the elastic
properties which can be explained by a swelling process.
This might also be a possible explanation for the particle
surface smoothening found after 15 weeks of degradation.
Comparing the transport properties of (A) FA-PLGA
nanoparticles across Caco-2 monolayers with those
of (B) partially degraded FA-PLGA nanoparticles and
(C) their degradation products (Table I), it is highly prob-
able that the ﬂuorescence signal detected in the receiver
compartment reﬂects the transport of released FA-PLGA
degradation products. This was further conﬁrmed by the
result that centrifugation of the receptor solutions did not
lead to any decrease of ﬂuorescence. Flux values of the
three test substances were in the same size range. How-
ever we observed a slightly decreased ﬂux for the (C) FA-
PLGA nanoparticle degradation products which can be
explained by a decreasing concentration gradient during
the experiment due to a lack of FA-PLGA nanoparticles
in the donor compartment. No additional transport mech-
anism except diffusion seems to be activated. Moreover,
it was shown that these degradation products were trans-
ported only to a very small extent, approximately 500
times less than the low permeability marker FC (Table I).
This result might be due to a high molecular weight when
FA is additionally bound to short lactide-glycolide chains.
Different problems arise when comparing the three
test substances (A) FA-PLGA nanoparticles, (B) partially
degraded FA-PLGA nanoparticles, and the (C) degradation
products:
One point is particle degradation during the transport
experiments which results in a concentration increase of
free FA-PLGA degradation products in the donor compart-
ment in case of the test substances (A) FA-PLGA nanopar-
ticles and (B) partially degraded FA-PLGA nanoparticles.
Another point is that ﬂuorescent degradation products of
FA-PLGA, which we expect to be ﬂuoresceinamine-bound
8 J. Nanosci. Nanotechnol. 6, 1–9, 2006
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short PLGA chains, are likely to undergo further degra-
dation during the experiments. However, by a comparison
of the transport properties of (A) FA-PLGA nanoparticles
and (B) partially degraded FA-PLGA nanoparticles it was
shown that this degradation does not affect the transport.
In terms of an in vivo application in a clinical study
in humans, FA-PLGA nanoparticles were assayed for
their cytotoxic effects on human intestinal epithelial cells
(Caco-2). The IC50 value was shown to be 10 mg/ml. It
was in the same order as found with nanoparticles from
pure PLGA which is well-known for its excellent biocom-
patibility. Apparently, covalent labelling of PLGA with
FA did not affect the cytotoxic potential of the nanoparti-
cles. Compared to the non-toxic compound FC, FA-PLGA
nanoparticles exhibited an even 750 fold higher IC50
(Fig. 5). This means that the nanoparticles are signiﬁcantly
less cytotoxic than this small molecular weight ﬂuorescent
molecule which is obviously non-toxic in vivo, as can be
judged from its common use in high doses as a dignos-
tic agent in man. With respect to a potential absorption of
FA-PLGA nanoparticles from the lumen of the intestine,
our results from the Caco-2 transport experiments indicate
that only the degradation products are transported across
the intestinal epithelial barrier. Even if absorption due to
a compromised barrier function of the intestinal mucosa
under conditions of IBD might occur to some extent, a
progressive shortening of the polymer chains would facil-
itate their elimination.
5. CONCLUSION
From the present study, it is evident that a covalent cou-
pling of FA to PLGA using carbodiimide as an activat-
ing agent represents a simple, reproducible, and efﬁcient
method for polymer labelling. Nanoparticles from FA-
PLGA exhibited a much better labelling stability compared
to nanoparticles prepared by FC encapsulation using the
classic W/O/W method. Due to well-known biocompatibil-
ity and biodegradability of PLGA, FA-PLGA nanoparticles
appear as valuable tool to study their potential to target
inﬂamed mucosal areas in IBD patients. In experiments
with intestinal epithelial cells the cytotoxicity was found
to be low. Moreover, there was no detectable nanopar-
ticle transport across Caco-2 cell monolayers and only
an extremely small transport of FA-PLGA degradation
products.
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Unpublished results 
 
1 Introduction 
The publication `Nanoparticles made of fluorescence labelled PLGA: 
preparation, stability and biocompatibility´ describes the development of drug-free but 
fluorescence labelled non-toxic NP to study their interaction with inflamed areas of the 
colonic mucosa of patients with irritable bowel disease (IBD) in a future clinical study. 
This approach is based on recent findings in an animal model where NP were 
demonstrated to exhibit enhanced accumulation and prolonged retention in inflamed 
intestinal tissue whilst concentrating anti-inflammatory drugs at their site of action.1-3 
From the publication, it is evident that a covalent coupling of 5-fluoresceinamine (FA) to 
PLGA represents a simple, reproducible, and efficient method for polymer labelling. 
There, the labelling efficiency of FA-modified PLGA (FA-PLGA) was determined and NP 
made of FA-PLGA were characterized for their size, zeta potential, morphology, stability, 
and leakage of fluorescence marker. In experiments with intestinal epithelial cells the 
cytotoxicity and the transport of NP across Caco-2 cell monolayers was studied. 
The first part of the present chapter provides physicochemical characterizations of FA-
PLGA and FA-PLGA NP which have not been included in the study `Nanoparticles 
made of fluorescence labelled PLGA: preparation, stability and biocompatibility´. This 
additional information contributes to a more precise specification of such systems. 
First, the glass transition temperature of FA-PLGA was determined to investigate if this 
special attribute of polymers has been changed due to modification. Second, the 
density of FA-PLGA NP was determined to enable a more conceivable quantification of 
particles when applied in biological systems. Finally, lyophilisation of FA-PLGA NP was 
studied since re-suspendability of those particles after lyophilisation becomes highly 
important in the context of a future clinical study when lyophilised particles are re-
constituted directly before application to patients. 
The second part of this chapter focuses on a first proof of determining FA-PLGA NP in 
intestinal tissue. After administration of FA-PLGA NP formulations to IBD patients, 
particles should be well visualisable by confocal laser scanning microscopy when 
accumulating in inflamed areas of the intestinal mucosa. Moreover, in case of taking 
biopsies of such tissue, the tissue attached particle amount should be quantifiable with 
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low analytical detection limit. In the following, both approaches have been studied using 
porcine intestine from the abattoir as a model. 
 
2 Materials and methods 
 
2.1 Materials 
FA-PLGA NP were prepared as described in the publication `Nanoparticles 
made of fluorescence labelled PLGA: preparation, stability and biocompatibility´. 
Excised porcine intestine was obtained from the abattoir. The tissue was rinsed with 
water and frozen at -20°C until use. Ammonium chloride buffer pH 9.5 was composed 
as described in the European Pharmacopoeia 5. Phosphate buffered solution pH 7.4 
(PBS) was composed of KCl 0.20 g/l, NaCl 8.00 g/l, KH2PO4 0.20 g/l, 
Na2HPO4 x 2H2O 1.44 g/l. 
 
2.2 Extended physicochemical characterization of FA-PLGA nanoparticles 
 
2.2.1 Differential scanning calorimetry investigation of FA-PLGA 
The glass transition temperature (Tg) of FA-PLGA was determined by differential 
scanning calorimetry (DSC) using a differential scanning calorimeter DSC Q100 (Waters 
GmbH, TA Instruments, Eschborn, GE). The instrument calibration was carried out with 
an indium standard. Amounts between 5 and 10 mg of lyophilised polymer were 
qualitatively analyzed in an air tight aluminium pan. Samples were scanned from -50°C 
to 200°C at a rate of 10°C/min. Results are expressed as mean ± SD and the number 
of replicates was n = 6 (polymer derived from 2 batches). 
 
2.2.2 Determination of the density of FA-PLGA nanoparticles 
The density of lyophilised FA-PLGA NP ρp was determined after re-suspension of 
the particles in demineralised water using a water pyknometer at 23°C. The calculation 
was performed according to the formula: 
 
´MmM
m
p
wp
p −+
⋅= ρρ  
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where ρw is the density of demineralised water at 23°C, mp the mass of lyophilised 
particles applied, M the mass of the pyknometer when completely filled with degassed 
demineralised water, and M´ the mass of the water-filled pyknometer additionally 
containing the FA-PLGA NP. The experiment was performed with a number of n = 2 
replicates. 
 
2.2.3  Lyophilisation of FA-PLGA nanoparticles 
FA-PLGA nanoparticles were lyophilised by means of an Alpha 2-4 LSC freeze-
dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode, GE). Samples were 
entirely frozen at -40°C. Main drying was performed at 20°C and 0.05 mbar for 24 h. 
Then, the pressure was decreased to 0.001 mbar and drying was continued for another 
2 h. After lyophilisation particles were stored in sealed vessels and under protection 
from light until being re-hydrated (within less than 10 days). Nanoparticle size and 
polydispersity index (PI) were determined before and after lyophilisation. The ratios of 
the final particle size and PI (after lyophilisation) to the initial size and PI (before 
lyophilisation) were expressed as Sf/Si and PIf/PIi, respectively. The number of replicates 
was n = 3. 
 
2.3 Detection of FA-PLGA nanoparticles in intestinal tissue 
 
2.3.1 Visualization by confocal laser scanning microscopy 
Confocal laser scanning microscopy (CLSM) was performed at a sample depth 
of 15 μm (from the luminal side) using a Bio-Rad MRC-1024 CLSM (Bio-Rad 
Laboratories, Hercules, CA, USA) equipped with an argon/krypton laser. The objective 
used was an oil immersion objective 40× NA=1.3. Green fluorescence was collected 
with a band pass filter (Zeiss: 520/35) and red fluorescence was collected with a long 
pass filter (Zeiss: LP585) after excitation at 488 nm and 568 nm, respectively. Imaging 
was performed after washing a piece of thawed excised porcine intestine twice with 
PBS and incubating it with a 10 mg/ml suspension of FA-PLGA NP of average size 
(270 nm) for 15 min. 
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2.3.2 Determination of the analytical detection limit 
Pieces of 14 mm2 were punched out from thawed porcine intestine. 4 ml of FA-
PLGA NP suspension in ammonium chloride buffer pH 9.5 were added to each punch 
and incubated at room temperature for 24 h under protection from light until complete 
decomposition of the particles. Then, the preparations were centrifuged at 222 g in 
order to remove the tissue material, and the fluorescence of the supernatant was 
determined using a fluorescence spectrophotometer at an excitation and emission 
wavelength of 485 and 510 nm, respectively. In preliminary experiments it was 
confirmed that porcine tissue material without NP, however treated analogously, did not 
exhibit significant fluorescence under these conditions. The particle concentrations 
applied ranged from 0 to 1.06 mg/ml. The experiment was performed with n = 2 
repeats. 
 
3 Results and discussion 
 
3.1 Differential scanning calorimetry results 
The mean Tg of FA-PLGA designated as the inflexion point of the curve in the 
thermograms was 28.8 ± 3.1°C. At a temperature above 100°C the polymer was 
degraded. Figure 1 shows a typical DSC thermogram of FA-PLGA. 
 
 
Figure 1: DSC thermogram of a representative FA-PLGA sample; the heat flow is plotted against the 
temperature (exo up). The inflexion point of the curve represents the glass transition temperature. At a 
temperature above 100°C the polymer was degraded. 
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In literature, PLGA polymers made of D,L-PLA and PGA with a content of less than 70% 
(w/w) are described to be amorphous in nature.4 Generally, amorphous polymers are 
characterized by their Tg which is the transition point between a highly viscous brittle 
structure called glass and a less viscous, more mobile, rubbery state. The Tg can be 
modified by blending with a small amount of a low molecular weight substance 
resulting in either plasticization or anti-plasticization of the polymer and, thus, a 
decrease or increase of the Tg.
5 According to the information of the manufacturer, the Tg 
of blank PLGA (poly(D,L-lactide-co-glycolide), Resomer RG 50:50 H, inherent viscosity 
0.31 dl/g) used for the preparation of FA-PLGA is 43°C. In case of FA-PLGA, the Tg was 
roughly 29°C indicating a decrease of Tg as consequence of polymer modification. 
There are two possible explanations for this result. First, polymer modification may have 
led to irregularities in polymer structure i.e. polymer chains may be more flexible and 
mobile due to the binding of FA to its carboxylic acid end groups. Second, 
lyophilisation of FA-PLGA may not have resulted in a complete removal of water which 
was, thus, acting as a plasticizer. The recent speculation is based on findings of Blasi et 
al.5 who reported the presence of water residues in larger amounts to become visible in 
the appearance of ice melting peaks in the thermograms, whereas water closely 
associated with the polymer matrix only gives influence on Tg. 
 
3.2 Density of FA-PLGA nanoparticles 
The density of FA-PLGA NP ρp was determined to a mean of 1.46 ± 0.04 g/ml. It 
did not differ relevantly from the density of pure PLGA applied for FA-PLGA NP 
preparation which the manufacturer reported to roughly 1.25 - 1.3 g/ml. By means of 
the density of FA-PLGA NP a number of roughly 6.6·1013 particles of mean size 
(270 nm) could be calculated to correspond to 1 g. 
 
3.3 Lyophilisation of FA-PLGA nanoparticles 
The ratios of particle size Sf/Si and polydispersity index PIf/PIi were 1.06 ± 0.05 
and 1.76 ± 0.50. After re-constitution of the lyophilised FA-PLGA NP the Tyndall effect 
was maintained. The particle size ratio shows only minor increase of NP size as 
consequence of lyophilisation whereas the PI ratio indicates a broadening of the size 
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distribution. However, the maximum PI was 0.21 still indicating a narrow particle size 
distribution in all cases. 
Lyophilisation is one of the most suitable methods in order to stabilize and to facilitate 
the handling of nanoparticulate systems which, stored as suspensions, would suffer 
alteration in a brief period of time.6 Several authors have claimed that additives like 
saccharides, polyalcohols and high molecular weight compounds are necessary in 
order to prevent PLGA NP from aggregation during lyophilisation and to maintain the 
integrity after re-hydration of the lyophilised samples.6-9 Saez et al. reported that only an 
addition of 20% of sucrose or 20% of glucose exerted sufficient lyoprotection of NP 
from blank PLGA resulting in a Sf/Si of roughly 1.5.
6 Chacón et al.8 found that at least 5% 
of the cryoprotectants glucose and trehalose were essential to keep the initial size of 
PLGA NP still resulting in particle aggregation. In contrast, in the present study it was 
found that NP from FA-PLGA maintained their size and still showed narrow size 
distribution when lyophilised without any additives. In literature, this behaviour was 
described as an effect of the stabilizer PVA used for the preparation of NP10-12 forming a 
stable thick layer on the particle surface.10 Even after repeated washing, a fraction of 
PVA generally remains well associated with the particle surface.13, 14 The reasons for that 
effect are a fixation of the hydroxyl groups of PVA molecules to the acetyl groups of 
PLGA via hydrophobic bonding13 and/or a interpenetration of PVA and PLGA during 
particle preparation.11 It has been suggested that stabilization of NP during 
lyophilisation only requires their maintenance in a vitrified state.15 Similar to other 
cryoprotectants, PVA is described to form a glassy state at low temperature due to 
hydrogen bonding between the polymer and the water molecules, thus stabilizing NP 
during lyophilisation and preventing particle aggregation.11 
With respect to a future administration in a clinical study FA-PLGA NP may be easily 
lyophilised and re-suspended without any significant changes in particle size and size 
distribution. Thereby, an addition of cryoprotectants, which may possibly interfere with 
other ingredients of the final formulation to be applied to patients, or at least increase 
the osmolarity does not appear as necessary. 
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3.4 Visualization and analytical quantification of FA-PLGA NP in porcine intestinal 
tissue 
For a first evaluation of particle visualization and quantification in intestinal tissue, 
excised intestine from pig was used as a model without confirming the maintenance of 
the intestinal integrity. To ascertain the traceability of FA-PLGA NP, the tissue was 
imaged by CLSM after incubation with such particles. Green fluorescent NP could be 
well visualized by imaging in different depths of the tissue. Slight red fluorescence 
derives from the autofluorescence of the tissue. Figure 2 represents an image at a 
sample depth of 15 μm. 
 
Figure 2: CLSM image of porcine intestinal tissue at a sample depth of 15 μm after 5 min incubation with 
FA-PLGA NP. Particles are green fluorescent. Slight red fluorescence derives from the autofluorescence of 
the tissue. (bar = 100 μm) 
 
The approach to determine the detection limit of FA-PLGA NP in intestinal tissue is 
based on the idea of an analytical quantification of tissue attached particles in biopsies 
taken from patients with IBD in a future clinical study. For that purpose, a 
decomposition of FA-PLGA NP in alkaline buffer in the presence of porcine intestinal 
tissue and a determination of the fluorescence of the tissue-free supernatant were 
opted. Linearity was given within the applied particle concentration range (0 -
 1.06 mg/ml; R2 > 0.999). The detection limit, which was determined at a FA-PLGA NP 
concentration exhibiting a fluorescence signal of 10fold the background fluorescence, 
was 3 μg/ml corresponding to a total number of 9.2·108 NP with the experimental setup 
applied. To enable an efficient absorption of nutrients, the surface of the intestinal 
mucosa exhibits wrinkles and villi, thus leading to a surface increase up to 600fold (e.g. 
in case of healthy tissue from the small intestine). Assuming a mono-particular 
occupation of such tissue, a number of 9.2·108 NP would cover a real surface area of 
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0.6% on a 14 mm2 tissue punch. In inflamed intestinal tissue physiological conditions 
may be strongly different, however, perforation of the inflamed mucosa may even 
enhance particle accumulation. 
 
4 Conclusion 
The present study fortified that NP made of FA-PLGA may represent a powerful 
tool to investigate their potential to target inflamed mucosal areas in IBD patients in a 
clinical study. In regard to a clinical application, it was shown that FA-PLGA NP 
lyophilized without addition of cryoprotectants may be easily re-constituted without any 
alteration of size or size distribution before administration to patients. In preliminary 
investigations with porcine intestinal tissue, FA-PLGA NP turned out to be well 
visualisable by CLSM indicating good aspects of such technique in vivo in humans. 
Furthermore, it was shown that extraction of biopsies taken from IBD patients may 
represent an easy method to quantify particle accumulation in inflamed intestinal tissue 
with low detection limit. 
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Abstract  
The penetration and storage behavior of dye containing nanoparticles (diameter 320 
nm) into the hair follicles was investigated. The results were compared to the findings 
obtained with the same amount of dye in the non-particle form. 
In the first part of the experiments, the penetration of the dye into the hair follicles 
was investigated in vitro on porcine skin, which is an appropriate model for human 
tissue. It was found that the nanoparticles penetrate much deeper into the hair 
follicles than the dye in the non-particle form, if a massage had been applied. Without 
massage, similar results were obtained for both formulations. 
Subsequently, the storage behavior of both formulations in the hair follicles was 
analyzed in vivo on human skin by differential stripping. Using the same application 
protocol, the nanoparticles were stored in the hair follicles up to 10 days, while the 
non-particle form could be detected only up to 4 days. 
Taking into consideration the surface structure of the hair follicles, it was assumed 
that the movement of the hairs may act as a pumping mechanism pushing the 
nanoparticles deep into the hair follicles.  
 
Introduction 
The knowledge of the penetration efficacy of topically applied substances into and 
through the skin is important for the development and optimization of cosmetic 
products and drugs. Whilst in the last decades, the penetration of topically applied 
substances through the skin barrier (stratum corneum) was assumed to be diffusion 
inside the lipid layers surrounding the corneocytes [1-3], recent investigations have 
attributed that the hair follicles perform a significant part in skin penetration [4-7]. 
Several in vivo and in vitro investigations have revealed a significant influence of the 
hair follicles on the penetration process [8-11]. Feldmann and Maibach [8] showed 
6.2 Nanoparticles - an efficient carrier for drug delivery into the hair follicles
80
  
 
ACCEPTED MANUSCRIPT 
 
 3 
higher absorption rates in skin areas with higher follicle density. Hueber et al. [9] and 
Tenjarla et al.[10] found a decrease in percutaneous absorption of appendage-free 
scarred skin compared to normal skin.  
Barry[11] explored a novel in vitro technique by comparing drug delivery through 
epidermal membranes with penetration through a sandwich model, assuming that the 
top epidermal membrane essentially blocks all shunts in the lower membrane. 
Furthermore, the hair follicles represent an efficient reservoir for topically applied 
substances, which is comparable to the reservoir of the stratum corneum on a 
number of body sites [12]. The highest volume of hair follicles can be found on the 
scalp, calf and forehead regions. In contrast to the reservoir of the stratum corneum, 
which is located in the uppermost cell layers of the horny layer (approx. 5 µm)[13], 
the reservoir of the hair follicles is usually extended deep into the tissue up to 2,000 
µm [14]. Here, dendritic cells and a close network of blood capillaries surround the 
hair follicles. Whilst the storage of substances in the stratum corneum is rather short, 
due to its high turnover, the reservoir of the hair follicles can be depleted only by 
penetration into living tissue, or by leaving the hair follicles, with sebum flow and 
active hair growth [6]. Actually, the hair follicles appear to be an efficient long-term 
reservoir for topically applied substances; especially particles play an important role 
in follicular penetration [6, 14]. If the size of the particles is higher than 5 µm, they do 
not penetrate into the lipid layers of the stratum corneum but only into the infundibula 
of the hair follicles [15]. TiO2 particles with a diameter of approx. 100 nm, often used 
in sunscreens, penetrate into the hair follicles but do not pass out of the follicles into 
living tissue [16]. Additionally, 100-nm-particles do not penetrate into all hair follicles, 
but it must be distinguished between “open” and “closed” hair follicles. Closed hair 
follicles are covered by a plug, which can easily be removed by cyanoacrylate 
surface biopsy or by peeling [17, 18]. Toll et al.[14] used this procedure to open all 
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follicles of excised human skin samples, and investigated the penetration efficacy 
into the hair follicles of fluorescent dye-labeled microspheres in different sizes 
(1.5 µm – 0.75 µm). Small particles at a diameter of approx. 750 nm penetrated most 
efficiently into the follicles, a process which could even be enhanced by mechanical 
massage of the particles into the skin.  
The aim of the present investigation was the comparison of the efficacy of the 
penetration and storage of substances in particle and non-particle form into hair 
follicles. Penetration experiments were carried out using the fluorescent dye sodium 
fluorescein in vitro on porcine ear-skin, because of the necessity to analyze a high 
number of biopsies. Porcine skin is a highly suitable substitute for human tissue [19]. 
Subsequently, the storage behavior of substances in particle and non-particle form 
was investigated in vivo on human skin, using the recently developed method of 
differential stripping [20]. 
Additionally, the structure of the hair surface and the hair follicles was analyzed to 
explain the observed differences in penetration and storage behavior of particle and 
non-particle formulations.  
 
Materials and Methods 
Formulations 
The Department of Biopharmaceutics and Pharmaceutical Technology, University of 
Saarland, Saarbruecken prepared two formulations based on the same hydrogel. 
The formulations of both, the particle and non-particle form, contained the same 
concentration of the fluorescent dye, sodium fluorescein. This food dye was used on 
account of its good fluorescent properties and efficient penetration into and through 
the skin, depending on the formulation [21]. 
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Fluorescent particles: nanoparticles (average diameter 320 nm, PI 0.06) were 
prepared from Resomer® RG 50:50H (Boehringer Ingelheim, Ingelheim, Germany) 
covalently labeled with 5-fluoresceinamine (Sigma Chemical Co., St. Louis, MO, 
USA). 
The polymer dissolved in acetone was pumped into a 0.5% solution of 
polyvinylalcohol (PVA) Mowiol® 4-88 (Kuraray Specialities Europe GmbH, Frankfurt, 
Germany) and stirred during nanoprecipitation. Organic solvent was removed using a 
rotary evaporator. Particles were freeze-dried. 
Fluorescent particle-containing hydrogel: a 1% suspension of fluorescein labeled 
nanoparticles (average diameter 320 nm, PI 0.06) was prepared in water. A 3% 
hydroxyethylcellulose hydrogel (Natrosol® type 250 M pharma, Aqualon, 
Duesseldorf, Germany) was prepared separately. The polymer was dispersed in 
water under vigorous stirring (800 rpm) until it was homogeneously distributed; later 
on, the polymer was allowed to swell under low speed stirring (100 rpm) overnight. 
Both preparations were mixed at a proportion 1:1 and shaken until a homogeneous 
distribution of the particles in the gel was obtained, resulting in a nanoparticle 0.5% 
w/w hydrogel. 
Fluorescein-containing hydrogel: a 0.003% sodium fluorescein containing hydrogel 
(equivalent to the fluoresceinamine amount linked to the polymer) was prepared by 
dissolution of the dye in water and addition of the polymer under stirring. Again, the 
preparation was stirred overnight with low speed (100 rpm) to allow swelling of the 
polymer. Both gels showed similar viscosities. 
 
 
 
Pre-treatment of volunteers / porcine skin 
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The in vivo experiments were performed on the calves of six volunteers, and the in 
vitro investigations on ear skin of 12 freshly slaughtered pigs (6-month-old, German 
domestic pigs). The calves of the volunteers and the ear skin of the pigs were 
prepared by washing, drying with soft tissue, and abscising the hairs; defined skin 
areas of 10 cm x 4 cm were demarcated using a permanent marker. Approval for this 
study had been obtained from the Ethics Committee of the Charité and from the 
Veterinary Board of Control, Berlin, Treptow-Köpenick. The study was conducted 
according to the ethical rules stated in the Declaration of Helsinki Principles. The 
volunteers participating in the study had given their written consent. 
 
Study designs 
 Study design A: In vitro investigation of the follicular penetration depth of a 
topically applied dye in particle and non-particle form by analyzing biopsies. 
 Study design B: In vivo analysis of the storage effect of the topically applied 
dye in particle and non-particle form by differential stripping 
  
Study design A 
Application 
2 mg/cm² of each of the two formulations were applied homogeneously onto the ear 
skin of 12 pigs. In the case of six pig ears, the formulations were massaged into the 
tissue for 3 min by means of a massage appliance (Massage Gerät PC60, Petra 
electric, Burgau, Germany). In the case of the other six pig ears, the formulations 
were applied lightly without massage. 
 
 
Biopsies and Microscopy 
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After a penetration time of 1 h, biopsies were taken from the pretreated porcine 
tissue, using 3 mm punch biopsies. Subsequently, the samples were frozen and 
histological sections were obtained. These were analyzed using a laser scanning 
microscope LSM 2000 (Carl Zeiss, Jena, Germany). The samples were measured in 
the transmission and the fluorescent modus. By superposition of the images, it was 
possible to investigate the distribution of the fluorescent dye inside the hair follicles 
as previously described by Toll et al [14]. Fifty hair follicles from skin areas treated 
with the particle-containing formulation and fifty hair follicles from skin areas treated 
with the non-particle formulation were investigated. The penetration depths of the 
fluorescence were measured; mean values and standard deviations were calculated 
and compared. 
 
Study design B 
Application 
2 mg/cm² of both formulations were applied homogeneously on the calves of six 
volunteers. The formulations were massaged into the skin for 3 min by means of a 
massage appliance. 
 
Differential stripping 
After increasing penetration times of 24, h, 72 h and 120 h, differential stripping was 
applied on adjacent pretreated skin areas of each volunteer as described previously 
by Teichmann et al. [20]. Therefore, the upper part of the stratum corneum, which 
serves as a reservoir for topically applied substances, was removed by tape stripping 
as described by Weigmann et al. [22]. A roller was used to press the adhesive film 
(tesa Film No. 5529, Beiersdorf, Hamburg, Germany). During the rolling movement, 
the skin became stretched and the adhesive film was in contact with the flat skin 
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surface. In this way, the influence of the furrows and wrinkles of the skin surface on 
the tape stripping procedure could be avoided [23]. Fifteen to twenty tapes strips 
were removed from the skin. The tape strips were checked using a laser scanning 
microscope, in order to ensure that the fluorescent dye had been removed 
completely from the stratum corneum and was located only in the orifices of the hair 
follicles. Subsequently, a drop of superglue (UHU GmbH & Co. KG, Brühl, Germany) 
was placed on the surface of the treated skin and covered with a glass slide under 
slight pressure. After polymerization (approx. 2 min), the cyanoacrylate was strongly 
linked with the upper layers of the stratum corneum, the hair shafts and the content 
of the follicular infundibula and was removed with one quick movement. After 
removal, the cyanoacrylate skin surface biopsies were checked microscopically to 
make sure that the dye was only located in the casts of the hair follicles.  
Afterwards, the samples were punched to a constant size of 15 mm in diameter and 
were extracted in ethanol (Uvasol, Merck, Darmstadt, Germany) using ultrasound 
(Sonorex Super RK102H, Bandelin Electronic, Berlin, Germany) and centrifugation 
(at 4,000 rpm for 10 min at 20°C, Centrifuge MR1812, Jouan GmbH, Unterhaching, 
Germany). Then, the solvents were analyzed in the fluorescence spectrometer 
LS50B (Perkin Elmer Instruments GmbH, Überlingen, Germany). The fluorescence of 
the dye was excited in the maximum of the absorption band at 450 nm; the 
fluorescence signal was detected in the spectral region from 520 to 650 nm. The 
intensity of the fluorescence signal was used as a measure for the concentration of 
the dye penetrated into the hair follicles.  
 
 
 
Statistical analysis 
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Statistical analysis was performed with the software program SPSS 12.0. Based on 
non-significant results (p > 0.05) of the Kolomogorov-Smirnov test, mean values and 
standard deviations were calculated using the software program Microsoft Excel 
2003.  
In the case of study design A, the Wilcoxon test was utilized to analyze the 
penetration depth of the fluorescent dye in particle and non-particle form and with 
and without massage appliance affording a significance p < 0.05. 
 
Results 
Study design A: 
In the case of study design A, the follicular penetration depth of the topically applied 
fluorescein in particle and non-particle form was determined by analyzing biopsies of 
porcine skin. In figure 1, the penetration of the fluorescent dye in the particle and 
non-particle form into the hair follicles of porcine skin, after the application of 
massage, is demonstrated by the superposition of a transmission and fluorescent 
image. The distribution of the fluorescent dye in the hair follicles is depicted in white. 
Figure 1a shows the penetration into the hair follicles of the fluorescent dye in the 
particle form, whilst figure 1b demonstrates the penetration of the fluorescent dye in 
the non-particle form. Significant differences can be observed: the particles penetrate 
much deeper into the hair follicles than the non-particle form if massage is applied. 
Figure 2 represents the mean values and standard deviations of the follicular 
penetration depths of the fluorescent dye in particle and non-particle form. The 
results were obtained at an average on 50 hair follicles. The penetration depth was 
significantly deeper (p < 0.05), if the fluorescent dye had been applied in the particle 
form. 
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On the skin of six further pig ears, the same two formulations were gently applied to 
the skin without massage. Typical results can be seen in figure 3, where the 
superposition of fluorescent and transmission images are presented. The penetration 
depth of the two formulations is nearly identical (p > 0.05). The average penetration 
depth determined for the non-particle formulation was 300.74 ± 65.37 µm, for the 
particle formulation 297.45 ± 71.6 µm (figure 4). For both formulations, the 
penetration depth was significantly lower for non-massage appliance than in the case 
of a massage being applied (p < 0.05).  
 
Study design B 
In the case of study design B, the concentration of the fluorescent dye, applied in 
particle and non-particle form by means of massage, penetrated into the hair follicle 
infundibula of the calf region of volunteers, was analyzed quantitatively utilizing 
differential stripping. The concentration of the fluorescent dye was analyzed at 
different time points after application. The obtained results are summarized in figure 
5. 
As the absolute amounts of fluorescein detected after one day in the hair follicles of 
different volunteers varied by a factor of 3, the concentration values determined after 
one day were standardized to 100% for better comparison of the mean values and 
standard deviations. The concentration of the dye decreased in time. If the skin had 
been treated with the formulation containing the fluorescent dye in the non-particle 
form, the dye could be detected only up to 4 days in the hair follicles. In contrast, the 
fluorescent dye in the particle form could still be detected 10 days after application. 
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Discussion 
Follicular penetration is an important and promising pathway for selective 
dermatotherapy. To optimize penetration and storage of topically applied molecules, 
innovative formulations are conceived. These approaches are mainly focused on 
nano- or microsphere technology.  
In the present study, we were able to demonstrate the superiority of particles versus 
non-particle formulations, not only for penetration but also for storage behavior. 
Interestingly, penetration of particle-containing formulations was enhanced by 
mechanical massage, reaching significant deeper penetration depths than without 
massage. However, without any mechanical manipulation on the skin surface, no 
significant differences between the two formulations were observed.  
Regarding the storage behavior of human hair follicles, striking results could be 
obtained: the nanoparticles remained in the hair follicles much longer than the non-
particle substances.  
These results appear to be surprising, as it could be expected that the small amounts 
of non-particle substances, with their relatively small size, penetrate better into the 
small hair follicles than the much larger particles. The results obtained show the 
opposite effect, but only in the case of a massage being applied. Possibly, apart from 
fluid mixing, this effect can be explained by the structure of the hairs and the hair 
follicles, which are very similar in porcine and human skin. The stratum corneum 
extends deeply into the hair follicles. From the structure analysis of hair surface and 
hair follicles, it is known that the cuticle produced by keratinocyte desquamation 
forms a structured surface, which can be approximated by a zigzag relief [24].This 
relief is determined by the thickness of the keratin cells, which is between 
500 and 800 nm. If the hairs are moved by massage, the cuticle cells may act as a 
geared pump. Particles, comparable in size to the surface structure of the hairs and 
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hair follicles are probably pushed into the follicles by means of the pump movement 
of the hairs. 
These findings are in agreement with the results obtained by Toll et al. [14], the 
microparticles with a diameter of 750 nm penetrated better into the hair follicles of 
excised human skin than larger particles, when a massage had been applied. 
 
Under in vivo conditions, this assumed pump mechanism also occurs without a 
massage, on account of the continuous movement of the body, which is able to 
stimulate the pump mechanism of the terminal and vellus hairs. This in vivo 
movement is less than in the case of a massage, but it occurs continuously.  
The in vivo storage experiments demonstrated that the penetration into the hair 
follicles is a fast process (1 hour), in comparison to the release of the nanoparticles 
out of the follicles, which continues for some days. The penetration process into the 
hair follicles is determined by the concentration gradient of the topically applied 
substances. If the reservoir of the skin surface and the stratum corneum, as the 
source of the penetration into the hair follicles, is depleted by textile contact and 
desquamation, the sebum production seems to be mainly responsible for the 
penetration of the substances out of the hair follicles. The non-particle substances 
are quickly moved out by the sebum production, probably, because they are not 
inhibited by the surface structures of the follicles and the hairs, whereas, the 
movement of the particles out of the hair follicles is assumed to be retarded by the 
surface structure. Taking into consideration the experiments concerning the follicle 
penetration of TiO2 microparticles [16], it can be expected that all particles at a size 
of >100 nm, which penetrate into the hair follicles, will also be moved out after some 
time on account of the sebum production not having reached the living cells.  
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Conclusions 
Nanoparticles are well suited to penetrate efficiently into the hair follicles, reaching 
deeper functional structures, where they can be stored for some days. In the case of 
non-particle substances, such a long-term effect cannot be observed, either in the 
hair follicles or in the stratum corneum. In principle, the stratum corneum is not suited 
as a long-term reservoir of topically applied substances, as these substances are 
mainly located on the skin surface or in the upper-cell layers after topical application 
[13]. These upper-cell layers are later continuously scuffed by desquamation. 
Therefore, the hair follicles are the only long-term reservoir for topically applied 
substances; consequently, they are important targets for drug delivery, as they are 
surrounded by a close network of blood capillaries and dendritic cells (Langerhans 
cells). Additionally, the hair follicles contain stem cells. Selecting the correct size of 
particles as drug carriers, thus, an efficient selective drug delivery and storage of 
topically applied substances into hair follicles is possible, which is important for 
selective dermatotherapy.  
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Figure legends 
 
Figure 1 
Superposition of a transmission and fluorescent image, demonstrating the in vitro 
penetration of the dye-containing formulation into the hair follicles of porcine skin 
after application of a massage  
A: dye in particle form 
B: dye in non-particle form 
 
Figure 2 
Average penetration depth of the particle and non-particle containing formulations 
after massage appliance (porcine skin). Significant differences (p < 0.05) are 
indicated with *. 
 
Figure 3 
Superposition of a transmission and fluorescent image, demonstrating the in vitro 
penetration of the dye containing formulation into the hair follicles of porcine skin 
without massage 
A: dye in particle form 
B: dye in non-particle form 
 
Figure 4 
Average penetration depth of the particle and non-particle containing formulations 
without massage appliance (porcine skin). Significant differences (p < 0.05) are 
indicated with *. 
 
 
Figure 5 
Semi-quantitative determination of the fluorescent dye in the hair follicle infundibula 
by cyanoacrylate skin surface biopsy at different time points after application (calves 
of 6 volunteers, mean values and standard deviations) 
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Multiphoton Microscopy for the Investigation of
Dermal Penetration of Nanoparticle-Borne Drugs
Frank Stracke1, Barbara Weiss2, Claus-Michael Lehr2, Karsten Ko¨nig1, Ulrich F. Schaefer2 and
Marc Schneider2
Multiphoton microscopy (MPM) of a dually fluorescence-labeled model system in excised human skin is
employed for high-resolution three-dimensional (3D) visualization in order to study the release, accumulation,
and penetration properties of drugs released from nanoscale carrier particles in dermal administration. Polymer
particles were covalently labeled with fluorescein, whereas Texas Red as a drug-model was dissolved in the
particles to be released to the formulation matrix. Single nanoparticles on skin could easily be localized and
imaged with diffraction-limited resolution. The temporal evolution of the fluorescent drug-model concentra-
tion in various skin compartments over more than 5 hours was investigated by multiphoton spectral imaging of
the same area of the specimen. The 3D penetration profile of the drug model in correlation with skin
morphology and particle localization information is obtained by multiple laser line excitation experiments.
MPM combined with spectral imaging was found to allow noninvasive long-term studies of particle-borne drug-
model penetration into skin with subcellular resolution. By dual color labeling, a clear discrimination between
particle-bound and released drug model was possible. The introduced technique was shown to be a powerful
tool in revealing the dermal penetration properties and pathways of drugs and nanoscale drug vehicles on
microscopic level.
Journal of Investigative Dermatology (2006) 126, 2224–2233. doi:10.1038/sj.jid.5700374; published online 18 May 2006
INTRODUCTION
The encapsulation of active substances is a common
pharmaceutical strategy to modify the transport and release
properties of a drug. Especially to nanoparticulate systems,
great potential is attributed in the field of drug delivery. This
is partly due to the fact that sensitive drugs can be hidden
from degradation in the particles (Volodkin et al., 2004;
Daniels, 2006). Further powerful properties of nanoscale drug
carriers are the sustained release (El-Samaligy et al., 1986;
Daniels, 2006) of the active substances, resulting in an
extended activity or enhanced uptake (Alvarez-Roman et al.,
2004c; Lombardi Borgia et al., 2005) and the possible
reduction of adverse effects (Lamprecht et al., 2001).
Functional coatings of the particles may allow the targeted
accumulation and release of drugs at their therapeutic sites
(Wartlick et al., 2004; Dinauer et al., 2005; Kotrotsiou et al.,
2005).
Widely used nanoparticle formulations are based on
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their
co-polymers, poly(lactide-co-glycolide) (PLGA), which are
known for their good biocompatibility and degradability
through natural pathways (Brannon-Peppas, 1995). In oral
and parenteral applications, these solid biodegradable poly-
meric nanoparticles have already shown their advantage over
liposomes by their increased stability (Soppimath et al., 2001;
Hans and Lowman, 2002; Ravi Kumar et al., 2003).
Nanoscale polymeric drug vehicles have also been proposed
for transdermal delivery (Kohli and Alpar, 2004; Alvarez-
Roman et al., 2004c; Lombardi Borgia et al., 2005; Luengo
et al., 2006). Penetration (Alvarez-Roman et al., 2004c;
Luengo et al., 2006), permeation (Luengo et al., 2006), and
accumulation (Toll et al., 2004) of some particle-borne drugs
and drug models after topical application have been
investigated by conventional techniques and confocal
microscopy of single stained particles.
Established methods for the investigation of drug penetra-
tion into the skin are mostly destructive: a representative
sample of a defined skin layer is isolated and extracted for
chemical analysis (tape stripping method, cryo-sectioning)
(Wagner et al., 2001; Brain et al., 2002). The result of such an
experiment is an area-averaged depth profile of the drug in
the skin to a certain time (Luengo et al., 2006). The depth
profiles for different incubation times have to be investigated
with different samples, neglecting the individual character-
istics of biological specimens. To evaluate and optimize
novel dermal drug delivery strategies using nanoscale drug
ORIGINAL ARTICLE
2224 Journal of Investigative Dermatology (2006), Volume 126 & 2006 The Society for Investigative Dermatology
Received 17 February 2006; accepted 27 March 2006; published online 18
May 2006
1Fraunhofer Institute for Biomedical Technology, St Ingbert, Germany and
2Department of Biopharmaceutics & Pharmaceutical Technology, Saarland
University, Saarbru¨cken, Germany
Correspondence: Dr Frank Stracke, Fraunhofer Institute for Biomedical
Technology, Ensheimer Str. 48, 66386 St Ingbert, Germany.
E-mail: frank.stracke@ibmt.fraunhofer.de
Abbreviations: FA, fluoresceinamine; MPM, multiphoton microscopy; PLGA,
polylactide-co-glycolide; PMT, photomultiplier tube; PVA, polyvinylalcohol;
ROI, region of interest; x, y, lateral dimensions; z, normal dimension/
subsurface depth
6.3 Multiphoton microscopy for the investigation of dermal penetration of nanoparticle-borne drugs
103
carriers, more versatile techniques are required. Such a
technique must allow the discrimination between free and
carrier-bound drugs, the tracing of the carrier nanoparticles,
the allocation of microscopic delivery pathways to specific
dermal sites, and time studies on the same skin area. After
application of nanoparticles as topical vehicles, one can
imagine different routes of drug delivery. It could be assumed
that the whole nanoparticulate system is taken up without
being destroyed (Kohli and Alpar, 2004) or that the
nanocarrier is decomposed close to the skin surface and
thereafter the active substance penetrates depending on the
local environment (acidification or absorption of drug/
nanoparticle-complexes) as speculated in Luengo et al. for
the enhanced long-term uptake of flufenamic acid (Luengo
et al., 2006). Furthermore, a direct diffusion from the carrier
into the stratum corneum is reasonable as described by
Bouwstra et al. (Meuwissen et al., 1998; Van Kuijk-
Meuwissen et al., 1998a). In any case, it is essential to
distinguish between particles, particle-bound drug, and
released drug. Herein we describe how multiphoton laser
scanning microscopy (MPM) and confocal laser scanning
microscopy can be very beneficial tools in order to meet all
these demands in one experiment. In particular, multiphoton
microscopy enables repeated noninvasive investigations of
skin tissue down to the dermis with virtually no out-of-focus
effects of the scanning laser beam (Ko¨nig and Riemann,
2003). Owing to multiple labeling techniques in combination
with multiphoton spectral imaging or selective excitation of
the labels, a clear discrimination between particles and free
drug model is possible, as well as tracking of single particles.
Owing to the excitation of endogenous fluorophores of the
skin by multiphoton excitation and the correlation of the
resulting autofluorescence image with the drug fluorescence
pattern, the identification of accumulative spots and pene-
tration pathways is possible with subcellular resolution
(Yu et al., 2002, 2003). MPM provides several considerable
advantages over conventional fluorescence and confocal
microscopy (Xu et al., 1996; Ko¨nig, 2000). Three of which are
relevant to the present investigation: the concentration of all
light–matter interactions to the focal volume, the convenient
separation of fluorescence from scattered excitation light due
to the large blueshift of fluorescence, and the capability to
excite compounds that else require ultraviolet excitation,
in particular native fluorophores as nicotineamide adenine
dinucleotide (hydrogenated form, NADH) and keratin
(Huang et al., 2002; Ko¨nig and Riemann, 2003; Pena et al.,
2005). The confined interaction volume at the focal point is
due to the In-dependence of n-photon absorption processes
on the illumination intensity I. Hence, already two-photon
absorptions are confined to a sub-femtoliter focal volume, in
which the illumination intensity is sufficiently high. As the
excitation with near infrared lasers matches the optical
window of biological matter (700–1100 nm), virtually no
single-photon absorptions occur in the illumination cones.
As a consequence, no fluorescence is generated outside
the focal volume and, therefore, three-dimensional spatial
resolution is an inherent feature of multiphoton laser scan-
ning microscopy. Furthermore, out-of-focus photo-damage
is drastically reduced and light penetration depth into tissue is
significantly enhanced (Centonze and White, 1998; Ko¨nig
and Riemann, 2003).
As most pharmaceutical substances are basically non-
fluorescent, the usage of appropriate fluorescent model
compounds is reasonable. Such a model compound has to
match the molecular size, charge, membrane permeability,
distribution, and diffusion coefficients as good as possible. A
fluorescent label fixed to the actual drug molecule changes
these properties and, thus, the penetration behavior con-
siderably. Hence labeling makes sense only if specific
interactions of the drug to certain sites are investigated. In
contrast, the nonsuperficial fluorescent labeling of the
nanoscale carrier particles does not change the particle’s
pharmacokinetics significantly. In addition, the fate of the
nanocarrier itself and its role in the changed uptake behavior
may be investigated. In this work, a two-color labeling
technique was used to trace the migration of the nanopar-
ticles and to observe the release and uptake of the drug-
model compound. To this end, fluoresceinamine (FA) was
covalently linked to the polymeric particle material and
Texas Red was physically resolved in the particle matrix. It is
shown that individual subdiffraction sized nanoparticles can
be localized, traced, and spectrally analyzed. Owing to the
two-color staining, a clear discrimination between free and
particle-bound dye was achieved. The method turned out to
allow stable measurements on excised human skin over hours
with no significant drift of the specimen.
RESULTS
Multiphoton fluorescence imaging
The multiphoton optical sections were recorded from the skin
surface down to the bottom of the shown dermatoglyph
at z¼42 mm over 5 hours under identical conditions
(Figure 1). It was found that the subdiffraction-limit-sized
particles can easily be detected and localized, as long as their
mean distance is well above this limit. They appear as lateral
diffraction-limited spots with widths of about 0.5 mm, which
is in reasonable agreement with theoretical predictions for
the minimum achievable full-width half-maximum of
302 nm. (The theoretical full-width half-maximum was
calculated by convolution of a sphere profile of d¼290 nm
with the squared intensity point spread function IPSF2. The
IPSF2 was derived according to Zipfel et al. (2003).) A typical
fluorescence profile of two particles in situ is displayed in
Figure 2. The minimal fluorescence spot size may be
broadened by Brownian motion and distorted by flux motions
of the gel in the dermatoglyphs. In the case of the bright
spots, the detector went into saturation, which additionally
caused a considerable broadening of the spot size. The mean
distance between the nanoparticles in the present formulation
is of the order of 5 mm. Three-dimensional tracing of
individual particles is easily possible under the outlined
conditions and allows detailed studies on the migration of
nanoscale drug carriers in the skin.
The significant endogenous fluorescence of keratin under
two-photon excitation enables imaging of the outermost layer
of the stratum corneum and hence the dermal topography.
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The PLGA particles are obviously not able to penetrate the
stratum corneum, and stay in the gel-filled dermatoglyphs
over the entire observation time (Figure 3). This corresponds
with former findings of the authors in which no penetration of
PLGA particles loaded with flufenamic acid into the human
skin could be observed (Luengo et al., 2006). It is noteworthy
that even after more than 5 hours, swelling, shrinking, and
stress relaxation motions of the skin sample lead only to
minute deformations within the field of view. No drift of the
specimen occurred.
No significant changes in the background fluorescence
intensity of the gelly suspension matrix or in the stratum
corneum as a consequence of the Texas Red release and
accumulation were observed in the multiphoton fluorescence
mode. The reason for this finding is the comparable low two-
photon absorption cross-section of Texas Red at l¼800 nm
(Figure 4), whereas fluorescein and keratin are efficiently
excited.
a b c
d e f
Figure 1. 325 325 lm2 multiphoton optical sections of human skin treated with a hydrogel suspension of two-color-labeled nanoparticles. The subsurface
depths of the displayed images are (a) –6 mm, (b) 9 mm, (c) 12 mm, (d) 15 mm, (e) 24 mm, and (f) –33 mm. The keratin autofluorescence clearly shows the
surface of the dermatoglyphs. The excitation power for the multiphoton optical sections was PEX¼5 mW, the pixel acquisition time tPx¼ 3.2ms (Bar¼ 50 mm).
0 2 4 6 8 10 12 14 16
× /m
Fl
uo
re
sc
en
ce
 (a
.u.
)
Figure 2. Fluorescence intensity profile of two multiphoton excited
nanoparticles in situ. The bimodal fit yields a full-width at half-maximum of
0.5mm. This is a reasonable value for the diffraction-limited resolution of
nanoscale particles under the present conditions.
a b c
Figure 3. 325 325 lm2 multiphoton optical sections at a depth of 27 lm
(a) 15, (b) 50, and (c) 315 minutes after application of the nanoparticulate
formulation. (Bar¼ 50 mm).
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Multiphoton spectral imaging
In order to investigate the distribution of the drug-model
Texas Red as a function of time, two-photon spectral imaging
was applied. In this technique, the luminescence signal
from the specimen is spectrally resolved and the spectrum is
stored for each pixel or voxel, respectively. From these data,
fluorescence spectra for arbitrary regions of interest can
be calculated. The laser wavelength of 800 nm leads to an
image, which is dominated by the fluorescein emission and
the endogenous fluorescence of the stratum corneum.
However, owing to the different sensitivity spectrum of the
META detector array, the sensitivity loss in the red spectral
range is less drastic than for the photomultiplier tubes. Even
faint contributions of the Texas Red fluorescence to any pixel
or region of interest (ROI) of the image can now be isolated
from the other emissions by spectral separation. In the present
study, a 145 145mm2 area from the middle of Figure 1 was
investigated. The spectral images were recorded to similar
times as that of the optical sections. In Figure 5a, a typical
example of such a spectral image is displayed in true color
mode. The nanoparticles appear clearly green, indicating that
their fluorescence originates predominantly from the cova-
lently bound fluorescein. The outermost layer of the stratum
corneum shows a heterogeneous distribution of colors. For an
interpretation, the fluorescence spectrum of the respective
region is taken (Figure 6a, ROI 2). The reddish color of the
deeper skin is mainly caused by residual scattered excitation
light beyond 700 nm (Figure 6a, ROI 3).
In Figure 5a, three regions of interest are indicated: ROI 1
contains the gel matrix including the nanoparticles, ROI 2
contains the keratinous surface layer of the stratum corneum,
and ROI 3 covers the deeper layers down to approximately
20 mm. Average fluorescence spectra are calculated from
the ROIs at different times to reveal the evolution of the
Texas Red concentration in these regions. Owing to the small
deformations of the specimen, especially in vertical direction,
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Figure 4. One- (solid line) and two-photon (open circles plus B-spline fit)
excitation spectra are displayed in the left panels. The right panels show the
related fluorescence spectra of (a) FITC dextran and (b) Texas Red. All spectra
are normalized, the one- and two-photon abscissa are aligned for equal
transition energies. One- and two-photon excitation spectra may differ
considerably because of the converse selection rules of the related absorption
processes. The excitation wavelengths at l1P¼ 488 nm and 543 nm as well as
at l2P¼ 800 nm are accentuated by dotted vertical lines.
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Figure 5. Multiphoton spectral imaging. (a) True color representation of a
spectral image at z¼21 mm with plots of the ROIs used for spectral analysis
(Bar¼20 mm). (b) Fluorescence spectra series of ROI 1 showing the decline of
Texas Red in the gel matrix (including particles). The Texas Red content in the
particles is low and shows no clear trend as depicted in the series of the
average spectra of 15 particles per image in (c). As the Texas Red content of
the particles does not change significantly, the decline of Texas Red in ROI 1
must occur in the gel matrix itself. The excitation power for the multiphoton
spectral images was PEX¼ 15 mW, the pixel acquisition time tPx¼3.2 ms.
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the ROIs do not enclose exactly identical skin domains at the
different times. This may be a cause for small discrepancies
in the spectral analysis. However, as the ROIs were always
chosen to enclose only skin compartments according to the
definitions above, the spectral analysis will still reveal the
accurate trends. To rule out errors due to varying offsets and
fluctuations in the absolute signal, the Texas Red fluorescence
is determined relative to an emission, which is expected to
be constant in time. For ROI 1, the fluorescein emission from
the nanoparticles at 525 nm is used, for ROI 2 the keratin
autofluorescence around 510 nm, and for ROI 3 the back-
scattered excitation light at 714 nm. Linear baselines are applied
to reduce the influence of the background (Figure 6a). As in
particular the autofluorescence in ROI 2 and the Texas Red
emission in ROI 3 show only dim intensities, the determined
intensity ratios for ROI 2 and ROI 3 have large uncertainties.
However, the rough trends are visible in those plots.
Whereas the Texas Red content in the nanoparticles
showed up to be low and basically constant already from the
first measurement at t¼30 minutes (Figure 5c), the concen-
tration of Texas Red in the gel matrix drops significantly with
time (Figures 5b and 6b). The Texas Red concentration in
the superficial layer of the stratum corneum is also declining,
but less rapidly (Figure 6c). The observation of declining
concentration in this compartment from the earliest measure-
ment at t¼ 30 minutes on means that the vast fraction of
Texas Red was taken up from the gel to the stratum corneum
surface almost immediately after application. Furthermore,
the release of Texas Red from the nanoparticles to the matrix
started well before application to the skin. Probably, the
predominant fraction was released to the solvent even before
suspension of the particles to the hydrogel. As the concentra-
tion of the released dye is decreasing in the gel-filled
dermatoglyphs and in the stratum corneum surface, it must
have penetrated the skin (or metabolism of the dye occurred,
which is unlikely). In fact, an increase of Texas Red
concentration in the deeper stratum corneum and stratum
granulosum is evident (Figure 6d), indicating a slow penetra-
tion of the dye. The fits to the plots are mono-exponential
decays and growth, respectively. The fit curves have no
theoretical pharmacokinetic background, but allow a con-
venient comparison of decay and rise times. Advanced
interpretations of the release, uptake, and penetration of the
dye will be possible only on the basis of an appropriate
pharmacokinetic model. The decay times of the mono-
exponential fits are tROI1¼ 3576 minutes and tROI2¼ 1487
319 minutes, and the rise time is tROI3¼59738 minutes.
Multitracking studies
After 320 minutes, a multitracking experiment visualizes the
distribution of Texas Red, fluorescein, and keratin fluores-
cence (Figure 7). In this technique, the signals from the
different fluorophores are separated by their excitation
spectra, not by their fluorescence spectra as performed in
spectral imaging. As opposed to the spectral images, which
are recorded with one excitation wavelength, herein the
successive use of three excitation sources may lead to small
mismatches between the channels. The vertical mismatch of
the near infrared two-photon excitation image to the images
excited by visible laser sources is due to chromatic
aberrations of the objective. The small average lateral shift
from the fluorescein image, excited by the 488 nm argon ion
laser line, to the Texas Red image, excited by the 543 nm
helium neon laser line, is due to the microscope optics and
could be compensated by image processing. Furthermore, a
multitracking experiment yields an overlay of successive scan
images. If the specimen shows dynamics, any motion is
reflected by shifts from one scan to the next. One must keep
these mismatches in mind when performing colocalization
studies on different dyes. In Figure 7d, an average lateral shift
of about 6 mm is evident between the fluorescein image and
the Texas Red image. The shift is not uniform for all particles,
but varies owing to flux motions within the hydrogel during
the acquisition times of the three single images of the
multitracking experiment. The particle pattern in the two-
photon excited image exhibits no correlation with the visibly
excited images, indicating a vertical mismatch of the focal
planes exceeding the normal size of the focal volumes
(approximately 1 mm). This mismatch is also evident in the
missing congruency of the dermatoglyph borders in the two-
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Figure 6. Quantitative spectral analysis of the Texas Red concentration in
different skin compartments. Scheme (a) shows the baselines and spectral
positions used for calculating the emission ratios for the determination of the
relative contents of the drug-model Texas Red in the ROIs. (b–d) Temporal
evolution of the emission ratios as a measure of Texas Red content in the
ROIs. In ROI 2 the Texas Red emission at 612 nm is divided by the average
keratin autofluorescence intensity at 500 and 525 nm because of the
interference of the broad autofluorescence emission with noise effects around
500 nm.
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photon excited image and the 543 nm excited image
(Figure 7). The keratin autofluorescence seems to be located
not at the surface of the Texas Red stained dermatoglyph,
but some microns inside the skin. This is a consequence
of the vertical mismatch between the near infrared and visible
focus. Nevertheless, detailed distribution analysis for
each isolated dye can be performed as well as a rough
colocalization study, as fluorescein and keratin are not
excited by the 543 nm laser line and Texas Red is virtually
exclusively excited by this excitation source (Figure 4).
The 488 nm excited image (green) proves that FA is strictly
bound to the particles and not released during the time of
observation. Previous experiments showed that released
fluorescein is rapidly bound to the keratinous layer of the
stratum corneum. In the present study, no such accumulation
was found. The fluorescence spots of the particles are mostly
broadened owing to saturation. In the 543 nm excited
images (orange), the distribution of Texas Red is visible.
The predominant fraction of the dye is to be found within the
skin, but the particles are also slightly observable. Obviously,
a b
c d
Figure 7. Multitracking experiments. (a–c) 325 325mm2 combined optical sections in 4, 20, and 32 mm depth (Bar¼100 mm). (d) A detailed image of
particles and skin surface (Bar¼ 25 mm). Each panel consists of a multiphoton excited image (predominantly keratin autofluorescence and fluorescein, gray
scale, top left image), a 488 nm excited image (fluorescein, green scale, top right image) and a 543 nm excited image (Texas Red, orange scale, bottom left
image), as well as an overlay of which (bottom right image). The excitation powers for the optical sections in the multitracking study were PEX(800 nm)¼ 10 mW,
PEX(488 nm)¼50 mW, and PEX(543 nm)¼ 36 mW, and the pixel acquisition time was always tPx¼3.2 ms.
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there is still a certain amount of the dye stored in the
nanoparticles, although the release process has proceeded
far. The released Texas Red penetrated the skin and
accumulated in the stratum corneum down to approximately
20 mm (Figure 7b). In Figure 7c, recorded at a depth of 32 mm,
the penetration into deeper skin compartments can be
recognized, as the walls of the dermatoglyph are steep
enough to reveal the diffusion from the superficial layers
inwards. The distribution of Texas Red in the skin is not
uniform, but structured. It is conspicuous that the superficial
accumulation is strongest, where the skin adjoins to large
gel-filled spaces. Beneath the superficial layer, the distri-
bution of the drug model is more uniform, which indicates
faster diffusion of the compound in these skin compartments.
The fundamental discrepancy between the visible excited
images and the two-photon image proves that the visible skin
structures from the two-photon image are predominantly due
to keratin autofluorescence and not due to the superficial
accumulation of Texas Red. xz-Sections can be extracted
from the multitracking z-stacks, which nicely exhibit the
concentration profile in normal direction (Figure 8). The
highest concentrations of Texas Red in the deeper layers are
found under superficial areas with pronounced keratin
autofluorescence. This supports the hypothesis of a fast
resorption of Texas Red from the hydrogel to the keratinous
compartments and a slower diffusion from there to the skin
tissue underneath. A vertical mismatch of several microns
between the 543 nm excited Texas Red fluorescence and the
multiphoton excited endogenous keratin fluorescence due
to the chromatic aberration of the optics is apparent in all
xz-sections.
DISCUSSION
A major challenge in the design of nanoscale drug delivery
entities is the development of mechanisms that trigger the
release of the drug when the nanoparticle attains its
therapeutic site. For dermal applications, such mechanisms
may consist of an intrinsic recognition element for specific
sites or compounds of the skin and thereby a controlled
release step. Another approach to this end is to modify the
particle surface in a way that they accumulate at the
therapeutic site and to start the drug release by external
stimuli like light illumination or the delayed application of a
kick-off agent. A pure diffusive release of a drug from
suspended particles starts at the moment of suspension, and
after a certain storage time the drug is predominantly
dissolved in the suspension matrix. Hence, this way of
formulation compromises all advantages of nanoparticulate
drug delivery. As so far no such intelligent trigger techniques
are established for topical application of nanoscale drug
carriers, the simple diffusive release mechanism is observed
in the present work to demonstrate the capabilities of laser
scanning microscopy in this field. As a consequence, it was
found that the major fraction of Texas Red was already
released to the gel matrix at the moment of the first
measurement. This observation demonstrates that diffusive
release of drugs from the particle cannot be employed for the
practical use of nanoscale drug carriers and, in general,
stresses the need for the design of intelligent nanocarriers
with controllable release behavior. The three-dimensional
microscopic and spectral resolution of the utilized techniques
showed up to have a more versatile potential for the
evaluation of such smart nanoparticle formulations than
conventional penetration study methods.
In general, multiphoton and confocal microscopy of
dually labeled nanoparticles in human skin biopsies have
been demonstrated to be very suitable techniques to inves-
tigate the migration, accumulation, release, and penetration
of nanoparticle-borne drugs in dermal application. By
different fluorescence spectra of the covalently fixed and
the physically dissolved dye, discrimination between parti-
cle-bound and released compounds is possible. By perfor-
ming spectral imaging, the quantitative analysis of the release
process is much less interfered by background emissions and
crosstalk errors than in a conventional two detector channel
study with a dichroic beamsplitter. Furthermore, an emission
can be attributed to a certain compound with a high degree of
accuracy by resolving the fluorescence spectrum.
It was shown that tracing of even single particles of about
300 nm diameter in the gel matrix inside the dermatoglyphs is
not a difficult task. The observation depth of MPM even in
turbid media is on the order of several hundred microns
(Centonze and White, 1998) and is mostly limited by the
working distance of the applied high numerical aperture
objectives. Hence, single fluorescent nanoparticles should be
observable within the skin down to the dermis. This is of
particular importance if particles are investigated, which are
able to penetrate the epidermal layers. No penetration of
particles into the skin was found in the present study. Owing
to the three-dimensional subcellular resolution and the
possibility of repeated noninvasive investigations of the same
skin area, detailed information on the penetration pathways
of particle-bound and free drug models are accessible.
As confocal microscopy with visible excitation does not
provide such enhanced observation depths, the multitracking
Figure 8. xz-Multitracking sections composed from a stack of xy-optical
sections with 3 lm distance in between each. This representation nicely
reveals the penetration profiles of Texas Red into the skin and the correlation
of the penetration behavior with skin morphology. The color coding is in
accordance with Figure 7 (Bar¼ 50 mm10 mm).
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technique is primarily adequate for investigations on the
upper skin layers. Problems may arise from possible lateral
mismatches, the chromatic shift of the focal planes in case of
strongly differing excitation wavelengths, and the time lag
between the single scans. The influences of these interfer-
ences have to be carefully regarded in the interpretations of
multitracking studies. Nevertheless, it can be a powerful tool
if the applied fluorophores are basically excited exclusively
by the chosen laser lines, as demonstrated in the present
study.
The specimen mounting fulfilled the objectives of keeping
the skin sample in place with an accuracy of few microns in
three dimensions, to avoid desiccation and to minimize
swelling and shrinking effects. In the present study, excised,
frozen, and thawed human skin was used. The properties of a
skin specimen treated accordingly will certainly differ from
skin in vivo and freshly excised biopsies, as for example, the
pH depth profile changes rapidly after excision (Wagner
et al., 2003) and the endogenous NADH fluorescence of
the vital epidermal layers is virtually vanished after frozen
storage. In spite of these physiological changes, permeation
measurements did not exhibit a changed passage behavior for
the investigated compounds after frozen storage of human
skin, indicating that the nonvital superficial layer of the
stratum corneum was the main penetration barrier (Wagner
et al., 2004). An MPM experiment on freshly excised human
skin or in vivo could reveal even more detailed information
on the drug penetration into the vital skin layers, as the
cellular autofluorescence would allow the allocation of the
drug pathways on single cell level.
By deliberate variation of the fluorescent drug-model,
correlations of the microscopic penetration behavior with
various physicochemical properties of the drug models could
be investigated. An intelligent release mechanism providing
for a defined initial time of release from the nanoscale drug
carrier would allow to study the accurate evolution of drug
concentrations in the diverse skin compartments and to
derive a pharmacokinetic model of the drug uptake from
nanoparticulate formulations.
Concluding, we demonstrated the benefits of multicolor
labeling of biodegradable nanoparticles and the intriguing
insights into the penetration behavior of particle-borne
drugs due to the combination with MPM and confocal laser
scanning microscopy. The usage of two fluorescent dyes of
well-separated absorption and emission spectra enabled the
investigation of the transport of a fluorescent drug model in
situ. This might be extended to multiple loading of
nanoparticles with two or more drug-models that differ in
spectral and physicochemical properties for direct compar-
ison. Furthermore, relevant pharmaceutical compounds with
native fluorescence may be investigated as well as intelligent
release mechanisms. The kinetics of the drug transport from
the initial formulation to the subcutaneous compartments can
be studied in elementary steps, as the enrichment of particles
in certain dermal sites (Toll et al., 2004), the release of the
drug from the particles, its uptake into the stratum corneum,
the diffusion into the deeper skin layers, etc. The determina-
tion of the enrichment in dependence of time as well as the
visualization of the ‘structured’ diffusion process into the
skin envisages the potential of this approach. In addition, the
covalent label to the nanoparticle itself enables the investi-
gator to follow the fate of the nano-carrier, its uptake,
accumulation, or decomposition. This might be very mean-
ingful in particular for the exploration of the penetration
function of hair shafts. First evidence was observed that these
follicles might play an important role (Van Kuijk-Meuwissen
et al., 1998b; Toll et al., 2004; Alvarez-Roman et al., 2004b).
MATERIALS AND METHODS
Materials
Poly(L-lactide-co-glycolide) (Resomer RG 50:50 H) was kindly
provided by Boehringer Ingelheim (Boehringer Ingelheim GmbH &
Co. KG, Ingelheim, Germany). 5-Fluoresceinamine and 1-ethyl-3-(3-
Dimethylaminopropyl)-carbodiimide hydrochloride were obtained
from Sigma (Sigma Chemical Co., St Louis, MO, USA). Polyvinyl-
alcohol (Mowiol 4-88) was purchased from Kuraray (Kuraray
Specialities GmbH, Frankfurt am Main, Germany). Texas Reds
was provided by Atto-Tec (Atto-Tec GmbH, Siegen, Germany). We
gratefully acknowledge the kind provision of Natrosols 250 M
hydrogel (Aqualon, Hercules Inc., DE, USA) by J. Luengo. All other
chemicals are of analytical grade.
Polymer labeling and preparation of dual color nanoparticles
FA-bound PLGA (FA-PLGA) was prepared based upon the method
described by Horisawa et al. (Horisawa et al., 2002). Briefly, PLGA
(3.07 g) and FA (0.0583 g) were dissolved entirely in 30 ml of
acetonitrile with 0.0408 g of 1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride and incubated at room temperature
for 24 h under light protection and gentle stirring. The resultant
FA-PLGA was precipitated by the addition of purified water and
separated by centrifugation. The polymer was rinsed from excessive
reagents (dissolution in acetone and precipitation with ethanol in
terms) and then lyophilized (Alpha 2-4 LSC, Martin Christ
Gefriertrocknungsanlagen GmbH, Osterode, Germany).
Texas Red nanoparticles were prepared from FA-PLGA, employ-
ing a single emulsion method (oil in water). The emulsion was
formed between an organic FA-PLGA solution (2% (w/v) in ethyl
acetate), which additionally contained 30 ml of a saturated Texas Red
solution and 5 ml of a polyvinylalcohol solution (1% in deminer-
alized water) under stirring on a magnetic stirrer for 2 hours. Then
the emulsion was homogenized using an Ultra-Turraxs T 25 Mixer
(Janke und Kunkel GmbH & Co., Staufen, Germany) at 13,500 r.p.m.
and the organic solvent was removed by a rotary evaporator. The
mean particle size was determined to d¼ 29075 nm using photo-
correlation spectroscopy (Zetasizers3000HSA, Malvern Instruments
GmbH, Herrenberg, Germany), and the homogeneity of the particles
was verified using scanning probe microscopy (BioScope, Veeco,
Santa Barbara, USA) (Figure 9). To prepare the gelly nanoparticle
suspension, a Natrosols gel (3% w/w) was mixed with an aqueous
suspension of the nanoparticles in a 1:1 ratio.
Skin preparation
Excised human skin from Caucasian female patients who had
undergone abdominal plastic surgery was used. The procedure was
approved by the Ethical Committee of the Caritas-Traegerge-
sellschaft, Trier, Germany (6 July 1998) and conducted according
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to the Declaration of Helsinki Principles. Adequate health and no
medical history of dermatological disease were required. After
excision the skin was cut into 10 10 cm2 pieces, and the
subcutaneous fatty tissue was removed from the skin specimen by
using a scalpel. Afterwards the surface of each specimen was
cleaned with water, wrapped in aluminum foil, and stored in
polyethylene bags at 261C until use. Previous investigations have
shown that no change in the penetration characteristics occurs
during the storage time of 6 months (Bronaugh et al., 1986; Wagner
et al., 2004).
Laser scanning microscopy
The microscopy studies were performed on a versatile laser scanning
microscope (LSM 510 NLO META, Carl Zeiss Jena GmbH, Germany)
for conventional confocal microscopy with multiple excitation laser
lines and multiphoton excitation microscopy. Herein, the 488 nm
laser line of the internal argon ion laser and the 543 nm line of the
internal helium neon laser were applied for confocal imaging. For
MPM, a femtosecond pulsed titan:sapphire laser at l¼ 800 nm with
90 fs pulse width and 80 MHz repetition rate (Vitesse, Coherent Inc.,
Santa Clara, USA) was coupled into the microscope.
The META scanning and detection module offers different ways
to detect the fluorescence light. First, the complete emission is
distributed between two sensitive photomultiplier tubes by means of
neutral and dichroic mirrors. Second, the emission signal is
spectrally dispersed by a diffraction grating and guided on a 32
channel photomultiplier array for spectral analysis. Each channel
detects a spectral range of about 10 nm in this arrangement. Three
different imaging modes were applied in the present study: (a) the
multiphoton fluorescence mode for the cumulative detection of the
emitted fluorescence. Here, the fluorescence intensity is recorded by
one photomultiplier tube. The laser line is blocked by a 650 nm
shortpass beamsplitter and a 685 nm shortpass filter. This detection
mode is the most sensitive one, but any spectral information will be
lost. (b) In the multiphoton spectral imaging mode, the emitted light
is separated from the laser line by the 650 nm shortpass beamsplitter
and recorded spectrally resolved by means of the grating and the
detector array. Each pixel of a spectral image contains the data of the
32 detector channels, so that emission spectra for each pixel or for
defined areas of the image are accessible. The displayed images are
true color coded. The spectral data are converted into appropriate
RGB values. (c) The multitracking mode is actually an overlay
of three fluorescence intensity images, subsequently acquired at
different excitation wavelengths. An overlay procedure with two
visible excitation laser lines was utilized on similar specimens by
Alvarez-Roman et al. (2004a). The excitation wavelengths are
chosen to be preferably absorbed by exclusively one fluorophore
(Figure 4). The 488 nm argon ion laser line is predominantly
absorbed by fluorescein, the 543 nm helium neon laser line by
Texas Red exclusively. Two-photon excitation at 800 nm is strong for
fluorescein and the endogenous fluorophore keratin, but poor for
Texas Red.
Two-photon excitation spectra (Figure 4) were acquired accord-
ing to a modified ‘‘excitation fingerprinting’’ procedure introduced
by Dickinson et al. (2003). In contrast to the excitation fingerprinting
technique, where the excitation power is kept constant for different
wavelengths, herein the laser power calibration is adjusted for
constant photon flux at different wavelengths to yield correct two-
photon excitation spectra (Schneider et al., 2005). One-photon
excitation and fluorescence spectra were acquired with a Hitachi FL
4500 fluorometer using 50 mM aqueous solutions of FITC dextran
and Texas Red. FITC dextran was used in order to investigate a
compound preferably akin to FA-PLGA while showing good water
solubility. The spectral properties of the fluorescein derivatives are
almost unaffected by different substituents in the 5-position.
Sample preparation
For microscopy, discs of 0.8 cm diameter were punched out of
frozen skin and placed surface-up on a microscopy slide inside a
circular vertical spacer. After application of the gelly suspension to
the skin surface, a cover slide was fixed onto the spacer by double-
faced adhesive tape in a way that the skin surface was gently pressed
against the cover slide. This setup provides constant specimen
thickness and prevents desiccation of the skin sample. The
observation was performed through the cover slide by means of a
40 /1.3 numerical aperture Oil Objective (Plan Neofluar, Carl
Zeiss Jena GmbH, Germany).
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cally signifi cantly enhanced transport and accumulation 
(p  ! 0.05). Additionally, nanoencapsulated fl ufenamic 
acid was visualized by multiphoton fl uorescence micros-
copy. Particles were found homogeneously distributed 
on the skin surface and within the dermatoglyphs, but 
no nanoparticles were detected within or between the 
corneocytes. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Due to its special structure, the skin provides the main 
barrier between the body and the environment, at the 
same time limiting the drug delivery along this route  [1–
5] . Many strategies have been employed to improve the 
dermal and transdermal delivery of drugs, e.g. increasing 
the effective concentration of the drug in the vehicle, im-
proving the partitioning between the formulation and the 
skin, the use of chemical penetration enhancers and dif-
ferent physical enhancement methods like iontophoresis, 
electroporation and microneedles  [5, 6] . Furthermore, 
carrier systems like liposomes, microparticles or nanopar-
ticles (NP)  [7–9] have been explored. For microparticles, 
some targeting to the hair follicles has been shown by Toll 
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 Abstract 
 The effect of the inclusion of fl ufenamic acid in 
poly(lactide- co -glycolide) nanoparticles on the transport 
of fl ufenamic acid into excised human skin was investi-
gated. Penetration and permeation data were acquired 
using two different  in vitro test systems: the Saarbrücken 
penetration model, where the skin acts as its own recep-
tor medium, and the Franz diffusion cell, where the 
 receptor medium is a buffer solution. For the stratum 
corneum, no differences were found between nanoen-
capsulated and free drug. Drug accumulation in the 
deeper skin layers and drug transport across human epi-
dermis were slightly delayed for the nanoencapsulated 
drug compared to the free drug after shorter incubation 
times ( ! 12 h). In contrast, after longer incubation times 
( 1 12 h), the nanoencapsulated drug showed a statisti-
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et al.  [10] , using polystyrene microspheres in a range of 
0.75–6   m, and Lademann et al.  [11] , using titanium di-
oxide particles in a range of 0.1–0.3   m also resulting in 
an enhanced delivery to the deeper skin layers. Studies 
on solid lipid NP  [12–14] also showed increased trans-
dermal drug delivery induced by their occlusive effects. 
Alvarez-Román et al.  [15] reported preferential accumu-
lation of non-biodegradable drug-free polymeric NP in 
the hair follicle opening of pig skin. In addition, the same 
authors reported an increased level within the stratum 
corneum of the pig ear of the highly lipophilic sun-pro-
tecting agent, octyl methoxycinnamate, when nanoen-
capsulated in the biodegradable polymer poly(  -caprolac-
tone)  [16] . 
 Some of the most widely used polymers in the NP for-
mulation are poly(lactic acid), poly(glycolic acid), and 
their co-polymer, poly(lactide- co -glycolide) (PLGA), 
which are known for their good biocompatibility and re-
sorbability through natural pathways  [17] . In oral and 
parenteral applications, solid biodegradable polymeric 
NP based on PLGA have shown their advantage over li-
posomes by their increased stability  [18–20] , but in the 
ﬁ eld of dermal delivery their potential appears to be rath-
er unexplored. 
 The objective of this study was to investigate the inﬂ u-
ence of nanoencapsulation on the permeation and pene-
tration of the lipophilic model drug ﬂ ufenamic acid (FFA) 
into skin using PLGA as carrier polymer. In order to mon-
itor drug penetration, the Saarbrücken model  [21] (SB-M) 
was used in which the skin itself acts as a receptor com-
partment. A tape stripping technique followed by cryo-
sectioning of the deeper skin layers allows to quantify the 
penetrated drug amount. Drug release from the formula-
tion and drug permeation through the epidermis were 
studied using the static Franz diffusion cell (FD-C) tech-
nique. Due to the size differences between the hair folli-
cles of pig skin and of human skin  [22] , which may play 
an important role in the results, we decided to use excised 
human skin from abdominal plastic surgery instead of pig 
skin. As polymer PLGA was chosen in view of its excel-
lent biocompatibility and the availability of various 
methods to prepare drug-loaded NP from this polymer. 
To verify the presence and to visualize the distribution of 
the applied NP on the skin, multiphoton ﬂ uorescence im-
aging was used. This technique allows to excite the natu-
ral ﬂ uorescence of the FFA in non-polar surroundings 
(  max  = 420 nm) by a two-photon absorption process. 
Two-photon excitation induced with femtosecond near-
infrared laser pulses offers the possibility of high-resolu-
tion 3-dimensional imaging of the skin  [23] . 
 Materials and Methods 
 Materials 
 Natrosol ®  250 M (Aqualon, Hercules Inc., Del., USA), FFA, 
modiﬁ cation II (Kali-Chemie Pharma, Hannover, Germany), 
poly( D,L -lactide- co -glycolide) (50:  50) with a molecular weight of 
40,000–75,000 Da (Sigma Chemical Co., St. Louis, Mo., USA), 
polyvinyl alcohol Mowiol ®  4-88 (Kuraray Specialities Europe 
GmbH, Frankfurt, Germany), Ringer solution, McIlvaine citric 
acid-phosphate buffer (pH 2.2), sodium hydroxide solution
(0.05  M ) (all components from Merck, Darmstadt, Germany), 
 Plastibase ®  (Heiden GmbH, München, Germany), methanol 
 Chromasolv ®  (Sigma-Aldrich GmbH, Seelze, Germany), Tesa 
Film kristall-klar 19 mm (Tesa AG, Hamburg, Germany), ethyl 
acetate (Fluka Chemie GmbH, Buchs, Switzerland), and cellulose 
membrane MWCO 12,000–14,000 Da (Medicell International 
Ltd., London, UK) were used as obtained from the suppliers. 
 Equipment 
 High-performance liquid chromatography (HPLC) system was 
used: Chromeleon ™  version 6.5 SP2, build 968; P580 pump; ASI-
100 automated sample injector; STH 585 column oven; UVD 170S 
detector (Dionex Softro GmbH, Germering, Germany); FD-C type 
4G-01-00-15 (Perme Gear, Riegelsville, Pa., USA); cryomicrotome 
HR Mark II, model 1978 (Slee, Mainz, Germany); centrifuge Sigma 
3E-1 (Sigma, Aichach, Germany); high-speed homogenizer Ultra-
Turrax ®  T25 (Jahnke & Kunkel GmbH & Co. KG, Staufen, Ger-
many); atomic force microscope nanoscope IV Bioscope ™  (Veeco 
Instruments, Santa Barbara, Calif., USA); freeze-drier Alpha 2-4 
LSC (Christ, Osterode, Germany); Rotavapor ®  R-205 (Büchi, 
Flawil, Switzerland); Zetasizer ®  3000 HS A (Malvern Instruments 
GmbH, Herrenberg, Germany); for multiphoton ﬂ uorescence im-
aging, the femtosecond laser imaging system DermaInspect ®  (Jen-
Lab GmbH, Jena, Germany), equipped with a Chameleon laser 
system (Coherent Inc., Santa Clara, Calif., USA) and a Hamamat-
su PMT(H7732) detector (Hamamatsu Photonics Deutschland 
GmbH, Herrsching am Ammersee, Germany), was used. 
 Methods 
 NP Preparation and Characterization 
 PLGA NP loaded with FFA (FFA NP) were prepared using a 
solvent extraction method. Thirty milligrams of FFA were dis-
solved in a solution of 600 mg of PLGA in 20 ml of ethyl acetate. 
This organic phase was added dropwise into 20 ml of an aqueous 
phase, containing 1% of polyvinyl alcohol as a quasi-emulsiﬁ er, 
under stirring with a magnetic stirring bar. The resulting o/w 
 emulsion was homogenized with a high-speed homogenizer at 
13,500 rpm for 10 min. To complete the precipitation, water was 
added up to 200 ml under stirring with a magnetic bar. Organic 
solvent was then removed using a rotating evaporator. The result-
ing NP suspension was freeze-dried and stored until use. 
 For reference, standard drug-free NP were prepared in the same 
way. 
 Size and surface morphology of the FFA NP were determined 
using photon correlation spectroscopy and atomic force micros-
copy (AFM). For the AFM measurements, a drop of the NP suspen-
sion and hydrogel (HG), respectively, were air-dried on a silica 
wafer. Imaging was done using a silicon cantilever with a spring 
constant of approximately 40 N/m and a resonance frequency of 
about 170 kHz. The scan speed applied was 0.2 Hz. The resolution 
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was 512  ! 512 pixels. In order to avoid generating sample artefacts, 
the tip loading force was minimized. 
 The content of FFA in the particles was determined using the 
following equation: 
 FFA NP  =  FFA Total  –  FFA Free 
 Whereas  FFA Free  was determined in the supernatant obtained 
from a centrifuged suspension (23,147  g ),  FFA Total     was obtained 
after a proper extraction of the NP suspension using 0.05  M sodium 
hydroxide solution. The obtained drug entrapment was 63.6% 
w/w. 
 Gel Preparation 
 FFA Natrosol HG was prepared with FFA dissolved in water 
under vigorous stirring. Afterwards, Natrosol was added in a pro-
portion equivalent to 1.5% (w/w) and stirred overnight until the 
polymer was completely swollen. The absence of crystals was de-
termined by microscopic inspection of the gels. 
 To prepare an FFA NP HG, a Natrosol gel (3% w/w) was mixed 
with an aqueous suspension of the NP in a 1:  1 ratio to obtain the 
same concentration as in FFA HG. The presence and integrity of 
the particles in the gel were conﬁ rmed by AFM ( ﬁ g. 1 ). In addition, 
the FFA concentration in each gel was veriﬁ ed by HPLC. 
 In the same way, an HG containing drug-free NP was pre-
pared. 
 Penetration and permeation experiments were carried out us-
ing FFA HG and FFA NP HG, each with a drug concentration of 
0.12 mg/g. 
 Skin Preparation 
 Excised human skin from Caucasian female patients, who had 
undergone abdominal plastic surgery, was used. The procedure was 
approved by the Ethics Committee of the Caritas Trägergesell-
schaft, Trier, Germany (July 6, 1998). Adequate health and no 
medical history of dermatological disease were required. After exci-
sion, the skin was cut into 10  ! 10 cm 2  pieces and the subcutane-
ous fatty tissue was removed from the skin specimen using a scalpel. 
Afterwards the surface of each specimen was cleaned with water, 
wrapped in aluminium foil and stored in polyethylene bags at 
–26  °  C until use. Previous investigations have shown that no 
change in the penetration characteristics occurs during the storage 
time of 6 months  [8, 24] . 
 Discs of 25 mm in diameter were punched out from frozen skin, 
thawed, cleaned with Ringer solution, and either transferred di-
rectly into the SB-M or used to prepare heat-separated epidermis 
sheets for the FD-C experiment. 
 Heat-Separated Epidermis Preparation 
 The epidermis was separated placing the thawed and cleaned 
skin disc in water at 60  °  C for 90 s. After that, the skin was removed 
from the water and placed, dermal side down, on a ﬁ lter paper. The 
epidermal layer was peeled off from the skin using forceps. Before 
use in the FD-C, the epidermal membrane was prehydrated for 
1 h. 
 Permeation Experiments 
 Using an FD-C, experiments were carried out using heat-sepa-
rated epidermis mounted on a cellulose membrane disc. The mem-
brane was positioned between the donor and acceptor compart-
ment. As donor 750   l of preparation and as receptor 12.1 ml of 
Sörensen phosphate buffer (pH 7.4) were used. The donor compart-
ment was sealed with aluminium foil and the system was main-
tained at 32  8 1  °  C in a water bath. The acceptor ﬂ uid was stirred 
using magnetic bars at 500 rpm. At predetermined time intervals, 
samples of 1.0 ml were collected from the acceptor medium and 
replaced immediately with fresh buffer solution. Samples were col-
lected for 29 h and analysed by HPLC. 
 Release experiments were done in the same way but using a cel-
lulose membrane to separate donor and receptor compartment. 
 Penetration Experiments 
 Using a SB-M apparatus, a full-thickness skin disc was trans-
ferred into the cavity of a Teﬂ on block on ﬁ lter paper soaked with 
Ringer solution to prevent any change in the hydration state of the 
skin. The cavity of the upper Teﬂ on punch was ﬁ lled with the drug 
preparation and ﬁ xed in position. The gap between the two Teﬂ on 
parts was sealed with Plastibase to avoid water loss from the skin. 
The whole apparatus was transferred into an oven at 32  8 1  °  C for 
a predetermined incubation time. For details, see Wagner et al. 
 [21] . 
 Skin Segmentation 
 After the incubation time, all the skin specimens investigated 
with SB-M were segmented using the tape stripping and cryosec-
tioning methods. For detailed descriptions, the reader is referred 
to Wagner et al.  [21] . 
 Tape Stripping Method. The samples obtained were pooled ac-
cording to the following scheme: No. 1 = 1 strip, No. 2 = 1 strip, 
No. 3 = 3 strips and No. 4–6 = 5 strips.  
 Cryosectioning. After tape stripping, the skin was rapidly frozen 
in a stream of expanding carbon dioxide. A specimen of 13 mm in 
diameter was punched out from the stripped area and transferred 
into a cryomicrotome. The sections were pooled using the following 
scheme: No. 1 = incomplete cuts, No. 2–5 = 2  ! 25   m, No. 6–10 
= 4  ! 25   m, No. 11–15 = 6  ! 25   m, No. 16 = 8  ! 25   m, No. 
17 = rest of skin.  
 Sample Extraction 
 The pooled samples were extracted with 0.05  M sodium hydrox-
ide solution and shaken during 2 h at room temperature. After that, 
tape stripping samples were separated from the solid content and 
directly transferred to the HPLC system. The samples of cryosec-
tioning were centrifuged at 456  g for 30 min; afterwards the super-
natant was separated and transferred to the HPLC system. 
 HPLC Method 
 All the samples were analysed using the following HPLC con-
ditions: column LiChrospher 100 RP-18, 5   m, 125  ! 4 mm 
(Merck); mobile phase: McIlvaine buffer pH 2.2, methanol (20:  80); 
ﬂ ow rate: 1.2 ml/min; wavelength: 284 nm; injection volume: 
20   l; retention time: 3.5  8 0.2 min. This method has been previ-
ously validated by Wagner et al.  [21] . 
 Area under the Penetration Curve  
 The area under the penetration curve (AUPC) was calculated 
from the curves of the penetrated amount per cubic centimetre of 
skin (C =   g/cm 3 ) versus depth (d =   m) obtained from the SB-M 
experiments, using the following equation: 
 
( ) ( )1
1
n
i i i i
i
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=
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 Statistical Evaluation 
 For statistical evaluation, SigmaStat 3.0.1 was used. 
 Multiphoton Fluorescence Imaging 
 Skin samples were punched out, thawed and cleaned before gel 
application and image acquisition. Plain Natrosol HG, HG con-
taining non-loaded NP or containing FFA-loaded  NP were applied 
to the skin and imaged using multiphoton ﬂ uorescence imaging 
with a 40 ! /NA 1.3 (oil) objective, at an excitation wavelength of 
  = 720 nm (pulse length 170 fs, repetition rate 90 MHz) and an 
average power of 13 mW. Images were acquired in less than 30 min 
after application of the gel onto the skin. Acquisition time was cho-
sen to be 25 s for a 512  ! 512 pixel image. Starting at the skin 
surface (z = 0   m) every 2.3   m an image was recorded to ﬁ nally 
obtain a 200  ! 200  ! 46   m 3  stack. The focal plane was varied by 
a piezo-driven objective, allowing to survey the entire epidermis 
down to the stratum basale. 
 Results 
 To avoid any interindividual variability of human 
skin, all penetration and permeation experiments were 
carried out with skin from the same donor and repeated 
6 times. Only for visualization studies was skin from a 
different donor used. 
 As shown by AFM in  ﬁ gure 1 , the incorporation of NP 
(mean size 328.2 nm, PI 0.16) into a hydroxyethyl cellu-
lose gel has no inﬂ uence on shape and size distribution of 
the particles, conﬁ rming that the HG contained undam-
aged NP. 
 Release Experiments 
 Release experiments have shown very similar proﬁ les 
for free and nanoencapsulated drug ( ﬁ g. 2 ). 
 Penetration Experiments 
 Stratum corneum  
 Between the free and the nanoencapsulated drug, no 
statistically signiﬁ cant difference in the amount of FFA 
accumulated in the stratum corneum, expressed as AUPC, 
was detected at any incubation time. Furthermore, it is 
remarkable that there was a slight decrease of the AUPC 
for both formulations with increasing incubation time 
( ﬁ g. 3 A). 
 Deeper Skin Layers (Viable Epidermis and Dermis)  
 For these layers, statistically signiﬁ cant differences in 
the FFA amounts between the 2 formulations (t test, p  ! 
 Fig. 2. Percentage of FFA released from FFA HG and FFA NP 
HG. 
 Fig. 1. AFM images of FFA containing NP.  A Aqueous suspension. 
 B Incorporated into Natrosol HG. 
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0.05) were observed at 3 and 24 h of incubation time, re-
spectively. Interestingly, after 3 h, higher levels were found 
for the preparation containing the free drug than for the 
NP formulation. In contrast, after 24 h, this relation was 
inverted, i.e. a considerably higher amount of drug has 
penetrated from NP compared to the free drug ( ﬁ g. 3 B). 
In addition, a decrease compared with the 6-hour values 
was observed for both preparations, although the same 
preparations were used. This may be due to a radial dif-
fusion in the SB-M. Considering that the drug was ex-
tracted only from samples obtained from a disc of 13 mm 
(in diameter) of the stripped area, not all the drug can be 
detected. For both preparations, FFA was detected in the 
ﬁ lter paper under the skin, indicating that the sink condi-
tions, which favour the vertical diffusion of the drug, were 
not maintained completely and therefore could have in-
ﬂ uenced the obtained results. However, one can assume 
that for both experimental series the effect occurs in the 
same magnitude. Therefore, direct comparison of the na-
noencapsulated drug preparation and the free drug prepa-
ration at this incubation time is still justiﬁ ed. 
 Permeation Experiments 
 For better comparison, the same time points as chosen 
in the penetration studies (SB-M) were used in the per-
meation experiments (FD-C). At shorter incubation times 
( ! 12 h), there were no signiﬁ cant differences in the per-
meated amount of the drug. The levels of the free drug 
formulation tended to be slightly increased, but the dif-
ferences were not statistically signiﬁ cant ( ﬁ g. 4 ). How-
ever, for longer incubation times (24 h and later), there 
was a statistically signiﬁ cant inversion of the drug amount 
permeated, i.e. more drug had permeated from the nano-
encapsulated drug formulation compared to the free drug 
formulation. 
 Visualization Experiments 
 Multiphoton ﬂ uorescence imaging experiments were 
carried out using a particle-free HG, an HG containing 
drug-free NP and an HG with FFA NP. As expected, the 
skin shows an autoﬂ uorescence and structure correspond-
 Fig. 3. AUPC of FFA penetrated into human skin using the SB-M 
at different incubation times (n = 6).  A Stratum corneum.  B Deep 
skin layers. 
 Fig. 4. Permeation of the FFA amount through heat-separated hu-
man epidermis using the FD-C system (asterisks indicate statisti-
cally signiﬁ cant differences). 
6.4 Influence of nanoencapsulation on human skin transport of flufenamic acid
117
 Inﬂ uence of Nanoencapsulation on Skin 
Transport of Flufenamic Acid  
 Skin Pharmacol Physiol 2006;19:190–197 195
ing to published data  [23] . In preliminary studies, it was 
found that neither FFA in solution nor FFA crystals could 
be visualized in the HG by this technique. However, 
 nanoencapsulated FFA yielded a ﬂ uorescence signal 
probably due to the fact that the ﬂ uorescence of the drug 
is favoured by the non-polar and acidic environment of 
the polymer ( ﬁ g. 5 )  [25] . The ostensive size of some of the 
NP in the multiphoton images on the order of a few mi-
crometres is due to (1) the system resolution (dx = dy = 
approx. 0.4   m, dz = approx. 1   m); (2) partial aggrega-
tion, and (3) the Brownian motion of the subdiffraction-
limit-sized particles during image acquisition. Transver-
sal drift of the particles led to stretched shapes of their 
ﬂ uorescence spots. 
 Fig. 5. Multiphoton ﬂ uorescence imaging 
of plain HG ( A ), FFA NP HG ( B ), skin with 
plain HG ( C ), skin with drug-free NP HG 
( D ), skin with FFA NP HG distributed on 
the surface ( E ) and skin with FFA NP HG 
in the dermatogyphs at a depth of 16   m 
( F ). 
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 The multiphoton sections taken at different relative 
depths (0–50   m) to the surface of the human epidermis 
after treatment with the FFA NP formulation showed a 
consistent lateral and normal uniform distribution of par-
ticles on the skin surface and within the dermatoglyphs. 
However, no particles were detected within and between 
the corneocytes ( ﬁ g. 5 E, F). The particle distribution was 
not indicative of accumulation in any skin structure at 
least after 30 min of incubation.  
 Discussion 
 Using the SB-M, no differences in drug transport into 
the stratum corneum could be detected for the nanoen-
capsulated compared to the free drug ( ﬁ g. 3 ). Normally for 
inﬁ nite dose experiments, it would be expected that the 
drug amount in the stratum corneum reaches a plateau 
while in the deep skin layers the drug amount increases. 
In our experiments, it is remarkable that a slight decrease 
of drug amounts for both preparations is visible for the 
stratum corneum. The reason might be a radial spreading 
of the preparation on the skin specimen surface. 
 For the deep skin layers, the permeation of the drug 
appeared lower when delivered by NP in comparison to 
the free drug preparation in both test systems for rela-
tively short incubation times ( ! 12 h). 
 In contrast to the results obtained at short incubation 
times, the proportion of drug transported into the deep 
skin layers was inverted after longer incubation times 
( 1 12 h). A statistically signiﬁ cantly higher level of drug 
was found for the nanoencapsulated drug compared to 
the free drug with both techniques, the FD-C and SB-M 
( ﬁ g. 3 ,  4 ). The mechanisms how NP increase the amount 
of FFA in the deep skin layers at longer incubation times 
remain unclear. Since the overall concentration of the 
FFA in the FFA HG and in FFA NP HG is equal, this 
should not affect the drug transport. However, it may be 
speculated that the degradation of the particles leads to 
some release of acidic compounds (lactic and glycolic 
acid). This acidiﬁ cation of the particles and their sur-
roundings favours the non-ionized form of FFA which 
penetrates the stratum corneum better. pH changes of the 
PLGA particles due to the degradation has been previ-
ously reported by Fu et al.  [26] . Furthermore, if particles 
were able to cross the stratum corneum  [9] after a certain 
incubation time, this could also increase the amount tak-
en up. However, multiphoton ﬂ uorescence imaging does 
not give any hint to this mechanism, at least not after a 
short incubation time (30 min). 
 Our attempts to visualize drug transport into the skin 
by multiphoton ﬂ uorescence microscopy were restricted 
to the nanoencapsulated drug, while the free FFA did not 
yield any ﬂ uorescence signal. The distribution of NP ap-
plied to the skin appeared to be homogeneous within the 
HG and followed the structure of the skin surface and the 
dermatoglyphs. No hair follicles or sweat glands were ob-
served, so that possible transport of NP along these struc-
tures such as previously reported by others  [10, 11, 15] 
could not be conﬁ rmed by this study. At least after the 
relatively short incubation time of 30 min, no particles 
were detected within or in between the corneocytes. The 
visualization of drug transport processes for NP after lon-
ger incubation times ( 1 12 h) is still ongoing and subject 
of further investigations. 
 In summary, while there were no differences between 
free and nanoencapsulated drug in the stratum corneum, 
such differences became visible at the level of the deep 
skin layers. After shorter incubation times ( ! 12 h), a sig-
niﬁ cantly higher penetration was obtained with the free 
drug preparation, suggesting that nanoencapsulation 
causes a slight delay of drug transport, whereas, for longer 
incubation times ( 1 12 h), the result was inverted and up 
to 50% more of drug was transported into the deep skin 
layers by the NP compared to the free drug formula-
tion. 
 Conclusion 
 In this study, the effect of the nanoencapsulated FFA 
on the skin transport was investigated at different incuba-
tion times using permeation and penetration systems 
(FD-C and SB-M, respectively). For shorter incubation 
times ( ! 12 h), a slight delay in the skin transport was ob-
served. In contrast, for longer incubation times ( 1 12 h), 
the drug transport was enhanced for the nanoencapsu-
lated drug compared to the free drug. Although not yet 
fully understood, such observation underscores the po-
tential of nanotechnology for transdermal drug delivery. 
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Abstract 
Generally, polymeric nanoparticles (NP) for drug targeting are designed to 
entrap the drug moiety in the core and to present the targeting moiety on the surface. 
However, in most cases, common preparation techniques of polymeric NP need to be 
specifically arranged for each compound to be entrapped or attached. In the present 
work we introduce a method for versatile conjugation of targeting moieties to the 
surface of preformed, polymeric NP. Moreover, due to taking advantage of biotin-avidin 
interactions, our regime opens the additional possibility of a rapid fluorescence labelling 
of NP. 
Poly(D,L-lactide-co-glycolide) (PLGA) NP in the size of 210 nm were prepared by the 
classic oil-in-water method. Such NP were functionalized with biotin-
(polyethyleneglycol)amine (BPEG) by means of cyanuric chloride chemistry. The 
amount of surface associated biotin was 850 pmol per mg polymer corresponding to 
roughly 2,650 molecules biotin per NP. When drawn to scale, such surface coating 
appeared to be well suited for subsequent binding of avidin or avidin-linked ligands. By 
resonant mirror measurements we could prove specific binding of biotinylated NP to a 
NeutrAvidin (NAv) coated surface. Furthermore, after coupling of NAv-linked 
fluorescence dyes to BPEG functionalized NP, differences in binding and uptake could 
be demonstrated using two epithelial cell lines (Caco-2, A549). 
 
 
 
 
 
 
 
 
 
 
 
Keywords: biotin, fluorescence dye, cyanuric chloride, neutravidin, PLGA 
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1 Introduction 
Polymeric nanoparticles (NP) have turned out to be a promising carrier system 
for a number of active pharmacological ingredients (API) because they allow controlled 
release, drug targeting, and overcoming certain biological barriers such as the blood 
brain barrier (1-4), the skin (5-9), or the intestinal mucosa (10-13). 
In this context, biocompatible and biodegradable polymers are highly preferred as they 
are eliminated from the body as small non-toxic fragments after having served their 
intended purpose (14). Well-known examples of such polymers are the aliphatic 
poly(esters) poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymers 
poly(lactic acid-co-glycolic acid) (PLGA); they have been extensively used since the 
1970s for biomedical applications like sutures, fibres, fracture repairs, implants, and 
vascular grafts (15). Later, mainly PLA and PLGA have also been applied for the 
preparation of NP (4, 6, 16-21) which resulted in a variety of well established methods 
for preparation and drug entrapment (14, 15). Nowadays, a major interest of research is 
the synthesis of novel biodegradable polymers for the preparation of NP with different 
drug loading properties, controlled release, and predictable degradation (22-28). Most 
of them are block-copolymers (22, 23, 26) or polymer blends (27) often also containing 
PLGA or PLA subunits (26-28).  
Generally, nanoparticulate drug targeting systems may bear different functionalities. 
The inner functionality is reflected by the NP core encapsulating the active moiety, small 
drug molecules (6, 8, 29-32), or therapeutic proteins (16, 33-35). The active compound 
is stabilized towards the physiological environment and its release can be controlled by 
the composition and structure of the polymer matrix. Complementarily, the outer 
functionality of a NP is represented by the NP surface which may establish specific and 
non-specific interactions with the target, e.g. some particular cells, tissues, or organs. In 
regard of drug targeting, specific interactions between NP and the target cells or 
tissues are favoured, requiring a sufficient number of targeting ligands on the NP 
surface to be available for such interaction (36-38). 
The aim of this study was to develop a procedure for surface functionalization of 
preformed NP, which may eventually already contain an API, for subsequent versatile 
conjugation of targeting ligands and fluorescence dyes under mild conditions. For such 
purpose we chose the avidin-biotin system as avidin (Av) and its homologues 
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streptavidin (SAv) and NeutrAvidinTM (NAv) exhibit very high affinities (Kd = 10
 -13 – 10 -
16 M) and a rapid and stable binding to biotin (39, 40). Taking into consideration the 
presence of free carboxylic acid groups on the surface of NP made of poly(esters) like 
PLA, PLGA, PGA and diverse lactide and/or glycolide containing blends and block-
copolymers (23, 26, 27) we have opted for an approach where surface biotinylated NP 
bind to conjugates of avidin (or homologues). Consequently, both targeting moieties 
(antibodies, Fab fragments, etc.) as well as fluorescence labels can be easily linked to 
the surface of thus functionalized NP as long as they are available as conjugates of 
avidin (or homologues) (Figure 1A). 
In the present study an effective surface biotinylation of preformed PLGA NP cores 
could be demonstrated. PLGA NP were characterized for their size, zeta potential and 
surface characteristics before and after biotin functionalization. The particle associated 
biotin amount was determined to scale. Resonant mirror measurements gave evidence 
for specific binding of biotinylated NP to a NAv surface. For first evaluation in a 
biological system, differences in binding and uptake of NP were studied in two epithelial 
cell lines after labelling the NP with Av linked fluorescence dyes. 
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2 Methods and materials 
 
2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLGA) (Resomer RG 50:50 H; inherent viscosity 
0.31 dl/g) was kindly provided by Boehringer Ingelheim (Boehringer Ingelheim GmbH & 
Co. KG, Ingelheim, GE). Biotin-(polyethyleneglycol)amine (BPEG) was obtained from 
Sigma (Sigma Chemical Co., St. Louis, MO, USA). Polyvinylalcohol (PVA) (Mowiol 4-88) 
was bought from Kuraray (Kuraray Specialities GmbH, Frankfurt am Main, GE). 
NeutrAvidinTM Biotin-Binding Protein (NAv), avidin - FITC conjugate (FITC-Av), 
streptavidin - FITC conjugate (FITC-SAv), and NeutrAvidinTM - FITC conjugate (FITC-
NAv) were purchased from Pierce (Perbio Science Deutschland GmbH, Bonn, GE). 
NeutrAvidinTM - Rhodamin RedTM – X conjugate (Rho-NAv) was obtained from Invitrogen 
(Molecular Probes, Inc., Eugene, OR, USA). Rhodamine ricinus communis agglutinin I 
(Rho-RCA) and fluorescein wheat germ agglutinin (FITC-WGA) were obtained from 
Vector (Vector Laboratories, Inc., Burlingame, CA, USA). Dulbecco’s modified Eagle’s 
medium (DMEM), RPMI-1640, non-essential amino acids (NeAA) and fetal bovine 
serum (FBS) were bought from GIBCO (Invitrogen Corp., Carlsbad, CA, USA). All other 
chemicals were of analytical grade. Phosphate buffered solution pH 7.4 (PBS) was 
composed of KCl 0.20 g/l, NaCl 8.00 g/l, KH2PO4 0.20 g/l, Na2HPO4 × 2H2O 1.44 g/l. 
 
2.2 Preparation of biotin-(polyethyleneglycol)amine coated PLGA nanoparticles 
PLGA NP were prepared by a single emulsion method (41). Briefly, 100 mg of 
PLGA were dissolved in 5 ml of ethyl acetate and emulsified into a 1% PVA solution. The 
system was stirred at room temperature for 2 h at 800 rpm on a magnetic stirrer and 
then homogenized for 10 min using an Ultra-Turrax® T 25 Mixer (Janke und Kunkel 
GmbH & Co., Staufen, GE) at 13,500 rpm. The volume was filled up to 50 ml with 
demineralised water and the organic solvent was evaporated using a rotary evaporator. 
BPEG coated PLGA NP (BPEG PLGA NP) were generated from PLGA NP via a triazine-
promoted amidation of the carboxylic acid groups present on the PLGA NP surface. 
The technique has been frequently described in the literature (42-44); here it was 
adapted to surface modification of PLGA NP. The carboxylic acid groups formed 
activated intermediates with cyanuric chloride and, subsequently, the desired carboxyl 
amides in a single one-step reaction (Figure 2). The amino groups for the amidation 
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reaction derived from BPEG. 1 ml of PLGA NP suspension was supplemented with 1 ml 
of saturated cyanuric chloride solution and 50 μl of 10 mg/ml BPEG solution and 
incubated at room temperature for 24 h under gentle shaking on a horizontal shaker. 
BPEG PLGA NP were rinsed from excessive reagents by dialysis against 2 l of 
demineralised water for 24 h using a dialysis membrane with a cut-off of 100,000 Da 
(Spectra Por® CE, Carl Roth GmbH, Karlsruhe, GE). The dialysis water was renewed 
after 8 h of dialysis time. In case blank PLGA NP were used for comparison, they were 
also dialysed as described above. The NP concentration was determined via the 
residue of a defined volume of NP suspension after lyophilization. NP were prepared 
with a total of n = 3 to 5 batches. 
 
2.3 Physicochemical characterization of the nanoparticles 
 
2.3.1 Particle size and surface charge (zeta potential) 
For determination of particle size and zeta potential, the NP suspensions were 
100 fold diluted in demineralised water and analysed using a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK). The measurement of the NP size was based upon 
photon correlation spectroscopy (PCS). This technique yields the particle mean 
diameter and the polydispersity index (PI) which is a dimensionless measure for the 
broadness of the particle size distribution. The zeta potential was analysed by laser 
doppler anemometry using the same instrument in appropriate settings. Results are 
expressed as mean ± SD. 
 
2.3.2 Morphology study 
NP shape and surface properties were imaged by means of Scanning probe 
microscopy (SPM). NP samples were prepared as dense layers by mounting a drop of 
a freshly prepared NP suspension on a silicon wafer and air-drying. Imaging was 
performed using a BioscopeTM SPM and a Nanoscope IVTM controller (Veeco 
Instruments, Santa Barbara, CA, USA) in a vibration-free environment. For all 
measurements, Tapping mode™ was employed using a commercially available 
pyramidal tip (silicon, Ultrasharp, MikroMasch, Tallinn, EST) on a cantilever with a 
length of 230 μm. The resonance frequency was approximately 170 kHz, the nominal 
force constant 40 N/m, and the scan frequency between 0.1 and 1 Hz.  
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2.4 Particle associated biotin amount 
The amount of biotin on BPEG PLGA NP was determined by means of 
FluoReporter® Biotin Quantitation Assay (Molecular ProbesTM, Invitrogen GmbH, 
Karlsruhe, GE). This assay uses BiotectiveTM Green reagent which consists of Av 
labelled with a fluorescence dye and with quencher dye ligands occupying the biotin 
binding sites. The ligand quenches the fluorescence through fluorescence resonance 
energy transfer. By addition of any biotin the ligand is displaced from BiotectiveTM Green 
reagent, yielding fluorescence proportional to the amount of added biotin. The assay 
was performed according to the protocol of the manufacturer. NP suspensions were 
used in concentrations between 0.49 and 0.88 mg/ml and experiments were performed 
with 3 batches and with a total of n = 2 to 3 samples each. The background was 
subtracted. Results are expressed as mean ± SD. 
 
2.5 Modelling of biotin-(polyethyleneglycol)amine 
To determine the dimensions of BPEG we built a single stretched molecule using 
the program HyperChem Professional 7.1 (ScienceServe, Pegnitz, GE). The geometry 
optimization was performed on a personal computer employing the MM + force field. 
For the energy minimization we used a conjugate gradient method with a termination 
value of the root mean square gradient of 0.1 kcal/mol/Å according to the HyperChem 
manual. 
 
2.6 Resonant mirror system (RMS) adhesion studies 
The interaction of BPEG PLGA NP and PLGA NP with two differently modified 
surfaces was examined by means of a RMS (IAsys, Cambridge, UK). First, the 
interaction of the NP with a NAv coated surface was investigated.  
In a second run, the binding sites of NAv were blocked using a 0.02 mg/ml BPEG 
solution (incubation time ~4.5 min) to study possible non-specific binding of NP with 
this surface. 
Briefly, NP suspensions were added to the coated sensor chip and allowed to bind to 
the surface. The adhesion process was monitored and the measurements were 
stopped after 5 to 10 min. The vertical displacement of the vibrostirrer was set to 
0.425 mm and the temperature of the instrument was set to 25°C. 
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The concentrations of BPEG PLGA NP and PLGA NP were 0.5 and 1.2 mg/ml, 
respectively. The NAv functionalized surface was generated by incubating a biotin 
coated cuvette (Thermo Electron LED GmbH, Langenselbold, GE) with NAv as 
described in the IAsys standard immobilization protocol. All reactions were performed in 
PBS. 
 
2.7 Cell culture 
 
2.7.1 Caco-2 cells 
Caco-2 cells, clone C2BBe1, were purchased at passage 60 from American 
Tissue Culture Collection (ATCC; Manassas, VA, USA) and used at passages 70 to 91. 
Cells were grown to a confluency of approximately 90 % in 75 cm2 T-flasks with DMEM 
supplemented with 10 % FBS and 1 % NeAA. Thereby, the culture medium was 
changed every second day and the temperature was 37°C in an atmosphere of around 
85 % relative humidity and 5 % CO2. 
 
2.7.2 A549 cells 
A549 cells (ATCC No. CCL-185) were purchased at passage 82 from ATCC 
(American Type Culture Collection, Manassas, VA, USA) and used at passages 88 to 
110. Cells were grown to a confluency of approximately 90% in 75 cm2 T-flasks with 
RPMI-1640 supplemented with 10% FBS. Thereby, the culture medium was changed 
every second day and the temperature was 37°C in an atmosphere of around 85% 
relative humidity and 5% CO2. 
 
2.7.3 Uptake studies 
After trypsinization Caco-2 and A549 cells were seeded on LAB-TEK® chamber 
slides (Nalge Nunc International, Rochester, NY, USA) at a density of roughly 20,000 
and 12,500 cells / ml, respectively, and grown for 3 days. Uptake of test substances 
was evaluated after 6 and 24 h of incubation with a test substance at 37°C under 
protection from light. In case of the 24 h incubation time the supernatant was replaced 
by cell culture medium after 6 h. For localization of fluorescent NP cell membranes were 
stained using Rho-RCA and FITC-WGA, respectively, by incubation with a 5 μg/ml 
solution in PBS for 10 min at 37°C under protection from light. Cells were washed twice 
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with PBS and fixed by 10 min of incubation with 4% formaldehyde solution at room 
temperature under protection from light. Again, cells were washed twice and, then, 
subjected to confocal laser scanning microscopy (CLSM) which was performed using a 
Bio-Rad MRC-1024 CLSM (Bio-Rad Laboratories, Hercules, CA, USA) equipped with an 
argon/krypton laser. The objective used was an oil immersion objective 40× NA=1.3. 
Green fluorescence was collected with a band pass filter (Zeiss: 520/35) and red 
fluorescence was collected with a long pass filter (Zeiss: LP585) after excitation at 
488 nm and 568 nm, respectively. For each set of samples the same detector settings 
were chosen. Test substances were: (i) 0.5 mg/ml BPEG PLGA NP which were pre-
incubated with FITC-NAv or Rho-NAv in excess for 30 min, dialysed in order to remove 
unbound proteins, and 1:1 diluted with the respective growth medium and (ii) a 
25 μg/ml FITC-NAv or Rho-NAv solution in the respective growth medium. The 
concentrations of the FITC-NAv and Rho-NAv solutions were well above the maximum 
of NP associated fluorescent proteins in a 0.25 mg/ml BPEG PLGA NP solution when all 
biotin molecules bound to one FITC-NAv or Rho-NAv molecule. References were only 
with the respective lectin conjugated fluorescence dye stained cells without incubating 
them with particles. 
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3 Results 
 
3.1 Physicochemical properties of biotinylated nanoparticles 
PCS measurements showed that size and PI of BPEG PLGA NP and PLGA NP 
were practically the same, i.e. there was no measurable increase in size of the original 
PLGA NP after functionalization with BPEG. Particle size distributions were 
monodisperse. However, the zeta potential changed from -32 mV to -23 mV (Table 1). 
Figure 3 presents SPM images of PLGA NP, BPEG PLGA NP and BPEG PLGA NP with 
associated FITC-Av. Before subjection to SPM measurements successful binding of 
FITC-Av to BPEG PLGA NP was confirmed via CLSM. The SPM topography images 
show the particle shape and surface structure. Obviously, all samples exhibited a 
spherical particle shape and a smooth surface irrespective of any surface modifications 
as in case of the BPEG PLGA NP and the BPEG PLGA NP with associated FITC-Av. 
However, clear differences were observed in the phase images of those samples, in 
contrast to the original PLGA NP. These alterations suggest changes of the elastic or 
adhesive properties as consequence of surface biotinylation of PLGA NP and also due 
to the binding of FITC-Av to thus modified surface. 
FluoReporter® Biotin Quantitation Assay was used to quantitatively analyse the extent of 
surface modification of PLGA NP resulting in BPEG PLGA NP. By that method an 
amount of 845 ± 145 pmol of biotin attached to the surface of 1 mg of BPEG PLGA NP 
was determined. Assuming a particle density of 1.25 g/ml (which corresponds to the 
real density of PLGA according to the information of the manufacturer) an approximate 
number of 2,600 biotin molecules on the surface of one single average-sized (210 nm) 
BPEG PLGA NP could be calculated. Assuming that BPEG chains are evenly 
distributed on the NP surface, the mean distance of two chains would be 69 Å. The 
length of the BPEG chains was calculated to maximally 46 Å. In solution, we would 
expect the BPEG molecule to adopt a more or less coiled conformation, here however, 
to roughly estimate surface conditions we deliberately assumed the molecule to exist in 
a stretched conformation. The size of Av is reported to 50 Å × 50 Å × 40 Å with the 
biotin binding sites being in a distance of 29.5 and 20 Å to each other (45). The 
dimensions of such a BPEG functionalized NP surface is drawn to scale in Figure 1B 
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indicating that each single BPEG graft on the NP surface should be well accessible to 
Av. 
 
3.2 Selection of suitable avidin homologues for further functionalization 
Each of the three proteins FITC-Av, FITC-SAv and FITC-NAv bound to BPEG 
PLGA NP, whereas only FITC-Av and FITC-SAv exhibited binding to blank PLGA NP, 
obviously due to non-specific interactions. In these cases we could visualize green 
fluorescent single NP or particle aggregates by means of CLSM. In contrast, we did not 
find binding of NAv-FITC to PLGA NP. Consequently, due to apparently weak non-
specific particle binding, we chose NAv for further RMS measurements and ligand 
coupling. 
 
3.3 RMS measurements 
Using RMS, we first studied the binding of BPEG PLGA NP with a NAv 
functionalized surface (total binding) (Figure 4). We obtained a clear response, 
however, the binding curve did not reach equilibrium during the measurement, possibly 
due to particle rearrangement on the NAv coated surface. There was no observable NP 
dissociation and particles could not be washed easily from the surface indicating a 
strong binding. In a second experiment, non-specific binding was studied by blocking 
the biotin binding sites of a NAv functionalized cuvette using free BPEG. Here, we 
received only a small response. The extent of specific binding of BPEG PLGA NP to the 
NAv surface is described by a calculated curve, which was obtained by subtracting the 
curve representing the non-specific binding from the curve representing the total 
binding. Again, the curve did not reach equilibrium for reasons described above. 
For comparison, we also investigated the binding behaviour of non-functionalized PLGA 
NP to a NAv surface. Here, the equilibrium response was very small and readily 
established after approximately 100 s. 
 
3.4 Uptake studies 
Figure 5 shows xz-cross sections from a stack of confocal laser scans of Rho-
RCA stained A549 cells, Rho-RCA stained Caco-2 cells, and FITC-WGA stained Caco-2 
cells after 6 and 24 h incubation with fluorescent NP formulations. In order to investigate 
and visualise binding and uptake, we applied FITC-NAv labelled NP if the cell 
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membranes were stained with Rho-RCA, and Rho-NAv labelled NP if the membranes 
were stained with FITC-WGA. 
In case of A549 cells, NP appeared in close association with the cell membranes after 
6 h of incubation whereas we found a clear NP uptake after 24 h. In case of Caco-2 
cells, there was no particle uptake even after 24 h of incubation. However, particles 
were attached to the cell membranes. 
These results in Caco-2 cells were found with both FITC-NAv and Rho-NAv labelled 
BPEG PLGA NP, thus evidencing the suitability of this approach for rapid versatile 
fluorescence labelling. 
In all cases employing plain FITC-NAv and Rho-NAv solutions (i.e. not coupled to NP), 
we did not find any fluorescence within the cells or at the membranes which had 
derived from the protein solutions (images not shown). 
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4 Discussion 
The overall goal of this study was the evaluation of a procedure for surface 
functionalization of preformed NP made from biodegradable polymers such as PLGA. 
Surface modified NP are intended to be used for subsequent versatile conjugation of 
targeting moieties and for rapid fluorescence labelling under mild conditions. 
Preformed PLGA NP were modified by easy covalent binding of a biotin derivative via a 
short PEG spacer (Figure 2). The biotinylated particle surface forms a platform for 
further specific binding of Av (and homologues) conjugated compounds, which may 
either be targeting moieties or fluorescence dyes, by brief incubation in aqueous 
medium (Figure 1A). By this NP modification method, harsh preparation conditions like 
shearing, heating or the presence of organic solvents are avoided. Another benefit of 
this technique concerns the detachment of compounds from the NP surface for 
potential targeting purposes. If NP are made from functionalized polymers (46-48), 
ongoing polymer erosion may uncover further active groups, thus leading to a 
subsequent re-binding of detached proteins. In contrast, with our approach, the NP 
core will not provide further biotin groups as soon as they are cleaved from the surface 
i.e. specific re-binding is most unlikely. 
Regarding the biocompatibility of BPEG PLGA NP, biotin is a natural vitamin, and both 
substances, PEG and PLGA, may be considered as non-toxic (as they are part of FDA 
approved drug products for parenteral administration). 
Surface functionalization of PLGA NP to yield BPEG PLGA NP did not involve an 
increase in size as determined by PCS, i.e. any change in the hydrodynamic diameter 
was beneath the detection limit (Table 1). As evidenced in SPM studies surface 
modification of PLGA NP and binding of Av to BPEG PLGA NP did not lead to changes 
in particle shape and surface structure (Figure 3). Obviously, however, as indicated in 
the phase images those modifications resulted in changes of elasticity or adhesion of 
the cantilever tip. 
We found a decrease in the zeta potential for the BPEG PLGA NP in comparison to 
non-modified PLGA NP (Table 1). The negative surface charge of both particle species 
is attributed to the presence of carboxyl end groups deriving from PLGA chain ends. 
However, in case of the BPEG PLGA NP, the particle surface was partially shielded 
owing to covalent modification of the carboxyl groups by means of BPEG molecules. 
The PEG chain linking the biotin compound with the NP core consisted of 10 ethylene 
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oxide subunits and was conceived to facilitate the surface modification reaction by 
provision of amino groups and, at the same time, to increase biotin flexibility whilst 
protein binding. 
Studying the binding specificity of Av and its homologues to BPEG PLGA NP and PLGA 
NP, we found specific binding to BPEG PLGA NP only in case of NAv. This finding has 
to be attributed to the character of the proteins: Av and its bacterially produced 
counterpart SAv represent positively charged glycoproteins with well known tendency of 
non-specific interactions with negatively charged compounds e.g. PLGA NP. NAv is 
manufactured from Av by deglycosylation, consequently, reducing charge and non-
specific binding (49). 
The binding specificity was confirmed in RMS measurements where BPEG PLGA NP 
showed specific binding to a NAv surface (Figure 4). Attachment of BPEG PLGA NP to 
the NAv surface did not reach equilibrium during the measurement which probably is to 
be attributed to particle rearrangement; in contrast minor non-specific binding of PLGA 
NP was completed rapidly. 
For drug delivery applications, investigation and imaging of NP in biological systems, 
their penetration pathways, and their final localization at cellular or tissue level is of 
major interest (9, 18, 50). Common strategies represent the entrapment of fluorescence 
markers or visualisable drugs and the imaging of NP by fluorescence, confocal, or 
multiphoton microscopy (6, 9, 50, 51). The present work illustrates the application of 
fluorescence-labelled BPEG PLGA NP to demonstrate differences in binding and 
uptake behaviour between flat squameous epithelial cells from the alveolar epithelium 
(A549) in comparison to the relatively thick columnar epithelial cells from the intestinal 
mucosa (Caco-2) (Figure 5). Moreover, dependent on the staining of the cell 
membranes we applied NP decorated with different fluorescent NAv conjugates, thus 
demonstrating the ease of versatile fluorescence labelling of BPEG PLGA NP. 
From calculations to scale of the surface of BPEG PLGA NP we hypothesized that 
particles are optimally covered by BPEG molecules. Presumably, those molecules are 
able to reach each site on the particle surface due to the flexibility of their PEG spacer in 
order to mediate specific binding of Av (and homologues). Considering Av and 
homologues being tetrameric with four biotin binding sites it is evident that this fact may 
lead to binding of biotin molecules deriving from several NP and subsequently to cross-
linking. Nowadays, in order to overcome this cross-linking problem, one can find 
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different approaches in literature. Active monomeric Av and SAv mutants have been 
produced by means of biotechnological methods (52, 53). Since monomerization of 
those proteins generally involves loss of biotin binding affinity a SAv tetramer with only 
one functional biotin binding subunit was recently developed (54).  
Those protein mutants would help to avoid particle cross-linking, whereas the choice of 
NAv as biotin binding protein can further minimize non-specific binding. Such 
refinement of our approach by using monovalent NAv appears well possible, however, 
this is still subject to ongoing research. 
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 5 Conclusion 
Successful surface biotinylation of preformed PLGA NP, representing a model 
for NP from any other polymer exhibiting free carboxylic acid groups, could be 
demonstrated. Without interfering with or being dependent on the methods of NP 
preparation and drug loading our approach allows versatile surface decoration with 
targeting moieties and fluorescence labels under mild conditions, provided they are 
available as conjugates of NAv. Binding studies and calculations to scale of the surface 
conditions of biotinylated NP revealed optimal conditions for subsequent specific 
binding of Av conjugated ligands. In a first biological evaluation with A549 and Caco-2 
cells, BPEG PLGA NP enabled us to demonstrate differences in binding and uptake. 
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 8 Captions 
Table 1: Size, polydispersity index (PI) and zeta potential of PLGA NP and BPEG PLGA 
NP (n = 3 – 5). 
 
Figure 1: Schematic illustration of a surface modified PLGA NP by means of BPEG. 
Figure 1A gives an overview of the aims of the study. Versatile binding of targeting 
moieties is realized employing avidin (and homologues) conjugates. Binding of 
fluorescence dye conjugated avidin (and homologues) opens the possibility of an 
additional fluorescence labelling of the NP. Figure 1B represents a virtual zoom into the 
NP surface. Assuming homogenous distribution of the BPEG molecules on the NP 
surface, the mean distance is calculated to 69 Å. The length of the BPEG molecule is 
determined to roughly 46 Å. The size of avidin is reported to 50 Å × 50 Å × 40 Å with 
the biotin binding sites in a distance of 29.5 and 20 Å. 
 
Figure 2: Reaction of chemical surface modification of PLGA NP resulting in BPEG 
PLGA NP. 
 
Figure 3: SPM topography and phase images of PLGA NP, BPEG PLGA NP, and BPEG 
PLGA NP with associated FITC-Av. (bar = 250 nm) 
 
Figure 4: Results of resonant mirror system (RMS) adhesion studies: interactions of 
BPEG PLGA NP with a NeutrAvidin (NAv) surface and a NAv surface with BPEG 
blocked biotin binding sites. An additional curve calculated as the difference of both 
binding curves represents the extent of specific binding. 
 
Figure 5:xz-Cross sections from a stack of confocal laser scans (apical up) of Rho-RCA 
stained A549 cells (A), Rho-RCA stained Caco-2 cells (B), and FITC-WGA stained 
Caco-2 cells (C). Cells were imaged after 6 and 24 h incubation with FITC-NAv labelled 
BPEG PLGA NP (in case of Rho-RCA stained A549 and Caco-2 cells) and Rho-NAv 
labelled BPEG PLGA NP (in case of FITC-WGA stained Caco-2 cells). 
(bar = 50 μm × 5 μm)
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Table 1: Size, polydispersity index (PI) and zeta potential of PLGA NP and BPEG PLGA NP. 
 
 
 Size [nm] PI Zeta potential [mV] 
PLGA NP 207 ± 4 0.042 ± 0.017 -32.0 ± 3.6 
BPEG PLGA NP 207 ± 2 0.051 ± 0.004 -23.0 ± 4.1 
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Figure 1: Schematic illustration of a surface modified PLGA NP by means of BPEG. Figure 1A gives an 
overview of the aims of the study. Versatile binding of targeting moieties is realized employing avidin (and 
homologues) conjugates. Binding of fluorescence dye conjugated avidin (and homologues) opens the 
possibility of an additional fluorescence labelling of the NP. Figure 1B represents a virtual zoom into the 
NP surface. Assuming homogenous distribution of the BPEG molecules on the NP surface, the mean 
distance is calculated to 69 Å. The length of the BPEG molecule is determined to roughly 46 Å. The size 
of avidin is reported to 50 Å × 50 Å × 40 Å with the biotin binding sites in a distance of 29.5 and 20 Å. 
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Figure 2: Reaction of chemical surface modification of PLGA NP resulting in BPEG PLGA NP. 
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Figure 3: SPM topography and phase images of PLGA NP, BPEG PLGA NP, and BPEG PLGA NP with 
associated FITC-Av. (bar = 250 nm) 
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Figure 4: Results of resonant mirror system (RMS) adhesion studies: interactions of BPEG PLGA NP with 
a NeutrAvidin (NAv) surface and a NAv surface with BPEG blocked biotin binding sites. An additional 
curve calculated as the difference of both binding curves represents the extent of specific binding. 
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Figure 5:xz-Cross sections from a stack of confocal laser scans (apical up) of Rho-RCA stained A549 
cells (A), Rho-RCA stained Caco-2 cells (B), and FITC-WGA stained Caco-2 cells (C). Cells were imaged 
after 6 and 24 h incubation with FITC-NAv labelled BPEG PLGA NP (in case of Rho-RCA stained A549 
and Caco-2 cells) and Rho-NAv labelled BPEG PLGA NP (in case of FITC-WGA stained Caco-2 cells). 
(bar = 50 μm × 5 μm) 
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 Unpublished results 
 
1 Introduction 
As described in detail in the publication `Coupling of biotin-(polyethylene-
glycol)amine to poly(D,L-lactide-co-glycolide) nanoparticles for versatile surface 
modification´, a procedure for surface functionalization of preformed NP was 
developed aming for subsequent versatile conjugation of targeting ligands and 
fluorescence dyes under mild conditions. For this purpose, the avidin-biotin system was 
chosen such that biotin-(polyethyleneglycol)amine (BPEG) modified poly(D,L-lactide-
co-glycolide) (PLGA) NP (BPEG PLGA NP) bind to conjugates of avidin (Av) and its 
homologues streptavidin (SAv) and NeutrAvidin (NAv). Consequently, both targeting 
moieties and fluorescence labels may be easily linked to the surface of thus 
functionalized NP by brief incubation in aqueous medium as long as they are available 
as conjugates of Av (or homologues). Such method may be well applicable to NP made 
from any other aliphatic polyester like PLA, PGA, or block-copolymers1-3 which may 
eventually already contain active pharmacological ingredients. Thereby, harsh 
preparation conditions like shearing, heating, or the presence of organic solvents can 
be avoided. 
In the publication, binding studies and calculations to scale of the surface of BPEG 
PLGA NP revealed optimal conditions for subsequent specific binding of Av linked 
compounds. Successful fluorescence labelling of BPEG PLGA NP was confirmed 
employing diverse NAv linked fluorescence dyes. In a first biological evaluation, such 
fluorescent NP were shown to be well suitable to study differences in binding and 
uptake using two epithelial cell lines (Caco-2, A549).  
Objectives of the present chapter were based on the results of the publication 
`Coupling of biotin-(polyethylene-glycol)amine to poly(D,L-lactide-co-glycolide) 
nanoparticles for versatile surface modification´. 
First, the fluorescence labelling of BPEG PLGA NP by means of FITC-NeutrAvidin (FITC-
NAv) was studied. This has already been qualitatively been proven in the publication, 
aiming for a quantification of the labelling efficiency. Second, the surface binding of 
horse radish peroxidase- streptavidin (HRP-SAv) as a model protein conjugate was 
examined. HRP-SAv may be replaced by any Av (or homologues) linked proteinogenic 
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 targeting moiety (e.g. lectins or antibodies) which may be easily produced by covalent 
cross-linking4, 5 or by biotechnological methods.6 In the context of those binding 
experiments and in order to illumine the results, additional studies on the effect of biotin 
and BPEG in solution on the fluorescence and enzymatic activity of FITC-NAv and HRP-
SAv, respectively, were performed. 
 
2 Materials and methods 
 
2.1 Materials 
BPEG PLGA NP and blank PLGA NP were prepared as described in the 
publication `Coupling of biotin-(polyethylene-glycol)amine to poly(D,L-lactide-co-
glycolide) nanoparticles for versatile surface modification´. 3,3´,5,5´-
Tetramethylbenzidine (TMB), biotin-(polyethyleneglycol)amine (BPEG), and biotin were 
obtained from Sigma (Sigma Chemical Co., St. Louis, MO, USA). FITC-NeutrAvidinTM 
conjugate (FITC-NAv) and horse radish peroxidase-streptavidin conjugate (HRP-SAv) 
were purchased from Pierce (Perbio Science Deutschland GmbH, Bonn, GE). All other 
chemicals were of analytical grade. 
 
2.2 Binding of proteins to biotin-(polyethyleneglycol)amine modified nanoparticles 
Binding studies were performed in an inverse setup. The fluorescence (FITC-
NAv) or absorption (HRP-SAv) derived from a protein containing particle suspension 
and from the supernatant of a centrifuged protein containing particle suspension were 
determined with respect to the fluorescence or absorption derived from the overall 
protein amount applied in the assays. Thereby, the protein concentrations were chosen 
in order to provide at least one protein molecule per biotin binding site on the BPEG 
PLGA NP. For comparison, binding to non-modified PLGA NP was investigated 
analogously. Reference samples were particle-free, however, treatment was the same. 
All experiments were performed in demineralised water. 
 
2.2.1 FITC-NeutrAvidin 
150 μl of NP suspension were incubated with 150 μl of FITC-NAv (100 μg/ml) for 
30 min at room temperature under gentle shaking and protection from light. From this 
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 mixture, 100 μl of sample were withdrawn to determine the overall fluorescence. After 
centrifugation at 23,147 for 10 min, 100 μl of sample were withdrawn from the 
supernatant to determine the supernatant fluorescence. The fluorescence of all 
samples was measured using a Cytofluor II fluorescence reader (PerSeptive 
Biosystems, Wiesbaden-Norderstedt, GE); excitation and emission wavelengths were 
485 and 530 nm, respectively. In preliminary experiments it was confirmed that blank 
BPEG PLGA NP and PLGA NP did not exhibit fluorescence under these conditions. The 
number of replicates was n = 3 and results are expressed as mean ± SD. Statistical 
analysis was performed using SigmaStat 3.0 (Systat Software GmbH, Erkrath, GE). 
 
2.2.2 Horse radish peroxidase-streptavidin 
100 μl of NP suspension were incubated with 100 μl of HRP-SAv (2 μg/ml) 
solution for 30 min at room temperature under gentle shaking. From this mixture, 50 μl 
were withdrawn (overall sample). After centrifugation at 23,147 g for 10 min, 50 μl were 
withdrawn from the supernatant (supernatant sample). The samples were diluted 
1:2000 until the concentrations were appropriate for subsequent reaction with TMB. 
Then, 100 μl of TMB was added to 50 μl of each diluted sample and incubated for 
30 min under protection from light. After addition of 100 μl of 0.5 M H2SO4, the formation 
of a bluish dye was determined at 450 nm using a Tecan SLT spectrophotometer 
(Tecan Deutschland GmbH, Crailsheim, GE). In preliminary experiments it was 
confirmed that blank BPEG PLGA NP and PLGA NP did not influence the formation of 
dye under these conditions. The number of replicates was n = 3 to 5 and results are 
expressed as mean ± SD. Statistical analysis was performed using SigmaStat 3.0. 
 
2.3 Effect of biotin and biotin-(polyethyleneglycol)amine on FITC-NeutrAvidin 
BPEG and biotin solutions were 1:2 diluted with a 142 μg/ml FITC-NAv solution 
in demineralised water and incubated for 10 min under gentle shaking and protection 
from light. Subsequently, fluorescence measurements were performed again using 
excitation and emission wavelengths of 485 and 530 nm, respectively. 
Biotin and BPEG solutions were applied in concentrations from 0 to 28 μg/ml and from 
0 to 100 μg/ml, respectively. The concentrations were chosen to comprise the intervals 
of a possible saturation of one to four biotin binding sites of NAv. The experiments were 
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 performed with n = 3 repeats. The results are expressed as relative fluorescence 
(mean ± SD) i.e. the fluorescence of the BPEG and biotin solutions in regard to the 
fluorescence of a blank FITC-NAv solution of the same concentration. 
 
2.4 Effect of biotin and biotin-(polyethyleneglycol)amine on horse radish peroxidase-
streptavidin 
BPEG and biotin solutions were 1:2 diluted with a 1·10-9 mg/ml HRP-SAv solution 
in demineralised water and incubated for 10 min under gentle shaking. 100 μl of TMB 
was added to 50 μl of each sample and incubated for 30 min under protection from 
light. After addition of 100 μl of 0.5 M H2SO4 the formation of a bluish dye was 
determined as described in 2.2.2.  
Biotin and BPEG solutions were applied in concentrations from 0 to 1·10-7 mg/ml and 
from 0 to 4·10-7 mg/ml, respectively. The concentrations were chosen to comprise the 
intervals of a possible saturation of one to four biotin binding sites of SAv. Experiments 
were performed with n = 3 repeats. Results are expressed as relative absorption i.e. the 
absorption derived from of the BPEG and biotin solutions in regard to the absorption 
derived from a blank HRP-SAv solution of the same concentration catalyzing the 
formation of a bluish dye. 
 
3 Results 
 
3.1 Binding of FITC-NeutrAvidin 
As outlined in Figure 1, there was no statistically significant difference between 
the relative fluorescence in the overall and in the supernatant samples of BPEG PLGA 
NP (ANOVA, P = 0.48). However, the difference between all other samples (ANOVA, 
P < 0.05) was statistically significant. In comparison to the reference, the relative 
fluorescence was increased in case of BPEG PLGA NP and PLGA NP. Moreover, 
centrifugation of the overall samples led to an obvious loss of fluorescence in case of 
the PLGA NP and the reference. 
Since employing the same FITC-NAv amount, the overall BPEG PLGA NP, the overall 
PLGA NP, and both reference samples should have exhibited the same relative 
fluorescence. Moreover, assuming a specific binding of FITC-NAv to BPEG PLGA NP 
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 and minor non-specific binding to PLGA NP the fluorescence in the supernatant should 
have been decreased when compared to the overall sample. 
 
 
Figure 1: Fluorescence of the overall and of the supernatant samples relative to the fluorescence of the 
applied FITC-NAv amount in the assay. Test substances were BPEG PLGA NP and PLGA NP. References 
were particle-free, however, treated analogously. 
 
3.2 Binding of horse radish peroxidase-streptavidin 
The absorption at 450 nm which derived from the formation of a bluish dye 
catalyzed by HRP was practically the same in all samples (Figure 2). There was no 
statistically significant difference (ANOVA, P = 0.985). 
In accordance to 3.1, a smaller relative absorption in the supernatant samples of both 
particle species than in the overall samples and in the reference samples was expected 
due to specific binding in case of BPEG PLGA NP and non-specific binding in case of 
PLGA NP. 
 
Figure 2: Absorption (450 nm) of the overall and of the supernatant samples relative to the absorption of 
the amount of HRP-SAv applied in the assay; absorption derived from the formation of a bluish dye 
catalyzed by HRP. Test substances were BPEG PLGA NP and PLGA NP. References were particle-free, 
however, treated analogously. 
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 3.3 Effects of biotin and biotin-(polyethyleneglycol)amine on FITC-NeutrAvidin 
 
3.3.1 Biotin 
Figure 3A shows that different biotin concentrations led to altered fluorescence 
of a FITC-NAv solution. The initial increase of the relative fluorescence could be 
described by an asymptotic function of the form y = a-b·cx (a = 1.4, b = 0.38, 
c = 7.3·10-7, R2 = 0.998; an exponential fit of same quality was also possible) 
(Figure 3B). For concentrations between 0.21 and 0.90 μg/ml the fluorescence reached 
a plateau, until, at higher concentration, the fluorescence decreased up to 31% with 
regard to a blank FITC-NAv solution. At a concentration of 1.4 μg/ml, biotin saturation of 
4 potential biotin binding sites of all FITC-NAv molecules applied in the assay was 
theoretically possible. 
 
  A  
B  
Figure 3: Fluorescence of a FITC-NAv solution containing different concentrations of biotin with regard to a 
blank FITC-NAv solution (A), and a zoom into A in a concentration range of 0 to 0.90 μg/ml fitted by an 
asymptotic function (B). 
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 3.3.2 Biotin-(polyethyleneglycol)amine 
BPEG led to an increased fluorescence of a FITC-NAv solution (Figure 4A). As 
with biotin, the initial increase in the relative fluorescence could be described by an 
asymptotic function of the form y = a-b·cx (a = 1.3, b = 0.36, c = 0.018, R2 = 0.862) 
(Figure 4B). For concentrations ranging from 0.49 to 6.30 μg/ml the fluorescence 
reached a plateau. However, in contrast to the results obtained with biotin, at higher 
concentration, the fluorescence increased up to 263% with regard to a blank FITC-NAv 
solution. At a concentration of 3.9 μg/ml BPEG, saturation of 4 potential biotin binding 
sites of all FITC-NAv molecules applied in the assay was theoretically possible. 
 
    A  
B  
Figure 4: Fluorescence of a FITC-NAv solution containing different concentrations of BPEG with regard to 
a blank FITC-NAv solution (A), and a zoom into A in a concentration range of 0 to 6.30 μg/ml fitted by an 
asymptotic function (B). 
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 3.4 Effects of biotin and biotin-(polyethyleneglycol)amine on horse radish peroxidase-
streptavidin 
In contrast to FITC-NAv, biotin and biotin-(polyethyleneglycol)amine in different 
concentrations did not exhibit influence on HRP-SAv i.e. the formation of a bluish dye 
from TMB catalyzed by HRP was practically the same when compared to a blank HRP-
SAv solution. 
 
4 Discussion 
Aiming for a quantification of particle bound proteins, first the interaction of BPEG 
PLGA NP and PLGA NP with FITC labelled NAv were studied. From those experiments 
a decrease in fluorescence of the supernatant samples was expected when compared 
to the overall samples being ascribed to a specific binding mediated by a number of 
roughly 2,600 biotin molecules surface associated to one single BPEG PLGA NP (see 
the publication `Coupling of biotin-(polyethylene-glycol)amine to poly(D,L-lactide-co-
glycolide) nanoparticles for versatile surface modification´), and due to a low non- 
specific binding in case of PLGA NP. However, with both NP species, an increase in 
fluorescence of the overall as well as the supernatant samples was found in regard to a 
blank FITC-NAv solution of the same concentration (Figure 1). To explain these results, 
the effects of BPEG and biotin on the fluorescence of FITC-NAv were investigated. Both 
biotin and BPEG containing FITC-NAv solutions showed an increase of fluorescence in 
regard to a blank FITC-NAv solution of the same concentration up to 140%. A plateau 
was reached close to concentrations where a saturation of all biotin binding sites of 
NAv is most likely (Figures 3A and 4A). At higher concentration, however, biotin 
decreased, whereas BPEG increased the fluorescence of FITC-NAv (Figures 3B and 
4B), thus indicating a strong influence of the PEG chain on those effects. 
The Av-biotin system is widely used in fluorescent immunoassays7, 8 where fluorescence 
labelled Av (and homologues) bind to a biotinylated primary antibody, whereas 
excessive reagents are generally removed by washing. Finally, the fluorescence of 
fluorescence labelled Av molecules in the same state, i.e. bound to an average number 
of biotin molecules linked to the primary antibody, is determined. In contrast, with the 
experimental setup applied, the overall fluorescence derived from free FITC-NAv as well 
as from biotin associated FITC-NAv. In the presence of different biotin concentrations, 
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 FITC-NAv molecules may exist in different states and their fluorescence might be not 
comparable due to different interactions between Av and biotin (e.g. fluorescence 
amplification or quenching). 
Considering the arrangement of the BPEG grafts on the surface of the NP, the PEG 
chain is connected to the particle core, whereas the biotin molecule may be directed 
versus the surrounding medium. It might be speculated that the effects of biotin - and 
not those of BPEG - can display the real effects of BPEG PLGA NP on FITC-NAv. 
However, in binding experiments FITC-NAv was applied in concentrations providing at 
least one protein molecule per each biotin binding site on the BPEG PLGA NP. 
Consequently, the concentration of biotin was in the range of the asymptotic increase of 
relative fluorescence of FITC-NAv, thus explaining the elevated relative fluorescence of 
a BPEG PLGA NP containing FITC-NAv solution, irrespective if the proteins finally 
interact with biotin or PEG linked biotin. 
The elevated fluorescence of FITC-NAv in the presence of PLGA NP has not been 
explored in detail, however, it might be suggested that non-specific interactions can 
also influence the fluorescence of FITC-NAv, comparable to effects of the PEG chain. 
The NP bound FITC-NAv amount was determined in an inverse setup in order to avoid 
quantification errors due to cross-linking of particles as with a direct method. 
Comparing the relative fluorescence of the overall and supernatant samples of BPEG 
PLGA NP, no statistically significant difference was detected (Figure 1). Obviously, 
either the NP bound amount of FITC-NAv was too small to be detected by the 
experimental setup, or, most likely, the BPEG chains had been sheared off the NP 
cores by high centrifugation forces when separating the NP from the supernatant. This 
theory is further confirmed by an increased relative fluorescence in case of BPEG PLGA 
NP which must have derived from binding of biotin to FITC-NAv resulting in effects as 
discussed above. 
In case of PLGA NP there was a significant decrease of relative fluorescence in the 
supernatant samples (Figure 1) which might result from stronger non-specific binding of 
the proteins directly to the NP surface, hence, resisting high centrifugation forces. 
However, also an unexpected decrease of fluorescence in the supernatant samples of 
the reference was detected. This may only be attributed to either protein loss by 
adsorption to plastic material or by small protein aggregation and removal during 
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 centrifugation, thus representing also a possible explanation for the findings with PLGA 
NP. 
 
In the second study, commercially available HRP-SAv was employed as a model to 
investigate the binding of protein conjugates to the surface of NP. Thereby, HRP-SAv 
may be replaced by versatile proteinogenic targeting moieties as long as they are 
available as conjugates of Av (and homologues). As in case of FITC-NAv, in order to 
investigate both specific and non-specific binding BPEG PLGA NP and PLGA NP were 
employed. However, with the experimental setup applied, an evidence of HRP-SAv 
binding to each of the particle species could not be provided. The relative absorption 
representing the particle associated and free protein amount was not significantly 
different when comparing the supernatant, the overall, and the reference samples 
(Figure 2). In contrast to FITC-NAv, no influence of biotin and BPEG interaction with the 
biotin binding sites of the SAv compound on the activity of HRP could be determined. 
Analogous to the results with FITC-NAv, the results obtained with HRP-SAv suggest that 
the proteins either bound to the surface of both NP species in amounts below the 
detection limit, or that they were sheared off by high centrifugation forces when 
separating the NP from the supernatant. In conclusion, the present results are not 
sufficiently clarified, yet. Studies of the protein binding combined with an improvement 
of the experimental setup ought to be subject of further investigations. 
 
5 Conclusion 
Successful binding of FITC-NAv to BPEG PLGA NP was confirmed, however, 
quantification of the binding of FITC-NAv and HRP-SAv to BPEG PLGA NP and PLGA 
NP was not possible by means of the inverse experimental setup applied in this study. 
The fluorescence intensity of FITC-NAv turned out to be dependent on the 
concentration of biotin and BPEG indicating that the determination of the particle 
attached amounts of FITC-NAv might only be possible by a direct method like 
quantification of the particle bound protein amount instead of the protein amount in the 
supernatant of the assay. In case of HRP-SAv, no effects of biotin and BPEG on the 
HRP enzyme activity were found within the applied range of concentration. 
Centrifugation in order to separate NP from the supernatant, is assumed to result in 
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 shearing off BPEG chains from the NP cores, thus strengthening the demand to apply a 
gentle method for particle separation in future. 
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7 Summary / Zusammenfassung 
 
Summary 
 
Subjects of the present thesis were the formulation, characterization, and 
evaluation of poly(lactic acid-co-glycolic acid) (PLGA) based nanoparticulate systems 
addressing the biological barriers intestine and skin. 
This work was focussed on the following three main subjects: 
 
- Preparation, characterization, and evaluation of fluoresceinamine labelled PLGA 
nanoparticles to study their interaction with inflamed intestinal tissue in vivo in 
humans 
- Studies on skin permeation and penetration of fluorescent and drug containing 
nanoparticles in vitro and in vivo 
- Development and evaluation of surface biotinylated nanoparticles for coupling of 
versatile ligands 
 
Preparation, characterization, and evaluation of fluoresceinamine labelled PLGA 
nanoparticles 
 
Previously, Alf Lamprecht and co-workers studied a size dependent 
accumulation and prolonged retention of orally administered micro- and nanoparticles 
(NP) in inflamed regions of the intestine - whilst concentrating anti-inflammatory drugs 
at their site of action - in an animal model. Based on these promising results, such 
novel concept has to be proven in vivo in a clinical study with patients suffering from 
inflammatory bowel diseases (IBD). For this purpose, drug-free but fluorescence 
labelled non-toxic NP were developed and evaluated to show their accumulation in 
inflamed areas of the intestinal mucosa in IBD patients by means of fluorescence 
microscopy. 
For a stable fluorescence labelling, PLGA was covalently modified with 5-
fluoresceinamine (FA), which was found to represent a simple, reproducible, and 
efficient method of polymer labelling (efficiency 65%). From such polymer (FA-PLGA), 
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fluorescent NP (FA-PLGA NP) in the size of 270 nm were prepared by means of 
nanoprecipitation. In regard to an in vivo application of the NP in IBD, this size order is 
expected to be adequate for the detection of even single particles in biological tissue, 
whilst still likely to display an enhanced accumulation and retention in inflamed mucosal 
areas. FA-PLGA NP were almost uncharged as consequence of polymer modification. 
Compared to NP prepared by encapsulation of FC using the classic water-in-oil-in-
water method, NP from FA-PLGA exhibited a much better labelling stability which is 
crucial for the intended studies. In degradation experiments, increasing pore formation 
and changes in the elastic properties of FA-PLGA NP was shown with time; thereby, the 
NP size stayed unchanged. With respect to future application in a clinical study, FA-
PLGA NP can be re-constituted without significant changes in size and size distribution 
after lyophilisation without cryoprotectants. Moreover, the NP were well to visualize and 
to quantify with low detection limit in preliminary experiments with porcine intestinal 
tissue. 
In order to evaluate the interaction with intestinal epithelial cells, FA-PLGA NP were 
applied on an in vitro model of the intestinal mucosa (Caco-2 cell culture) addressing 
absorption and potential cytotoxicity. A transport of FA-PLGA NP across Caco-2 
monolayers was not found, but transport of minor amounts of their fluorescent 
degradation products which, however, was approximately 500 times smaller than the 
transport of the low permeability marker FC. The cytotoxicity of FA-PLGA NP was 
studied to be significantly (750 fold) smaller than in case of the non-toxic diagnostic 
agent fluorescein sodium. 
In conclusion, polymer modification allowed to prepare fluorescence labelled NP from a 
biodegradable polymer with sufficient stability to be monitored over a period of several 
days. Due to very low cytotoxicity and only negligible transport of NP degradation 
products over an in vitro cell culture model of the intestinal mucosa, FA-PLGA NP 
appear as valuable tool to study their interaction with inflamed intestinal tissue in IBD in 
terms of an in vivo application in a clinical study. 
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Studies on skin permeation and penetration of fluorescent and drug containing 
nanoparticles 
 
Major subject of this part of the present thesis was to investigate and to visualize 
NP transport, storage and drug release in skin in vitro and in vivo, thereby, employing 
fluorescence labelled and drug containing NP from PLGA. The following three topics 
have been explored in detail: 
 
Several studies have recently revealed significant influence of hair follicles on the 
penetration of topically applied substances into the skin, such as low molecular weight 
compounds and NP. Still, however, penetration and storage features of topically 
applied NP formulations needs to be explored in detail. Here, the penetration and 
storage of compounds in free and nanoencapsulated form in hair follicles was 
compared in vitro on porcine skin using FA-PLGA NP and a particle-free sodium 
fluorescein formulation of the same dye concentration. It was found that NP penetrated 
much deeper into the hair follicles than the dye derived from the particle-free 
formulations if a massage had been applied. Analyzing the storage behaviour of both 
formulations in vivo in humans, NP were shown to be stored in the hair follicles much 
longer (up to 10 days) than the particle-free formulation. 
Explaining these results, it was hypothesized that the surface structure of the skin, in 
particular of the cuticle, may act as a geared pump pushing particles deeper into hair 
follicles than smaller sized compounds and, at the same time, decelerating particle 
removal by sebum excretion. 
 
Multiphoton microscopy was employed to simultaneously study and visualize the 
penetration and drug release of NP - embedded in a gel matrix - in excised human skin. 
For that purpose, a dually fluorescence labelled nanoparticulate model system was 
developed, where the first fluorescence dye was stable entrapped in the polymer core 
and the second dye mimicked a drug to be released. The FA-PLGA NP formulation was 
advanced to an additional encapsulation of Texas Red as a model drug employing an 
oil-in-water method. Two-colour labelled NP exhibited a size of 290 nm, narrow size 
distribution, spherical shape, and a smooth surface. 
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Multiphoton fluorescence imaging enabling three-dimensional tracing of individual NP 
with diffraction-limited resolution indicated that fluorescence labelled NP were not able 
to penetrate the stratum corneum, but stayed in the gel-filled dermatoglyphs over 5 h. 
Two-photon spectral imaging was applied to investigate the distribution of the model 
drug Texas Red as a function of time. The Texas Red content in the NP turned out to be 
low and basically constant, whereas the concentration of Texas Red dropped in the gel 
matrix and increased in the deeper stratum corneum and stratum granulosum, 
indicating a slow penetration of the dye from the gel into the skin with time. 
Multitracking experiments after 5 h of incubation allowed a co-localization of FA which 
was strictly bound to the NP, Texas Red which was found to be penetrated into the skin 
to a predominant fraction, and keratin. 
Concluding, multiphoton microscopy combined with spectral imaging was found to 
allow non invasive long term studies of the penetration of dually fluorescence labelled 
NP into skin with sub-cellular resolution, thereby, even discriminating between particle 
bound and released dye. Due to virtually no out-of-focus effects of the scanning laser 
beam, this technique is considered gentle for both in vitro and in vivo studies. 
 
Subsequently, PLGA NP were chosen as a valuable carrier system to investigate 
the influence of nanoencapsulation on the permeation and penetration of the lipophilic 
model drug flufenamic acid (FFA) into excised human skin. It was found that an oil-in-
water method was most appropriate to encapsulate FFA into PLGA NP. Resulting FFA 
NP were in the size order of 330 nm, had a narrow size distribution and a high drug 
entrapment. Moreover, the particles exhibited spherical shape and smooth surface 
which were even contained after incorporation in Natrosol hydrogel to give the final 
particle formulation. Penetration and permeation results were acquired using the 
Saarbrücken penetration model and Franz diffusion cells as in vitro test systems. 
Comparing the transport of a FFA NP formulation and FFA formulation with same drug 
content, no differences were found for the stratum corneum. Drug accumulation in the 
deeper skin layers and drug transport across the epidermis were slightly delayed in 
case of the nanoencapsulated FFA compared to free FFA after shorter incubation times 
(<12 h). However, after longer incubation times, nanoencapsulated FFA showed a 
statistically significantly enhanced transport and accumulation. The mechanisms for 
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such results remained unclear. It has been speculated that some acidification of the 
particles and their surroundings as a consequence of PLGA degradation may favour 
the non-ionized form of FFA, thus leading to enhanced penetration through the stratum 
corneum. When visualizing FFA NP on excised human skin, they were found to be 
homogeneously distributed on the skin surface and within the dermatoglyphs; no NP 
were within or between the corneocytes. 
 
Development and evaluation of surface biotinylated nanoparticles 
 
Generally, polymeric NP for drug targeting are designed to entrap the drug 
moiety in the core and to present the targeting moiety on the surface, thereby using 
specific techniques for each compound to be entrapped or attached.  
The subject of the final part of this thesis was to develop a procedure for surface 
functionalization of preformed NP, which may eventually already contain active 
pharmacological ingredients, for subsequent versatile conjugation of targeting ligands 
and fluorescence dyes under mild conditions. For that purpose, an approach where 
surface biotinylated NP bind to conjugates of avidin (or its homologues streptavidin or 
NeutrAvidin) was opted. Consequently, both targeting moieties as well as fluorescence 
labels may be easily linked to the surface of thus functionalized NP as long as they are 
available as conjugates of avidin. 
PLGA NP in the size of 210 nm were prepared by the classic oil-in-water method and, 
subsequently functionalized with biotin-(polyethyleneglycol)amine (BPEG) employing 
cyanuric chloride chemistry. By such method, an effective surface biotinylation of NP 
cores could be demonstrated which appeared to be well suited for subsequent binding 
of avidin or avidin linked ligands when described to scale. Surface modification did not 
involve an increase in size or alteration in shape and surface structure. However, 
functionalized PLGA NP (BPEG PLGA NP) were less negatively charged and exhibited 
changes in elastic or adhesive properties, which were even more significant after 
binding of avidin. So far, binding of avidin and homologues to BPEG PLGA NP could 
only be shown qualitatively, since the quantification of NP bound proteins was not 
possible using an inverse experimental setup. Specific binding to BPEG PLGA NP was 
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only given in case of NAv which was further confirmed by resonant mirror 
measurements.  
For a first evaluation in biological systems, differences in binding and uptake of NP 
were studied in two epithelial cell lines after labelling BPEG PLGA NP with avidin linked 
fluorescencence dyes. 
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Zusammenfassung 
 
Das Thema der vorliegenden Dissertationsarbeit ist die Formulierung, 
Charakterisierung und Evaluierung von Nanopartikeln aus Polymilchsäure-co-
glykolsäure (PLGA), die an den biologischen Barrieren Darm und Haut zum Einsatz 
kommen sollen. 
Die Arbeit konzentrierte sich auf folgende drei Schwerpunkte: 
 
- Herstellung, Charakterisierung und Evaluierung von fluoreszeinamin-markierten  
Nanopartikeln aus PLGA, die dazu bestimmt sind, die Wechselwirkung mit 
entzündeter Darmschleimhaut in einer In-vivo-Studie am Menschen zu 
untersuchen 
- In-vitro- und In-vivo-Untersuchungen von Permeation und Penetration 
fluoreszierender oder Arzneistoff enthaltender Nanopartikel in die Haut 
- Entwicklung und Evaluierung von mit Biotin oberflächenmodifizierten 
Nanopartikeln, an die vielfältig Liganden gebunden werden sollen 
 
Herstellung, Charakterisierung und Evaluierung von fluoreszeinamin-markierten Nano-
partikeln aus PLGA 
 
Alf Lamprecht und Mitarbeiter fanden in Untersuchungen am Tiermodell eine 
größenabhängige Anreicherung und eine verlängerte Retention von oral verabreichten 
Mikro- und Nanopartikeln (NP) an der entzündeten Darmschleimhaut. Durch 
Anwendung partikulärer Systeme gelang es zudem, antientzündliche Wirkstoffe an 
ihrem Wirkort zu konzentrieren. Auf diese viel versprechenden Ergebnisse aufbauend 
soll nun ein solches neuartiges Konzept auch in einer klinischen Studie an Patienten mit 
chronisch-entzündlichen Darmerkrankungen überprüft werden. 
Im Rahmen der vorliegenden Arbeit wurden fluoreszenz-markierte Nanopartikel 
formuliert, um damit in entzündetem Gewebe der Darmschleimhaut Partikel-
anreicherungen mittels Fluoreszenzmikroskopie aufzuzeigen. Zur stabilen 
Fluoreszenzmarkierung wurde PLGA kovalent mit 5-Fluoreszeinamin (FA) modifiziert. 
Diese Methode erwies sich als leicht durchführbar und reproduzierbar und führte zu 
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einer hohen Modifikationsrate (65%). Aus dem modifizierten Polymer (FA-PLGA) wurden 
durch Nanopräzipitation fluoreszierende NP (FA-PLGA NP) in der Größe von 270 nm 
hergestellt. Hinsichtlich einer In-vivo-Anwendung dieser NP bei chronisch-entzündlichen 
Darmerkrankungen ist von dieser Partikelgröße zu erwarten, dass sich einzelne NP gut 
detektieren lassen und dabei die am Tiermodell beschriebenen Effekte an der 
Darmschleimhaut zeigen. Infolge der Polymermodifikation waren die FA-PLGA NP 
nahezu ungeladen. 
Im Vergleich zu NP, in die Fluoreszein-Natrium mittels der klassischen Wasser-in-Öl-in-
Wasser-Methode verkapselt wurde, waren FA-PLGA NP wesentlich stabiler und setzten 
weniger Fluoreszenzmarker frei. Somit erschienen sie für eine zukünftige Studie als 
besser geeignet 
In Partikel-Degradationsexperimenten wurde gezeigt, dass FA-PLGA NP mit der Zeit 
zunehmend Poren entwickeln und Änderungen in den viskoelastischen Eigenschaften 
erfahren. Die Partikelgröße bleibt dabei aber konstant. Im Hinblick auf eine Anwendung 
der fluoreszierenden NP in einer klinischen Studie ist es wichtig, dass die 
fluoreszierenden NP sich ohne Änderungen der Größe und der Größenverteilung nach 
der Gefriertrocknung rekonstituieren lassen. Dies wurde im Falle der FA-PLGA NP 
gezeigt, wobei ein Einsatz von Kryoprotektiva nicht notwendig war. In Vorexperimenten 
am Schweinedarm ließen sich die fluoreszierenden NP gut abbilden und zudem mit 
niedrigem Detektionslimit quantifizieren. 
Um Wechselwirkungen mit epithelialen Darmzellen zu untersuchen, wurden die FA-
PLGA NP in einem Zellkulturmodell der Darmschleimhaut (Caco-2-Zellen) auf ihre 
Absorption und Zytotoxizität geprüft. Ein Transport von NP selbst über den Zell-
Monolayer fand nicht statt. Es trat jedoch ein Transport von sehr geringen Mengen ihrer 
fluoreszierenden Abbauprodukte (ca. 500mal weniger als der „low permeability marker“ 
Fluoreszein) auf. Die Zytotoxizität der FA-PLGA NP war signifikant geringer (ca. 750mal) 
als die des ungiftigen Diagnostikums Fluoreszein-Natrium. 
Zusammenfassend lässt sich sagen, dass es mit Hilfe der Polymermodifikation gelang, 
fluoreszierende NP herzustellen, welche sich durch eine ausreichende Stabilität 
auszeichnen, um über einen Zeitraum von mehreren Tagen im Gewebe verfolgt werden 
zu können. Da die Partikel sich zudem als wenig zytotoxisch erwiesen und nur ein 
geringer Anteil ihrer Abbauprodukte im Zellkulturmodell transportiert wurde, scheinen 
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sie sich sehr gut dazu zu eignen, um in einer zukünftigen In-vivo-Studie 
Wechselwirkungen mit der entzündeten Darmschleimhaut an Patienten mit chronisch-
entzündlichen Darmerkrankungen zu untersuchen. 
 
Untersuchung von Permeation und Penetration fluoreszierender oder Arzneistoff 
enthaltender Nanopartikel in die Haut 
 
Hauptschwerpunkt des zweiten Teils dieser Dissertation war es, den Transport, 
die Deposition sowie die Freisetzung von Arzneistoffen an der Haut in vitro und in vivo 
zu untersuchen und zu visualisieren. Dazu wurden fluoreszierende und arzneistoff-
beladene NP eingesetzt. Folgende drei Thematiken wurden dabei bearbeitet: 
 
Verschiedene Studien zeigten in jüngster Zeit, dass Haarfollikel einen 
bedeutenden Einfluss auf die Penetration von topisch angewendeten Substanzen, 
kleinen Molekülen wie NP, in die Haut besitzen. Dabei sind die Mechanismen der 
Penetration und Deposition von topisch applizierten NP noch relativ unklar. Diese 
wurden nun im Rahmen dieser Arbeit in Form eines Vergleichs zwischen 
fluoreszierenden FA-PLGA NP und einer partikelfreien Formulierung mit analoger 
Fluoreszein-Natrium-Konzentration in vitro auf Schweinehaut untersucht. Dabei wurde 
gezeigt, dass NP wesentlich tiefer in Haarfollikel penetrierten als der 
Fluoreszenzfarbstoff aus der partikelfreien Formulierung, jedoch nur, wenn eine 
Massage angewendet wurde. Die Untersuchung der In-vivo-Deposition beider 
Formulierungen auf der Haut am Menschen ergab, dass NP bedeutend länger (bis zu 
10 Tagen) in den Haarfollikeln verblieben als der freie Fluoreszenzfarbstoff. 
Aus diesen Ergebnissen ließ sich die Hypothese ableiten, dass die Struktur der Kutikula 
der Haarschäfte mit einer Zahnradpumpe vergleichbar ist, die Partikel möglicherweise 
tiefer in Haarfollikel befördert als kleinere Substanzen und gleichzeitig ihren Abtransport 
im Zuge der Talgabsonderung verlangsamt. 
 
Mittels Multiphotonen-Mikroskopie wurden simultan Penetration und Arzneistoff-
freisetzung aus NP auf exzidierter Humanhaut untersucht und visualisiert; die NP waren 
dabei in eine Gelmatrix eingebettet. Zu diesem Zweck wurde ein zweifach 
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fluoreszierendes nanopartikuläres Modellsystem entwickelt, bei dem ein Fluoreszenz-
farbstoff stabil im Partikel eingebettet war und der zweite einen Arzneistoff imitierte, der 
freigesetzt wird. Die im ersten Teil beschriebene NP-Formulierung wurde hierfür weiter 
entwickelt; Texas Red wurde als Modellarzneistoff unter Anwendung einer Öl-in-
Wasser-Methode in NP aus FA-PLGA eingearbeitet. Diese zweifach-fluoreszenz-
markierten NP besaßen eine Größe von 290 nm bei einer engen Größenverteilung. 
Zudem wiesen sie eine sphärische Form und eine glatte Oberfläche auf. 
Multiphotonen-Fluoreszenzmessungen ermöglichten eine dreidimensionale Darstellung 
von einzelnen NP mit einer Größe unterhalb der Auflösungsgrenze. Es wurde gezeigt, 
dass die fluoreszenz-markierten NP nicht in das Stratum Corneum penetrierten, 
sondern über einen Zeitraum von 5 Stunden in den mit Gel gefüllten Dermatoglyphen 
verblieben. 
Durch spektrale Auswertung der Signale konnte die Verteilung des Modellarzneistoffs 
Texas Red in der Haut als Funktion der Zeit dargestellt werden. Hierbei war 
offensichtlich, dass der Texas Red-Gehalt der NP zwar relativ gering, dennoch aber 
konstant war. Die Texas Red-Konzentration im Gel nahm dagegen mit der Zeit ab, 
während sie im tieferen Stratum Corneum und im Stratum Granulosum zunahm, was 
auf eine langsame Penetration des Farbstoffs aus dem Gel in die Haut schließen ließ. 
In „Multitracking“-Experimenten nach 5 Stunden Inkubation mit der fluoreszierenden 
NP-Formulierung ließen sich fluoreszierende Objekte co-lokalisieren: FA, das fest an die 
NP gebunden war, Texas Red, das zu einem großen Anteil in die Haut penetriert war, 
und Keratin. 
Die Ergebnisse zeigten, dass es Multiphotonen-Mikroskopie mit spektraler Detektion 
ermöglichen, in Langzeitstudien nicht-invasiv die Penetration von zweifach-fluoreszenz-
markierten NP in die Haut mit hoher Auflösung zu untersuchen. Dabei konnte zwischen 
Partikel-gebundenem und freiem Farbstoff unterschieden werden. Da mit dieser 
Technik nahezu keine „Out-of-focus“-Effekte auftreten, erscheint sie geeignet für 
schonende In-vitro- und In-vivo-Untersuchungen. 
 
In einer weiteren Studie auf Haut wurden PLGA NP eingesetzt, um den Einfluss 
von Nanoverkapselung auf die Permeation und Penetration des lipophilen 
Modellarzneistoffs Flufenaminsäure (FFA) in exzidierte Humanhaut zu untersuchen. 
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Um FFA in NP einzuarbeiten, erwies sich die Öl-in-Wasser-Methode als am besten 
geeignet. Die daraus resultierenden NP besaßen eine Größe von ca. 330 nm, eine enge 
Größenverteilung und eine hohe Verkapselungseffizienz. Sie waren sphärisch und 
hatten eine glatte Oberfläche, was auch noch in der endgültigen Formulierung, d.h. 
nach Einarbeitung in ein Hydrogel, gewährleistet war. 
Die Penetrations- und Permeationsversuche wurden mit Hilfe der In-vitro-Testsysteme 
„Saarbrücker Penetrationsmodell“ und „Franz´sche Diffussionszelle“ durchgeführt. 
Dabei wurde ein Vergleich zwischen dem Transport des Arzneistoffs aus einer NP-
Formulierung und dem aus einer Formulierung mit freiem Arzneistoff gleichen Gehalts 
angestellt. Für das Stratum Corneum zeigten sich keine Unterschiede. Die 
Arzneistoffanreicherung in tieferen Hautschichten sowie der Arzneistofftransport über 
die Epidermis erwiesen sich nach kurzen Inkubationszeiten (<12 Stunden) als leicht 
verzögert im Falle der nanoverkapselten FFA. Nach längeren Inkubationszeiten zeigte 
nanoverkapselte FFA jedoch signifikant höheren Transport und Anreicherung. 
Die genauen Mechanismen, die zu diesen Ergebnissen führten, sind noch nicht 
vollständig geklärt. Es lässt sich jedoch vermuten, dass der Partikelabbau zur 
Anhebung des pH-Werts in den Partikeln und in ihrer Umgebung führt. Dadurch würde 
FFA bevorzugt in der nicht-ionisierten Form vorliegen, was die Penetration durch das 
Stratum Corneum fördern würde. Die Abbildung von FFA NP auf exzidierter Humanhaut 
zeigte eine homogene Verteilung auf der Hautoberfläche und in den Dermatoglyphen; 
es wurden jedoch keine NP in oder zwischen den Korneozyten gefunden. 
 
Entwicklung und Evaluierung von mit Biotin oberflächenmodifizierten Nanopartikeln 
 
Im allgemeinen sind NP aus Polymeren so aufgebaut, dass die aktive 
Komponente im Inneren der NP verkapselt ist, während die „Targeting“-Komponente 
auf der Oberfläche sitzt. Für jede Formulierung muss dabei jedoch ein eigenes 
Verfahren entwickelt werden. 
Die Zielsetzung des letzten Teils dieser Arbeit war es, eine Methode zu entwickeln, um 
NP, die unter Umständen bereits eine pharmakologisch aktive Komponente enthalten, 
oberflächlich zu modifizieren. Diese NP sollen dann unter chemisch milden 
Bedingungen eine Bindung von vielfältigen „Targeting“-Komponenten und 
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Fluoreszenzfarbstoffen ermöglichen. Der Ansatz bestand darin, NP auf ihrer Oberfläche 
mit Biotin zu funktionalisieren, welches Konjugate von Avidin (und seinen Homologen 
Streptavidin und NeutrAvidin) binden kann. Folglich sollten damit sowohl „Targeting“-
Komponenten als auch Fluoreszenzfarbstoffe an diese NP gebunden werden können, 
voraus gesetzt sie sind als Konjugate von Avidin verfügbar. 
Mit Hilfe der klassischen Öl-in-Wasser-Methode wurden NP aus PLGA in einer Größe 
von 210 nm hergestellt und mit Biotin-(polyethylenglycol)amin (BPEG) unter 
Verwendung von Cyanurchlorid als Aktivierungsreagenz funktionalisiert. Es konnte 
gezeigt werden, dass mit dieser Methode eine effektive Biotinylierung der NP-
Oberfläche möglich war, die bei maßstabsgetreuer Betrachtung optimale Bedingungen 
für eine Bindung von Avidin oder von mit Avidin verknüpften Liganden darstellte. Die 
Oberfächenmodifizierung führte zu keinen Veränderungen der Größe, Form oder 
Oberflächenstruktur der NP. Jedoch waren die mit BPEG funktionalisierten NP (BPEG 
PLGA NP) weniger negativ geladen und wiesen deutlich veränderte elastische und 
adhäsive Eigenschaften auf, was durch Bindung von Avidin noch verstärkt wurde. 
Die Bindung von Avidin und Homologen an BEPG PLGA NP wurde im Rahmen dieser 
Arbeit qualitativ nachgewiesen; eine Quantifizierung der an die NP gebundenen 
Proteine war mit der verwendeten inversen Methode nicht möglich. Es wurde zudem 
deutlich, dass eine spezifische Bindung an BPEG PLGA NP nur im Falle von 
NeutrAvidin gegeben ist. Zur ersten Evaluation in biologischen Systemen wurden BPEG 
PLGA NP durch mit Avidin verbundenen Fluoreszenzfarbstoffen markiert. Mit diesen 
Partikeln konnten Unterschiede im Aufnahme- und im Adhäsionsverhalten an zwei 
epithelialen Zellinien aufgezeigt werden. 
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